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The format of my thesis is as follows: two literature reviews, three research chapters, a 
general discussion, references and appendices. During my candidature, I made a 
significant effort to publish my research findings. Each chapter is presented in its 
original publication format, with the exception of spelling changes to keep consistent 
English spelling, and the references which are listed in the final chapter. This may 
result in slight repetition between chapters arising from the same study.  
 
My thesis has two distinct themes relating to the pathobiology of gastrointestinal 
toxicity second to targeted cancer treatment. The first theme aims to characterise 
gastrointestinal toxicity induced by dacomitinib, a pan-human epidermal receptor 
(HER) tyrosine kinase inhibitor (TKI) associated with high levels of diarrhoea. This 
theme gives rise to the first four chapters. Chapter 1 was an invited review introducing 
dacomitinib, highlighting the increasing incidence of gastrointestinal toxicity seen with 
second generation small molecule HER-TKIs and incorporating basic information 
required for understanding of subsequent chapters. Chapter 2 is a detailed literature 
review proposing chloride secretion as a mechanistic hypothesis for development of 
HER TKI-induced diarrhoea. Chapter 3 is my first original research chapter, which 
characterised dacomitinib-induced gastrointestinal toxicity in a novel rat model. 
Chapter 4, my second original research chapter, advances on this characterisation, and 
introduces crofelemer, a chloride channel blocker as a therapeutic intervention for the 
prevention of dacomitinib-induced diarrhoea. During my candidature, I had the 
opportunity to work with Assistant Professor Tom Carney from the Institute of 
Molecular and Cell Biology (IMCB), Biopolis, Singapore. This collaboration 
 
xxiv  
comprises Chapter 5, the second theme of this thesis. This chapter attempted to 
address the need for an innovative model for the study of gastrointestinal toxicity, 
investigating transgenic zebrafish reporter lines as a novel model for the study of 
chemotherapy and targeted therapy-induced gastrointestinal toxicity.  
 
Parts of this thesis were funded by Pfizer Pharmaceuticals under an unrestricted 
investigator-initiated grant (Reference #WI175212). The report I generated for this grant, 
which partly formed the basis of the publications presented in Chapters 3 and 4, is 






Hypothesis and Aims 
The overarching themes of my thesis are based on the characterisation of pan-HER TKI-
induced gastrointestinal toxicity. The initial hypothesis presented in this thesis addressed 
chloride secretion as the proposed mechanism for pan-HER TKI-induced diarrhoea. This 
thesis extensively investigated the literature to formulate this hypothesis, which is 
presented in Chapter 2. This hypothesis drove my first three aims: 
 
1. To characterise second generation pan-HER TKI-induced gastrointestinal toxicity 
using dacomitinib in in vitro and rodent models (Chapter 3).  
 
2. Utilising crofelemer (an antisecretory, antidiarrhoeal), investigate the hypothesis 
of chloride secretion as a mechanism of HER TKI-induced diarrhoea utilising the 
previously developed in vitro and rodent models (Chapter 4) 
 
3. To determine if crofelemer is an effective prophylactic for dacomitinib-induced 
diarrhoea using an established rodent model (Chapter 4).  
 
An important feature arising from these chapters was the lack of translatability from in 
vitro to whole organism in vivo models. I utilised in vitro models as proof of concept, but 
when translated to rodent models, effects were not seen. This highlighted the need for a 
bridge between in vitro and in vivo models that allows for high throughput, time, and 
cost-efficient screening. The secondary theme of this thesis was therefore to try and 




4. Investigate zebrafish as a novel model to study gastrointestinal toxicity to bridge 





This thesis contains variations in terminology relating to gastrointestinal toxicity 
second to cancer treatment. This is in part reflected by the lack of an accurate 
definition of the pathophysiology in the field. There are also variances in terminology 
of receptors that are key to this thesis. Inconsistencies within this thesis are due to 
requests made by reviewers during peer-review of each publication. I did not change 
this terminology from what was used in the original publications to avoid altering their 
content.  
Please review the following nomenclature. 
 
Gut and gastrointestinal tract: the small and large intestine 
 
HER (Human Epidermal Receptor), ErbB, and EGFR (Epidermal Growth Factor 
Receptor): Interchangeable terms pertaining to the same class of proteins, HER is 
refined to humans, ErbB pertains to all species, EGFR refers to the HER1/ErbB1 
receptor.  
 
Mucositis or gastrointestinal toxicity: Mucositis is a term referring to ulceration and 
inflammation of the alimentary tract (any region from mouth to anus) that is 
characterised by a 5-phase model, typically induced from traditional chemotherapy. 
Gastrointestinal toxicity refers to side effects of gastrointestinal origin induced by any 
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Chapter 1 Gastrointestinal toxicities of first and second 
generation small molecule human epidermal growth factor 
receptor tyrosine kinase inhibitors in advanced non-small cell 
lung cancer 
 
This chapter was an invited editorial published in the special issue, Gastrointestinal 
Symptoms, in Current Opinion in Supportive and Palliative Care (Van Sebille, Y.Z., 
Gibson, R. J., Wardill, H.R., Bowen, J.M. 2016. Gastrointestinal toxicities of first and 
second-generation small molecule human epidermal growth factor receptor tyrosine 
kinase inhibitors in advanced non-small lung cancer. Current Opinion in Supportive and 
Palliative Care, 10, 152-156.) 
 
Abstract 
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptors 
(HER) are the standard of care treatment in non-small cell lung cancer (NSCLC). 
Gefitinib is a first generation HER1 TKI used first line HER1 mutation-positive NSLC. 
Initially, oncology end points were promising, however acquired resistance and 
mutations have occurred, triggering the development of second-generation pan-HER 
TKIs, such as dacomitinib.  
However, with the development of novel targeted therapies has come worsened side 
effects, in particular diarrhoea. Despite this toxicity being the most common side effect 





toxicity, comparing first generation to second generation HER TKIs for the treatment of 
NSCLC, using gefitinib and dacomitinib respectively.  
 
Introduction 
Lung cancer remains the leading cause of cancer-related death worldwide, with non-
small cell lung cancer (NSCLC) representing 85% of all lung cancer diagnoses [1, 2]. 
Platinum-based chemotherapy is recommended as standard first-line treatment; however, 
the objective response rate is modest and recurrence eventually occurs for most patients 
[3]. The landscape of NSCLC therapeutics has changed over the past decade in response 
to discovery that many tumours overexpress the human epidermal growth factor receptor 
(HER) family. This has resulted in the introduction of small molecule HER tyrosine 
kinase inhibitors (TKIs) for the treatment of NSCLC [4]. Many new HER TKIs have 
since emerged, moving from single HER targets (primarily HER1), such as gefitinib and 
erlotinib to pan-HER targets such as dacomitinib and afatinib. Additionally, these small 
molecule therapeutics have moved from first to second generation agents; now resistant 
to the acquired mutations of the first-generation class of drugs, such as the T790 
mutation. It was originally anticipated with the advent of these targeted therapies that 
patients would experience less toxicity than traditional cytotoxic therapies. While 
undoubtedly these new agents have improved therapy significantly, they also have 
downsides, namely, causing unexpected adverse event profiles. This editorial will focus 
on the predominant HER TKI-related side effect, namely diarrhoea, addressing the 
change in the gastrointestinal toxicity profiles seen from the single-HER targeted drugs 








TKIs were first described in 1988, and specifically inhibited the human epidermal 
growth factor receptor 1 (HER1) [5]. The activity of the HER receptors is dictated by the 
expression of their ligands, which can be classified into three groups: 1) those binding 
specifically to HER1; 2) those exhibiting dual specificity binding to HER1 and HER4; 
and 3) neuregulins sub classified upon their capacity to bind HER3 and HER4 or only 
HER4 [6] [7]. Currently, no ligand has been identified to be specific for HER2, however 
it is understood that this receptor forms heterodimers with the other HER receptors. 
Upon ligand binding to the HER receptor, heterodimerisation or homodimerisation of 
receptors occurs, leading to a cascade of signalling pathways [8]. Among the pathways 
activated are ERK, and PI3K/Akt. Pathway activation leads to changes in protein 
functions and activation of gene transcription [8-10]. Briefly, these complex signalling 
pathways result in interactions with apoptotic signalling, cell proliferation, 
differentiation, migration and survival, which can promote tumorigenesis [9, 11]. 
 
Diarrhoea 
For oral agents administered daily, toxicities of any grade are extremely important as 
they can determine compliance. Despite this, adverse events remain largely ignored, with 
the emphasis placed on efficacy. Diarrhoea is a severe, dose-limiting, and the most 
common adverse event of small molecule HER TKI treatment [12]. HER TKI-induced 
diarrhoea can become evident as early as 2-3 days after initiation of treatment, and given 
the daily and continuous manner of HER TKI treatment, can persist for substantial 
periods of time, significantly impacting on patients’ quality of life, resulting in poor 
compliance and therapy interruption [13]. The severity of diarrhoea is most commonly 





Events (Table 1). Grade 3 (severe) diarrhoea can result in fluid and electrolyte loss, 
which then can lead to dehydration, electrolyte imbalances, and renal insufficiency. 
Additionally, alterations in gastrointestinal transit and digestion can lead to nutritional 
deficiencies that can negatively impact the quality of life of patients. Furthermore, given 
that therapy with HER TKIs tends to continue for more than 10 months, grade 1-2 
toxicities should be considered equally important, and appropriate management of 







Table 1. Diarrhoea grading scale  
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Increase of <4 
stools over 
baseline 
Increase of 4-6 
stools over 
baseline; 
iv fluids <24 h 





















The underlying mechanism(s) of HER TKI-induced diarrhoea remain poorly understood. 
Despite a similar clinical manifestation to traditional chemotherapy treatment-induced 
diarrhoea, toxicities associated with targeted therapies are hypothesised to have different 
pathogenic mechanisms [14]. Preclinical studies using targeted therapies have shown 
diarrhoea is not correlative with intestinal mucosal damage [15], suggestive of 
pathogenic mechanisms that differ to traditional cytotoxic cancer treatments. Gaining 
significant momentum is the hypothesis that HER TKI-induced diarrhoea is a result of 
excess chloride secretion based on the established role of HERs in regulating ion 
conductance channels in the colon [16]. Currently, treatment for cancer-therapy induced 
diarrhoea is limited; coupled with increasing cancer prevalence, it is clear that the need 
for a fuller understanding of the mechanism(s), and subsequently therapeutic targets will 
not abate. Ultimately, such an understanding should eventually point to safer, more 
targeted and more effective therapies for cancer sufferers.   
 
First Generation HER-TKI- Gefitinib 
Gefitinib (Iressa; AstraZeneca, London, U.K., http://www. astrazeneca.com) was the first 
oral HER TKI approved in the U.S. Gefitinib reversibly binds to the adenosine 
triphosphate -binding pocket of the tyrosine kinase domain of HER1 subsequently 
inhibiting kinase-dependent signal transduction [17-19]. Gefitinib, has demonstrated 
benefit in terms of response rate and time to progression in adults with metastatic 
NSCLC who have activating HER1 mutations [20-22]. However, results from multiple 
clinical trials have demonstrated that between 25 – 55 % of patients receiving gefitinib 






Table 2. Clinical trials of gefitinib  
Study Experimental design Diarrhoea 
(all grades)  
Diarrhoea 
grade 3-4 
Thatcher et al., 2005 [23] NSCLC Phase III (n = 1688) 27 % 3 % 
Sun et al., 2012 [24] NSCLC Phase III (n = 135) 26.5 % 0 % 
Cufer et al., 2006 [25] NSCLC Phase II (n = 140) 26.5 % 2.9 % 
Kim et al., 2008 [26] NSCLC Phase III (n = 1466) 35 % 2.5 % 
Lee et al., 2010 [27] NSCLC Phase III (n =161) 25.9 % 1.2 % 
Mok et al., 2009 [28] NSCLC Phase III (n = 1217) 46.6 % 3.8 % 
Maemondo et al., 2010 [29] NSCLC Phase III (n = 161) 34.2 % 0.9% 
Goss et al., 2009 [30] NSCLC Phase II (n = 201) 51 % 3 % 
Morère et al., 2010 [31] NSCLC Phase II (n = 128) 28 %  5 % 
Mitsudomi et al., 2010 [32] NSCLC Phase III (n = 117) 54 % 1.1 % 
Zhang et al., 2012 [33] NSCLC Phase III (n = 298) 25 %  0 % 






Second Generation HER TKI- Dacomitinib 
Resistance to reversible HER1 TKIs such as gefitinib has increased, leading to the 
development of novel target-based therapies such as dacomitinib for the treatment of 
NSCLC harbouring exon 19 deletions or exon 21 (L858R) mutations [35-37]. 
Conventional HER TKIs such as gefitinib are reversible: they competitively bind to the 
HER1 tyrosine kinase domain [38]. However, the simultaneous activation of different 
HER family members through dynamic hetero- and homo- dimerisation can compromise 
the therapeutic efficacy by inhibition of a single receptor [39]. Dacomitinib (PF- 
00299804, Pfizer) was developed to irreversibly (covalently) bind to the ATP domain of 
each of the three kinase-active members of the HER family (HER1, HER2 and HER4) 
effectively inactivating them [40]. Subsequently, signal transduction pathways 
implicated in the proliferation and survival of cancer cells are blocked [41]. Dacomitinib 
has shown significant therapeutic efficacy in NSCLC, specifically to tumours that have 
not previously responded to conventional single receptor inhibitors, and also against 
tumours with mutations developed for acquired resistance of targeted therapies [37-39]. 
Dacomitinib is currently in phase III clinical trials, and the most commonly reported 
adverse event among all trials has been diarrhoea (Table 3), commonly resulting in dose 






Table 3.  Clinical trials of dacomitinib  
Study 
 
Experimental design Diarrhoea 
(all grades)  
Diarrhoea 
grade 3-4 
Jänne et al., 2011 [45] NSCLC Phase I (n = 121) 66.7 % 11 % 
Reckamp et al., 2014 [44] NSCLC Phase II (n = 66) 84.8 % 12.1 % 
Abdul Razak et al., 2013 [42] NSCLC Phase II (n = 69) 84.1 % 15.9 % 
Ramalingam et al., 2012[46] NSCLC Phase II (n = 94) 73.1 % 11.8 % 
Takahashi et al., 2012 [39] NSCLC Phase I (n = 13) 92 % 0 % 
Ruiz-Garcia et al., 2013 [47] NSCLC Phase I (n = 14) 14 % 0 % 
Ramalingam et al., 2014[48] NSCLC Phase III (n = 878) 72 % 12 % 
Jänne et al., 2016 [49] NSCLC Phase I (n = 70) 74 % 16 % 







Over the past decade, therapies for advanced NSCLC have significantly changed with 
the development of small molecule TKIs moving from single- to pan- HER targets. The 
median percentage of patients developing diarrhoea from gefitinib is 27.5 %, with a 
median of 2.5 % developing grade 3 or higher diarrhoea; compared to a median of 74 % 
of patients developing diarrhoea from dacomitinib, with a median of 12 % developing 
grade 3 or higher. Using gefitinib and dacomitinib as examples, it is clear that second 
generation, pan-HER TKIs induce diarrhoea in a higher proportion of patients, and to a 
worse degree than first generation single-HER TKIs. The HER family of receptors are 
mainly expressed on cells of epithelial origin, including those of the gastrointestinal 
tract, and inhibitors of the HER pathway are therefore associated with gastrointestinal 
side effects, with diarrhoea constituting the most frequent. Perhaps, the increased 
incidence and worse diarrhoea seen with pan-HER TKIs vs single-HER TKIs suggests 
that other members of the HER family, and not only HER1 are important in the 
mechanism(s) of HER-TKI induced diarrhoea. Whilst understanding of the role of HER1 
in growth and repair of the GIT is well understood, little is known of the role of other 
HER receptors in GIT homeostasis.  
 
Dacomitinib is a novel HER family blocker that has demonstrated anticancer activity in 
Phase II and III studies in NSCLC patients whose tumours harbor HER mutations. 
Gefitinib is currently the standard of care for these patients as first-line treatment. 
Following positive clinical trial data, dacomitinib may replace gefitinib as the first-line 
choice of treatment for EGFR mutation-positive advanced NSCLC patients. Given the 
aforementioned concerns associated with dacomitinib-induced diarrhoea, education on 





management and reassessment and close patient follow-up, will help to prevent adverse 
event aggravation, dose reductions or therapy discontinuation, thus encouraging patient 







Statement of Authorship 
Title of Paper 
 
ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a 





Publication Details Literature review published in Cancer Treatment Reviews (2015) 41: 646-652 
Principal Author 
Name of Principal Author 
(Candidate) 
Ysabella Van Sebille 
Contribution to the Paper 
 
 
First author and main contributor. I developed the concept, did the literature search and 
review, wrote the original draft, and was responsible for reviewing and editing. 
Overall percentage (%) 90% 
Certification: This paper reports on original research I conducted during the period of my Higher Degree 
by Research candidature and is not subject to any obligations or contractual agreements with 
a third party that would constrain its inclusion in this thesis. I am the primary author of this 
paper. 
Signature Date September, 2017 
Co-Author Contributions 
By signing the Statement of Authorship, each author certifies that: 
i. the candidate’s stated contribution to the publication is accurate (as detailed above);  
ii. permission is granted for the candidate in include the publication in the thesis; and 
iii. the sum of all co-author contributions is equal to 100% less the candidate’s stated contribution.  
 
Name of Co-Author Rachel Gibson  
Contribution to the Paper Rachel was involved in conceptualisation, supervision, and reviewing manuscript drafts. 
Signature 
 











Name of Co-Author Hannah Wardill 
Contribution to the Paper Hannah was involved in reviewing manuscript drafts. 
Signature 
 
Date September, 2017 
 
Name of Co-Author Joanne Bowen 
Contribution to the Paper Joanne was involved in conceptualisation, supervision, and reviewing manuscript drafts 
Signature 
 





Chapter 2 ErbB small molecule tyrosine kinase inhibitor 
(TKI) induced diarrhoea: chloride secretion as a mechanistic 
hypothesis.  
This chapter was published in Cancer Treatment Reviews (Van Sebille, Y.Z., Gibson, R. 
J., Wardill, H.R., Bowen, J.M. 2015. ErbB small molecule tyrosine kinase inhibitor 
(TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer 
Treatment Reviews, 41, 646-652.) 
 
Abstract 
Diarrhoea is a common, debilitating and potentially life threatening toxicity of many 
cancer therapies. While the mechanisms of diarrhoea induced by traditional 
chemotherapy have been the focus of much research, the mechanism(s) of diarrhoea 
induced by small molecule ErbB TKI, have received relatively little attention. Given the 
increasing use of small molecule ErbB TKIs, identifying this mechanism is key to 
optimal cancer care. This paper critically reviews the literature and forms a hypothesis 
that diarrhoea induced by small molecule ErbB TKIs is driven by intestinal chloride 
secretion based on the negative regulation of chloride secretion by ErbB receptors being 
disrupted by tyrosine kinase inhibition. 
 
Introduction 
In clinical oncology practice, diarrhoea is a very common and severe side effect of 
cancer treatments including radiotherapy, chemotherapy, and targeted therapies [51]. 
Diarrhoea occurs in between 50-100% of patients depending on their treatment regimen 





electrolyte loss associated with persistent and/or severe diarrhoea can result in electrolyte 
imbalances, renal insufficiency, malnutrition, and extreme dehydration, all of which can 
lead to cardiovascular compromise and death [53]. Furthermore, these often necessitate 
dose reductions and treatment breaks, compromising clinical outcomes [54, 55]. The 
need for prevention of cancer therapy-induced diarrhoea is critical. Identification of the 
pathogenesis may lead to a more accurate management to help reduce severe 
complications that may be irreversible [56, 57]. 
 
Cancer therapy-induced diarrhoea is also associated with considerable economic costs 
with recent reports suggesting that additional costs of up to $25,000 (USD) per 
chemotherapy cycle are incurred [58]. These costs are attributed to patients with cancer 
therapy-induced diarrhoea having an increased risk of infection, increased hospital stays 
and increased resource utilisation for supportive care measures [59, 60]. Consequently, 
prevention, minimisation, and/or prediction of cancer therapy-induced diarrhoea may 
significantly reduce health system costs over the total course of cancer treatment.  
 
Small molecule ErbB receptor tyrosine kinase inhibitors (TKIs) are used for the 
treatment of a variety of cancers that overexpress ErbB receptors. These cancers include, 
but are not limited to breast, non-small cell lung cancer (NSCLC) and head and neck 
cancers. Small molecule ErbB TKIs act by competitively binding to the intracellular 
ATP domain of the tyrosine kinase, effectively inhibiting phosphorylation of the receptor 
and therefore downstream signalling [61, 62]. To date, the mechanism(s) of action of 
ErbB TKI-induced diarrhoea has yet to be elucidated. This is in contrast to diarrhoea 
induced by traditional chemotherapy agents including fluropyrimidines, topotecans, 





that chemotherapy-induced diarrhoea is a result of severe intestinal damage caused by 
mucositis. Mucositis is a multi-factorial process whereby acute damage to the intestinal 
mucosa (including, increased apoptosis, villous atrophy, crypt hypoplasia and dilation, 
loss of epithelium, excessive mucous secretion, necrosis and inflammation) causes an 
imbalance between absorption and secretion, ultimately resulting in an anatomic 
derangement diarrhoea phenotype [12, 63, 64].  Numerous preclinical and clinical 
studies have documented the pathobiology of chemotherapy-induced diarrhoea and have 
reported that it is largely based on indirect biological signalling, rather than direct tissue 
damage [65-70]. The mechanisms of chemotherapy-induced diarrhoea are becoming 
better characterised, this is not the case for TKI-induced diarrhoea; this critical review 
will outline potential mechanisms of ErbB receptor TKI-induced diarrhoea.  
 
ErbB receptors 
Many tumours including but not limited to breast, NSCLC, and squamous cell cancers of 
the head and neck, have been identified as overexpressing ErbB receptors. This has 
meant that many targeted therapies have been developed to act on the ErbB family of 
receptors [14]. The ErbB family (interchangeably known as HER/EGFR), is comprised 
of four membrane receptor tyrosine kinases: ErbB1 (HER1 or EGFR), ErbB2 (HER2), 
ErbB3 (HER3), and ErbB4 (HER4) [39]. The activity of the ErbB receptors is dictated 
by the expression of their ligands [6], which can be classified into three groups: Group 1) 
those binding specifically to ErbB1; Group 2) ligands which exhibit dual specificity 
binding to both ErbB1 and ErbB4; and Group 3) neuregulins, which can be further sub-
classified based upon their ability to bind only ErbB4 or both ErbB3 and ErbB4 (Table 
1) [7]. To date, no ligand has been identified as being specific for ErbB2, although this 






Table 1: ErbB receptors and their ligands 
Receptor Ligands 
ErbB1 EGF, Areg, TGFα 
ErbB1 and ErbB4 Btc, HBEGF and Ereg 
ErbB3 and ErbB4 Nrg1 and Nrg2 
ErbB4 Nrg3 and Nrg4 
EGF: Epidermal Growth Factor; Areg: Amphiregulin; TGF: transforming growth factor; Btc: 






When ligands bind to the extracellular domain of the ErbB receptors, receptor 
dimerisation and phosphorylation of intracellular tyrosine kinase domains occur. This 
leads to activation of a cascade of signalling pathways including the mitogen activated 
protein kinases/ extracellular signal regulated kinases (MAPK/ERK), and 
phosphatidylinositol-3'-kinase (PI3K/Akt) pathways [8]. Once activated, these pathways 
lead to changes in both protein functions and activation of gene transcription [8-10], 
leading to interactions with apoptotic signalling, cell proliferation, differentiation, 
migration and survival. These can all promote tumorigenesis [9, 11].  
 
In addition to being expressed on cancer cells, ErbB receptors are also found on healthy 
cells throughout the body. Of specific interest to this review are the receptors expressed 
in the gastrointestinal tract. Specifically, they are abundantly expressed on the 
basolateral membranes of healthy intestinal epithelial cells and are crucial for essential 
normal functions and development in the gut [41, 71]. For example, ErbB receptors 
activated on intestinal epithelial cells cause a cascade of complex signalling pathways 
resulting in maintenance of mucosal integrity via induction of mucus and prostaglandin 
synthesis, promotion of enterocyte migration, prevention of intestinal epithelial cell 
apoptosis, decreasing bacterial translocation and preservation of gut barrier function after 
injury [40, 72]. 
 
The first anti-cancer agents targeting ErbB receptors were developed in the 1980’s. This 
led to the development of the first generation of two overarching subtypes of ErbB 
receptor inhibitors: monoclonal antibodies, and small molecule tyrosine kinase inhibitors 
[73-76]. Monoclonal antibodies are directed against the extracellular domain of ErbB 





TKI activity. The overexpression of ErbB receptors in many solid tumours is correlated 
with advanced stages and often a worse prognosis of the cancer [77]. In many different 
cancer cell types, the ErbB pathway becomes hyper-activated by a range of mechanisms, 
including overproduction of ligands, overproduction of receptors, or constitutive 
activation of receptors [71]. This hyper-activity and hence key role of the ErbB network 
has made it an attractive target for therapies. After an initial response however, patients 
being treated with first generation ErbB TKIs often develop secondary mutations such as 
T790M, MET or HER2 amplifications, resulting in acquired resistance [78]. Ultimately, 
this limits the effectiveness of these first-generation agents over time. Pan-ErbB TKIs 
are now considered second-generation and are resistant to acquired mutations. As a 
result, these TKIs are now commonly used. However, they are associated with clinical 
toxicities which are important to recognise and manage.  
 
ErbB TKIs and diarrhoea 
Toxicities are common in patients receiving first generation ErbB TKIs, including, but 
not limited to erlotinib, gefitinib, and lapatinib. In particular, up to 69% of patients 
experience diarrhoea [61]. Large randomised trials have shown that erlotinib and 
lapatinib induce diarrhoea in 40-60% of patients, with approximately 10% of these 
presenting with grade 3-4 symptoms (National Cancer Institute Common Toxicity 
Criteria) [79, 80]. One of the most frequent toxicities associated with second-generation 
pan-ErbB TKIs is also diarrhoea. Recent clinical data suggests that all grades of 
diarrhoea are more frequently seen with pan-ErbB TKIs than first generation ErbB TKIs 
(e.g. dacomitinib vs. eroltinib). Up to 96% of patients receiving second generation pan-
ErbB TKI’s develop diarrhoea, and perhaps more importantly, the incidence of grade 3 





many TKIs are given daily for months at a time, and side effects are therefore often 
chronic, unlike the acute manifestations typically seen following traditional 
chemotherapy regimens.  
 
Do ErbB TKIs induce diarrhoea via a distinctly different mechanism 
than chemotherapy-induced diarrhoea? 
One common hypothesis for the mechanism of action of diarrhoea following TKI 
treatment is thought to be due to inhibition of ErbB signalling within intestinal epithelia, 
leading to direct mucosal atrophy and damage [82-84]. Research suggested that this 
diarrhoea was associated with reduced growth, characterised by reduced growth and 
healing of the intestinal epithelium leading to mucosal atrophy due to the stimulatory 
effect of ErbB pathway on enterocyte proliferation [85], nutrient and electrolyte transport 
[86], brush border enzyme expression [87] and epithelial restitution being impeded [88]. 
Increased frequency of diarrhoea in patients using oral compounds (e.g. small molecule 
TKI’s) compared to monoclonal antibodies supports this theory. This direct mucosal 
damage hypothesis mimics chemotherapy-induced diarrhoea, bought about by the 








Figure 1: (A) In a normal villus fluid transport is tightly controlled and there is a net absorption of fluid. (B) In chemotherapy induced gut 
toxicity, the villus is blunted and there is less area for absorption of fluid. The manifestation of chemotherapy-induced diarrhoea is largely driven 
by small intestinal changes. (C) Small molecule ErbB TKI induced diarrhoea is likely due to secretory mechanisms within the colon. The tight 







A more recent hypothesis suggests that despite a similar clinical manifestation as is seen 
in traditional chemotherapy induced diarrhoea, ErbB TKI-induced diarrhoea is due to a 
distinctly different pathological mechanism [14, 89]. This followed the recent 
development of a preclinical model to study the gastrointestinal toxicity associated with 
ErbB inhibitors [15]. Using lapatinib, an oral small molecule ErbB1 and ErbB2 TKI for 
7-28 days, this large (n=128) study showed no significant pathology in the intestines of 
rats, despite rats displaying a dose-dependent diarrhoea profile consistent with that 
observed clinically [15]. No significant changes were noted in intestinal weights and no 
significant histopathology was noted in the jejunum or colon, indicating that no 
significant pathology in the intestines occurred as a result of lapatinib treatment [15]. In 
fact, it was found that jejunum crypts were significantly longer, and contained increased 
mitotic cells in rats treated with lapatinib [90]. This is in stark contrast to what is noted in 
mucositis models of rats treated with chemotherapeutic agents such as irinotecan causing 
severe intestinal damage and atrophy [63, 91]. This is therefore highly suggestive that 
the mechanism of ErbB TKI-induced diarrhoea is profoundly different from 
chemotherapy-induced diarrhoea. Further investigation found that serum biochemistry 
levels of chloride were decreased in rats treated with high dose lapatinib, correlating with 
diarrhoea incidence, suggesting that chloride loss via the intestinal lumen may be 
involved in the manifestation of small molecule ErbB TKI induced diarrhoea [90]. 
However, this was inconclusive. Furthermore, studies using another kinase inhibitor, 
flavopiridol, showed no intestinal damage, despite clinical manifestation of diarrhoea 
[92, 93]. Additional investigation showed treatment with flavopiridol directly stimulated 






Paradoxically, a study by Hoda et al. (2010), showed in a chemotherapy model of gut 
toxicity, that chloride secretion was increased in rats treated with methotrexate [95]. 
While the severity and incidence of diarrhoea was not reported, it was suggested by the 
authors that increased chloride secretion may be part of the mechanism responsible for 
chemotherapy induced diarrhoea. However, given the limited evidence of this in the 
wider literature, it requires further investigation.  
 
Other research has also established that ErbB receptors have a limited role in the 
development of mucositis induced diarrhoea [96]. Transgenic mice that overexpress EGF 
(a ligand for ErbB1) in the small intestine, showed no improvements in weight recovery, 
mucosal architecture, apoptosis or proliferation compared to controls following 
fluorouracil, a chemotherapeutic known to induce mucositis [96]. This was also the case 
in mice treated with exogenous EGF following fluorouracil. These findings are highly 
suggestive that the ErbB family of receptors does not play a significant role in the 
development of mucositis associated diarrhoea. Given that ErbB TKIs target these 
receptors, it is likely that their physiological function is critically involved in the 
development of the associated diarrhoea. This supports the indication that ErbB TKIs 
induce diarrhoea via a distinct mechanism to chemotherapy-induced diarrhoea. Together, 
this suggests that the pathogenic mechanisms of ErbB TKI-induced diarrhoea are not 
necessarily the same as for other cancer treatments, and there remains a vast gap in the 
knowledge regarding the biological mechanisms responsible.  
 
Chloride secretion and diarrhoea 
Chloride secretion occurs throughout the length of the gastrointestinal tract and is critical 





has several transmembrane transport pathways. In the colon, chloride is taken into the 
cell via the basolateral membrane through the sodium potassium chloride co-transporter 
in an electro-neutral manner. This process is driven largely by the sodium potassium 
ATPase pump [97]. Potassium channels are also located on the basolateral membranes, 
and allow for potassium recycling and prevention of cellular depolarisation. This 
preserves the electrical driving force for chloride secretion from the apical membrane of 
the cell. Chloride then accumulates in the lumen via the cAMP dependent cystic fibrosis 
transmembrane conductance regulator (CFTR) chloride channels, and the calcium 
activated chloride channels (CaCC). The presence of chloride in the lumen provides the 
electrochemical driving force for paracellular movement of sodium. The resulting 
accumulation of sodium chloride in the lumen provides the osmotic gradient for water to 
flow to the lumen [97]. The normal chloride secretory process is outlined in Figure 2. 
The secretion of chloride ions is important in controlling fluid flow across various 
epithelial surfaces, including the intestine, helping to keep it moist.  
 
There are two key mechanisms whereby chloride secretion is initiated. (1) a cAMP-
dependent pathway; which elicits a delayed and prolonged response and (2) a calcium 
ion-dependent pathway; which elicits a rapid and transient response [98]. The transient 
nature of the calcium ion-dependent response, even in the face of sustained increases in 
intracellular calcium suggests calcium dependent agonists generate an inhibitory signal. 
This inhibitory signal then serves to limit the extent of the chloride secretory response 
[99]. Under normal homeostasis, this process is tightly regulated. However, any 
homeostatic breakdown can lead to various complications, such as diarrhoea where 







Figure 2: Chloride secretory mechanism in normal intestinal epithelium. cAMP, cyclic adenosine monophosphate; CFTR, cystic fibrosis 






ErbB receptors are abundantly expressed on the basolateral membrane of intestinal 
epithelial cells and are critical regulators of intestinal ion transport via multiple 
downstream pathways [10]. The intricate pathways that result from binding and 
dimerisation lead to negative regulation of both chloride secretion and sodium absorption 
[10]. ErbB receptors have been shown to exert both an inhibitory effect on chloride 
secretion (Figure 3) [8]. Binding of EGF to ErbB1 leads to homodimerisation and 
heterodimerisation with ErbB2 exerting an inhibitory effect on chloride secretion 
signalling via PI3K/Akt and PKC pathways; these distinct pathways inhibit the 
basolateral potassium channels (Figure 3) [101, 102].  
 
Based on the negative regulatory roles ErbB receptors play in chloride secretion, it is 
reasonable to suggest that when receptors are inhibited from phosphorylating (as is the 
case with TKIs), they are no longer able to negatively regulate chloride secretion. This 
results in excessive movement of chloride into the lumen, providing the driving force for 
paracellular movement of sodium and subsequently water leading to a secretory 
diarrhoea phenotype. This hypothesis is supported by research with genistein, an 
isoflaovone that acts as an ErbB1 TKI, which has shown to reverse the inhibitory effect 
of EGF on chloride secretion [100, 103]. In contrast however, some TKIs including 
erbstatin analogue, tryphostin A23, tryrphostin A51 and herbimycin A are not associated 
with an increase in epithelial chloride secretion [104].  This is contradictory to the 
increased chloride secretion seen following tyrosine kinase inhibition with other agents 
[104]. This may be explained due to the differing mechanisms of action of each drug, 













TKI and chemotherapy concomitant therapy 
Concomitant chemotherapy and TKIs has increased due to a greater therapeutic 
effectiveness [62]. However, this has meant toxicities increase. A meta-analysis 
including 3918 patients from six trials of erlotinib, gefitinib, and vandetanib found that 
the addition of an ErbB1 inhibitor to a variety of different chemotherapeutics 
significantly increased the severity of diarrhoea [105]. Furthermore, concomitant 
lapatinib with capecitabine increased diarrhoea from 30% (when capecitabine is given 
alone) to 65% in combination. Likewise, the addition of lapatinib with paclitaxel 
increased diarrhoea incidence from 28% to 48% [106]. These combination therapies not 
only result in more severe diarrhoea, but also complicate identifying and treating the 
causes and underlying mechanisms, which are likely to be multifactorial. Understanding 
the mechanisms is important as attributing all mucosal toxicity on the concomitant 
chemotherapy, without considering the TKIs may lead to the wrong intervention [107]. 
Diarrhoea is not always the same and a distinction needs to be made between secretory 
and anatomic derangement diarrhoea in these cases. Diarrhoea seen in patients 
undergoing concomitant TKI/chemotherapy treatment may be due to either the direct 
mechanisms caused by the agents themselves, or amplification of injury mechanisms in 
combination [89]. There are known shared metabolic and drug efflux pathways of 
various TKIs and chemotherapeutic agents, which may explain the more severe 
diarrhoea associated with concomitant therapy. For example, concomitant treatment can 
down-regulate CYP3A4 and UGT1A1, increasing exposure to both TKI and 
chemotherapeutic agents sharing common metabolic pathways which may increase 
toxicity [108, 109]. Additionally, both TKIs and chemotherapeutics are substrates for 





impede drug clearance of the other drug, subsequently drug accumulation can result with 
potentially increased toxicity [110].  
 
While the use of concomitant treatment no doubt contributes to the toxicity profile, 
patients prescribed ErbB TKI monotherapy also demonstrate systemic treatment 
complications. Given the drugs different mechanisms of action, this supports a 
hypothesis suggesting that ErbB TKIs trigger deregulation of chloride channels, driving 
water into the lumen, resulting in a secretory diarrhoea phenotype, as opposed to the 
mucositis driven anatomical derangement diarrhoea phenotype typically seen in 
chemotherapy induced diarrhoea. Given the reduced quality of life associated with 
diarrhoea is further exacerbated in concomitant treatment, further research is crucial. 
 
Pharmacogenetic studies have shown a link between TKI-induced diarrhoea and allelic 
variants of ABCG2, a polymorphic efflux transporter protein (also known as breast 
cancer resistance gene BCRP), highly expressed in the intestines. A common functional 
single-nucleotide polymorphism (SNP) in the ABCG2 gene was associated with 
diarrhoea in patients treated with gefitinib, an ErbB1 small molecule TKI [111]. This 
suggests that patients with reduced ABCG2 activity due to a common genetic variation 
are at increased risk for substrate drug-induced diarrhoea, with implications for 
optimising treatment with small molecule ErbB TKIs. However, further research is 
required before meaningful conclusions can be made.  
 
Current treatment approaches for TKI-induced diarrhoea 
Currently, management of TKI-induced diarrhoea is very similar to management of 





pharmacologic and pharmacologic management strategies. This ignores the probability 
of a differing mechanism of diarrhoea development. 
 
Patient education includes advice on dietary changes for the management of ErbB TKI-
induced diarrhoea, based on dietary changes recommended for chemotherapy induced-
diarrhoea. These dietary modifications include incorporating bananas, rice, apple sauce 
and toast (BRAT diet), as well as increasing water consumption and avoiding 
foods/drinks that contain lactose/caffeine; however, these dietary changes are not 
recommended in anticipation of diarrhoea development [61]. Patients should also avoid 
foods that exacerbate symptoms, such as greasy, spicy and fried items; and foods that are 
difficult to digest. Increasing fluid intake to 2 litres/ per day is recommended to avoid 
dehydration; some fluids should contain sugar or salt to avoid hyponatremia and 
hypokalaemia caused by electrolyte loss associated with diarrhoea [61].  
 
Pharmacologic management of ErbB TKI-induced diarrhoea is largely limited to 
loperamide, with the dose based on the grade of diarrhoea experienced by the patient 
[61]. Loperamide, a synthetic oral opioid drug, works by a number of different 
mechanisms of action that decrease peristalsis and fluid secretion, resulting in longer 
gastrointestinal transit time and increased absorption of fluids and electrolytes from the 
gastrointestinal tract [112]. Alternatives to loperamide are also available for managing 
diarrhoea, however their use and effectiveness can differ by geographic location and the 
diarrhoea severity. Some of these include diphenoxylate–atropine and codeine, either of 
which can be used with loperamide [61]. Dose reductions are not recommended for 
grade 1 diarrhoea. At grade 2, if the patient does not respond to loperamide after 48 





returns to grade 1, at which time the ErbB TKI is resumed, often at a lower dose [61]. It 
is recommended that the ErbB TKI should be permanently discontinued if diarrhoea does 
not reach grade 1 within 14 days despite best supportive care and withholding of the 
ErbB TKI [61]. Patients presenting with grade 3-4 diarrhoea should be admitted to 
hospital for the administration of intravenous fluids and electrolyte replacement.  
 
Potential treatment approaches for TKI-induced diarrhoea 
If the hypothesis of increased chloride secretion being responsible for TKI-induced 
diarrhoea is correct, there may be more effective treatment strategies. If TKI-induced 
diarrhoea is induced by increased chloride secretion, the two major apical channels for 
chloride secretion in enterocytes, CFTR and CaCC, present as promising targets. Ideally, 
these treatment approaches would have minimal systemic absorption, and act on the 
external pore of the chloride channels, to limit systemic effects. While this is appealing 
in terms of reducing systemic absorption, and therefore potential drug interactions and 
toxicities, concerns have been raised in regards to the potential barrier of the inhibitor 
reaching the deep intestinal crypts given the strong convective washout force observed 
during secretory diarrhoeas [113]. CFTR inhibitors include CFTRinh-172, which binds 
to the cytoplasmic side of the channel and stabilises the channel closed state [114], and 
the glycine hydrazides, which target the extracellular CFTR surface in the channel pore 
[113]. CaCC inhibitors are less common and include CaCCinh-A01, a red wine extract 
that has been shown to prevent watery diarrhoea in a mouse model of rotavirus [115]. 
Recently, crofelemer, a natural product extract, was approved for the treatment of 
diarrhoea induced by antiretroviral medication for HIV patients. Crofelemer is extracted 
from the stem bark latex of the croton lechleri tree. It has been shown to dose-





117]. It has been used for many years in Peru and Ecuador to treat diarrhoea, and has 
been investigated for the treatment of traveller’s diarrhoea, infectious diarrhoea and 
diarrhoea predominant irritable bowel syndrome [116, 117]. While the precise 
mechanism of crofelemer is unclear, it is known that the antisecretory activity of 
crofelemer is due to its dual inhibitory action on the two principle Cl- channels in the 
apical membrane of intestinal epithelial cells, CFTR and CaCC [118]. As crofelemer 
effectively inhibits both of the principle Cl- channels, it is an attractive agent to reduce 
secretory diarrhoea. Clinical studies have demonstrated that crofelemer is a safe and 
tolerable drug, with no adverse effects being reported [119-121]. 
 
Conclusion 
With the increasing incidence of malignancy, coupled with the advent of more 
aggressive treatment modalities, ErbB TKI induced diarrhoea remains a significant 
clinical burden and a fuller understanding of the basic biological mechanisms is therefore 
required. The pathogenesis of ErbB TKI induced diarrhoea remains unknown, and 
understanding this is ultimately integral to developing interventions, leading to safer and 
more optimised cancer treatment. The negative regulation of chloride secretion by ErbB 
receptors being disrupted by tyrosine kinase inhibition provides a strong rationale for a 
secretory diarrhoea phenotype hypothesis. Considering the increased utilisation and 
therapeutic efficacy of ErbB TKIs, further research to gain the ability to prevent 
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Chapter 3 Dacomitinib-induced diarrhoea is associated with 
altered gastrointestinal permeability and disruption in ileal 
histology in rats 
This chapter was published in The International Journal of Cancer (Van Sebille, Y.Z., 
Gibson, R. J., Wardill, H.R., Secombe, K.R., Ball, I.A., Keefe, D.M., Finnie, J.W., 
Bowen, J.M. 2017. Dacomitinib-induced diarrhoea is associated with altered 
gastrointestinal permeability and disruption in ileal histology in rats. International 
Journal of Cancer, 140, 2820-2829.) 
 
Abstract 
Dacomitinib – an irreversible pan-ErbB tyrosine kinase inhibitor (TKI) – causes 
diarrhoea in 75% of patients. Dacomitinib-induced diarrhoea has not previously been 
investigated and the mechanisms remain poorly understood. The present study aimed to 
develop an in-vitro and in-vivo model of dacomitinib-induced diarrhoea to investigate 
underlying mechanisms. T84 cells were treated with 1-4 M dacomitinib and resistance 
and viability were measured using transepithelial electrical resistance (TEER) and XTT 
assays. Rats were treated with 7.5 mg/kg dacomitinib daily via oral gavage for 7 or 21 
days (n = 6/group). Weights, and diarrhoea incidence were recorded daily. Rats were 
administered FITC-dextran 2 hours before cull, and serum levels of FITC-dextran were 
measured and serum biochemistry analysis was conducted. Detailed histopathological 
analysis was conducted throughout the gastrointestinal tract. Gastrointestinal expression 
of ErbB1, ErbB2, and ErbB4 was analysed using RT-PCR. The ileum and the colon were 
analysed using multiplex for expression of various cytokines. T84 cells treated with 





dacomitinib developed severe diarrhoea, and had significantly lower weight gain. 
Further, dacomitinib treatment led to severe histopathological injury localised to the 
ileum. This damage coincided with increased levels of MCP1 in the ileum, and 
preferential expression of ErbB1 in this region compared to all other regions.   
This study showed dacomitinib induces severe ileal damage accompanied by increased 
MCP1 expression, and gastrointestinal permeability in rats.  The histological changes 
were most pronounced in the ileum, which was also the region with the highest relative 
expression of ErbB1.    
 
Introduction 
Dacomitinib (PF-00299804) is an orally administered, highly selective irreversible 
small-molecule pan-ErbB receptor tyrosine kinase inhibitor (TKI) under development for 
treatment of recurrent or metastatic non-small cell lung cancer (NSCLC) [42]. It acts by 
covalently binding to the intracellular adenosine triphosphate domain of each of the three 
kinase-active members of the ErbB family (ErbB1, ErbB2 and ErbB4). This effectively 
inhibits phosphorylation of the receptors and therefore downstream signalling [40]. In 
addition to being expressed on cancer cells, the ErbB family are also abundantly 
expressed on the basolateral membrane of healthy gastrointestinal epithelial cells, and 
are crucial for essential functions including maintenance of mucosal integrity via 
induction of mucus and prostaglandin synthesis, promotion of enterocyte migration, 
prevention of intestinal epithelial cell apoptosis, decreasing bacterial translocation and 
preservation of gut barrier function after injury [41, 71, 72].  
 
Dacomitinib is currently in phase III clinical trials for NSCLC and has shown significant 





conventional single receptor inhibitors [48]. Furthermore, dacomitinib has shown to be 
effective against tumours with mutations developed for acquired resistance of targeted 
therapies [123]. However a commonly reported adverse event among all trials has been 
diarrhoea, with up to 78% of patients developing some degree of diarrhoea [124]. Severe 
diarrhoea commonly results in dose reductions and patient withdrawal from clinical trials 
[124]. Of particular clinical importance is dacomitinib is delivered in a continuous 
manner over many months; therefore, to optimise dacomitinib therapy, adequate 
management or prevention of chronic diarrhoea is essential to minimise the impact on 
the patient’s quality of life, increase safety and the ability to complete the course of 
therapy. Currently management for dacomitinib-induced diarrhoea follows that used in 
conventional chemotherapy (daily loperamide), however the mechanisms underlying this 
diarrhoea are likely different [16]. Recent phase II research has investigated both 
antibiotic and probiotic prophylactic treatment for dacomitinib-induced diarrhoea, with 
no change in diarrhoea reported [125]. It is hypothesised that the development of 
dacomitinib-induced diarrhoea differs from conventional chemotherapy-induced 
diarrhoea and does not result due to direct cytotoxicity but rather occurs through 
alternative mechanisms [16, 82]. As such, traditional diarrhoea management may be not 
targeting the underlying changes for optimal management.  Therefore, this study 
assessed direct cytotoxicity in an in vitro model, and then aimed to develop an in vivo rat 
model of dacomitinib-induced diarrhoea, characterising the changes that dacomitinib 






Materials and Methods 
Chemicals  
Dacomitinib (PF-00299804) was kindly provided by Pfizer Pharmaceuticals. For all in 
vivo experiments dacomitinib was suspended in 0.5% (w/w) hydroxypropyl-
methylcellulose to a final concentration of 2 mg/ml. For all in vitro experiments 
dacomitinib was suspended in DMSO. SN38 and TX100 were used as positive controls 
in vitro, both suspended in DMSO. Exposure of DMSO to cells did not exceed 0.01%.  
 
In vitro Model 
The model utilised T84 cells (passage 5-15) derived from a human colorectal carcinoma 
(Culture Collections, Porton Down, UK). Cells were authenticated by Culture 
Collections by DNA profiling and were used within 6 months of receipt. Cells were 
maintained at 37C in 5% CO2/95% air in Dulbecco’s Modified Eagle Medium 
(DMEM)/Ham’s F-12 Nutrient Mixture containing 15mM HEPES, L-glutamine and 
10% foetal bovine serum (FBS) and were routinely screened for mycoplasma infection. 
Cells were seeded at a density of 100,000 cells/cm2 on 1.12 cm2, 0.4 m pore polyester 
transwell inserts (Corning Life Sciences, MA, USA) or at 10,000 cells in 96 well 
microtiter flat-bottom plates (Becton Dickinson, USA) for transepithelial electrical 
resistance (TEER) measurements and cell proliferation (XTT) assays (Roche, Australia) 
respectively. Dacomitinib was diluted to a series of concentrations (1 - 4 M) and 
exposed to cells via the apical side for 24 - 48 hours.  An equivalent dilution of DMSO 
was used as vehicle control treatment. SN-38 (5 M), an inhibitor of topoisomerase 1, 
was used as the positive control as it is recognised for its cytotoxicity [126]. Triton X-





permeabilse T84 cells [127]. All experiments were performed in triplicate and repeated 
twice.  
 
Polyester transwell inserts support a polarised T84 phenotype with functional tight 
junctions; TEER is a measure to assess the integrity of this monolayer [127]. Once cells 
had reached 1000 /cm2, indicating monolayer formation, cells were exposed to varying 
doses of dacomitinib for 24 or 48 hours. Transepithelial electrical resistance (TEER) was 
measured using an EVOM2 epithelial volt-ohm-meter with chopstick electrodes, STX2 
(World Precision Instruments, Sarasota, FL, USA) and area adjusted for analysis using 
the following formula;  
TEER monolayer (/cm2) = [raw TEER () – TEER blank ()/area of membrane (1.12 
cm2)].  
 
XTT assays were conducted on cells exposed to 1 - 4 M dacomitinib in total media for 
24 hours. Following 24 hours exposure, media and dacomitinib were removed and 
replaced with 100 l fresh media and 50 l of XTT solution; composed of 5 ml XTT 
labelling reagent and 100 l of electron coupling reagent (Roche cell proliferation kit, 
Germany). The microtitre plate was incubated again for 6 hours at 37C in 5% CO2/95% 
air. Absorbance was read at 490 nm using Bio Tek Synergy Mx Microplate Reader 
(Bio Tek, Vermont, USA) and Gen5 version 2.00.18 software to assess the cleavage of 
tetrazolium salt XTT in the presence of an electron-coupling reagent, producing a 






In vivo Model and Ethics 
The study was approved by the Animal Ethics Committee of The University of Adelaide, 
and complied with the National Health and Medical Research Council (Australia) Code 
of Practice for Animal Care in Research and Training (2014). Rats were group housed in 
ventilated cages with three to six animals per cage and were on a 12 h light/dark cycle. 
Food and water were provided ad libitum.  
 
Experimental Design 
All experiments were conducted on male Albino Wistar rats (initial age 6 weeks) 
obtained from The University of Adelaide Laboratory Animal Service (SA, Australia). 
Rats were treated with dacomitinib at a dose of 7.5 mg/kg administered daily for 7 or 21 
days, via oral gavage using a soft plastic feeding tube. This treatment schedule mimics 
the clinical oral administration over many weeks and allows assessment of acute damage 
(7 days) and prolonged damage (21 days). Control animals received daily gavage with 
dacomitinib vehicle (0.5% (w/w) hydroxypropyl-methylcellulose. Rats were randomly 
assigned to treatment groups and culled at 7 and 21 days (n = 6/group). Rats were 
anaesthetised using isoflurane inhalation, and were culled via cardiac exsanguination and 
cervical dislocation.  
 
Clinical Assessment of Gastrointestinal Toxicity 
All rats were monitored two times daily for the presence of diarrhoea. Two independent 
assessors quantified diarrhoea using a validated grading system where 0 = no diarrhoea, 
1 = mild diarrhoea with soft stools and perianal staining, 2 = moderate diarrhoea with 
loose stools and perianal staining of fur, 3 = severe diarrhoea with watery stools +/- 





weight loss/gain. Rats were culled if they displayed > 15 % weight loss or significant 
distress and deterioration, in compliance with animal ethical requirements. One animal 
was removed from the study due to > 15 % weight loss from the dacomitinib group. This 
animal was not included in any further analysis. 
 
Tissue Preparation 
At necropsy, the entire gastrointestinal tract from pyloric sphincter to rectum was 
dissected and flushed with saline to remove intestinal contents. Samples of jejunum, 
ileum and colon were collected and either (1) fixed in 10 % formalin for embedding in 
paraffin, (2) had the mucosal surface scraped and stored in RNA-later at -20 C for 
molecular analyses, or (3) had the mucosal surface scraped and snap frozen in liquid 
nitrogen and stored in -80 C for immunological analysis.  Other organs were collected 
as routine and fixed in formalin and embed in paraffin. All histopathological analysis 
was conducted on 5 m sections tissue cut on a rotary microtome and mounted onto 
glass Superfrost microscope slides (Menzel-Gläser, Braunschweig, Germany). Slides 
were scanned using a NanoZoomer (Hamamatsu Photonics, Japan) and assessed with 
NanoZoomer Digital Pathology software view.2 (Histalim, Montpellier, France). 
 
Blood Biochemistry 
Blood samples were collected by cardiac puncture. Serum was separated by 
centrifugation at 3,000 g for 5 min before being analysed by the Department of Clinical 
Pathology, SA Pathology, Adelaide, South Australia. A multiple blood analysis (MBA-






Gastrointestinal Histopathological Analysis 
Haematoxylin and eosin (H&E) staining was performed and a well described total tissue 
injury score was generated based on the occurrences of eight histological criteria in the 
jejunum and ileum, and six criteria in the colon [128, 129]. These criteria were villous 
fusion and villous atrophy (jejunum and ileum only), disruption of brush border and 
surface enterocytes, crypt loss/architectural disruption, disruption of crypts cells, 
infiltration of polymorphonuclear cells and lymphocytes, dilation of lymphatic’s and 
capillaries, and oedema. Each parameter was scored as present = 1, or absent = 0, in a 
blinded fashion. 
 
Goblet Cell Analysis 
Alcian Blue (1 % Alcian Blue 8GX (CI 74240) in 3 % glacial acetic)/ Periodic acid 
Schiff staining was performed on jejunum, ileum and colon. Sections were oxidised in 1 
% periodic acid before washing then treated in Schiff’s reagent. Goblet cells and 
cavitated cells in crypts and villi that were deemed to be greater than 80% complete were 
counted, and a total of at least 15 villi/crypts per section analysed. Data presented as 
average per crypt or villous. All analysis was done in a blinded fashion. 
 
Immunohistochemistry 
Immunohistochemical analysis was performed for apoptosis (caspase 3; Abcam, Vic, 
Australia; #ab4051), and proliferation (Ki67; Abcam, Vic, Australia #ab16667). Changes 
in these parameters are validated markers for altered tissue kinetics in previous models 
of cancer therapy induced-gastrointestinal toxicities [63, 69, 70, 90]. 
Immunohistochemical analysis was performed using Dako reagents on an automated 





the manufacturer. Briefly, sections were deparaffinised in histolene and rehydrated 
through graded ethanol before undergoing heat mediated antigen retrieval using an 
EDTA/Tris buffer (0.37 g/L EDTA, 1.21 g/L Tris; pH 9.0). Retrieval buffer was 
preheated to 65C using the Dako PT LINK (pre-treatment module). Slides were 
immersed in the buffer and the temperature raised to 97C for 20 minutes. After 
returning to 65C, slides were removed and placed in the Dako AutostainerPlus and 
stained following manufactures guidelines. Negative controls had the primary antibody 
omitted. Caspase 3 and Ki67 were quantified by counting the number of positively 
stained cells for 15 crypts. Data presented as average positively stained cells per crypt. 
All analysis was done in a blinded fashion.  
 
Real Time PCR 
To assess the expression of ErbB1, ErbB2 and ErbB4 receptors along the gastrointestinal 
tract, total RNA was isolated from duodenal, jejunal, ileal and colonic mucosal 
scrapings. Purification of mRNA was done using the Nucleospin mRNA purification 
RNA II kit (Macherey-Nagel) following the manufacturer’s protocol. 1 g of RNA was 
reverse transcribed using iScriptTM cDNA synthesis kit (Bio-Rad) according to the 
manufacturer’s protocol. cDNA was quantified and diluted to a working concentration of 
100 ng/l.  Primers for genes of interest were either designed using web-based primer 
design program Primer 3, version 4 (http://bioinfo.ut.ee/primer3-0.4.0/), or in the case of 
ErbB4 purchased from BioRad (Gladesville, Australia). Genes of interest were ErbB1 
(Forward: 5’-CCCACAGCAAGCCTTCTTCA; Reverse: R: 5’-
CACGGCAGCTCCCATTTCTA), ErbB2 (Forward: 5’-
GCTCCTCCTTGAGTTGAGTGT; Reverse: 5’-TAGCCTTGGAATGAGTGCGT) and 





denatured at 95C for 10 seconds, annealed at 52C for 15 seconds, and extended at 
72C for 20 seconds (40-45 cycles). ErbB4 was following manufactures instructions. 
Amplified transcripts were detected by SYBR Green (Quantitect, Qiagen) in a Rotor-
Gene Q (Qiagen). All reactions were completed in triplicate, with two housekeeping 
normaliser primers, UBC (Forward: 5’-TCGTACCTTTCTCACCACAGTATCTAG; 
Reverse: 5’-GAAAACTAAGACACCTCCCCATCA) and B2M (Forward: 5’-
TGACCGTGATCTTTCTGGTG; Reverse: 5’-ATCTGAGGTGGGTGGAACTG). 
Amplification was followed by a melt curve analysis to confirm product specificity. 
Relative gene expression was determined by delta Ct method [130].  
 
Tissue Cytokine Quantification   
Proinflammatory cytokine expression was assessed using 30 mg of ileal and colonic 
mucosal scraping samples. Mucosa samples were homogenised at room temperature 
using the QIAGEN TissueLyser LT (Qiagen) for 5 minutes at 50 Hz in 500 L of the 
Radioimmunoprecipitation Assay (RIPA) buffer (150 mmol/L NaCl, 1.0% IGEPAL CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mmol/L Tris, pH 8.0; Sigma 
Aldrich; #04693116001). Homogenates were centrifuged at 11,000 x g for 15 minutes at 
4C and the supernatant isolated, aliquoted, and stored at -80 C. Total protein 
concentration was quantified using the Pierce BCA Protein Assay Kit (ThermoFisher 
Scientific; #23225). A working concentration of 1 mg/ml was used for cytokine analysis. 
Levels of 7 different cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), 
interleukin-17 (IL-17), tumour necrosis factor alpha (TNF), monocyte chemoattractant 
protein-1 (MCP-1), interleukin-4 (IL-4) and interleukin-10 (IL-10), were measured in 
individual ileal and colonic homogenates using Luminex xMAP technology (Milliplex 





instructions. Each 96 well plate included a 6-point standard curve and two quality 
controls provided by Merck Millipore.   
 
FITC-dextran Assay 
Two hours prior to culling, rats received a 600 mg/kg dose (120 mg/ml) of 4 kDa 
fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, NSW, Australia, Cat# FD4) 
via oral gavage. Blood was collected via cardiac puncture at necropsy into serum-gel 
clotting activator tubes and protected from light. Samples were centrifuged at 3,000 g for 
5 minutes and serum isolated. Serum samples were diluted 1:3 with 1 X PBS and 
quantified using the Bio Tek Synergy Mx Microplate Reader (Bio Tek, Vermont, 
USA) and Gen5 version 2.00.18 software relative to a standard curve (range 0.0001-10 
g/ml).  
 
Statistical Analysis  
Data were compared using Prism version 7.0 (GraphPad Software, San Diego USA). A 
D’Agostino Pearson omnibus test was used to assess normality. When normality was 
confirmed, a two-way analysis of variance (ANOVA) with appropriate post hoc testing 
was performed to identify statistical significance between groups. In other cases, a 
Kruskal-Wallis test with Dunn’s multiple comparisons test and Bonferroni correction 








Dacomitinib Does Not Cause Direct Cytotoxicity to T84 Epithelial Cells 
T84 monolayers exhibited comparable TEER between controls and monolayers treated 
with dacomitinib (1 - 4 M), with no significant differences detected (p > 0.05). TEER 
readings for cells treated with all doses of dacomitinib were significantly higher than 
SN38, the positive control (p < 0.05) (Figure 1A). Cells treated with varying doses of 
dacomitinib (1 - 4 M) had no alterations in cell viability, as measured by XTT 
absorbance, with no significant differences seen between controls (Figure 1B). 
Compared to the positive control (SN38), cells treated with dacomitinib had significantly 
increased viability (p < 0.05) (Figure 1B). Combined these results demonstrate that 






Figure 1 A: Transepithelial electrical resistance (TEER) following dacomitinib exposure (1 – 4 M) for 24 - 48 hours did not decrease (p > 
0.05). Data presented as mean  SEM. Data analysed using two-way ANOVA. B: Absorbance of XTT assay did not decrease following 24 hours 
of dacomitinib exposure (1 - 4 M) compared to controls, but was significantly higher than SN-38 (p < 0.05). Data presented as mean  SEM. 





Dacomitinib Causes Reproducible, Severe Diarrhoea  
Rats treated with vehicle control did not develop diarrhoea at any time point (data not 
shown). Dacomitinib treatment induced diarrhoea in 100% of rats (Figure 2A), 
comparable to the incidence seen in clinical trials [124]. Mild diarrhoea developed in a 
small number of animals from as early as day 2 of treatment, with severe diarrhoea 
manifesting as early as day 3. Diarrhoea incidence peaked from day 7 onward. The 
average number of days with diarrhoea was 14 days.  Rats treated with dacomitinib had 
significantly worse diarrhoea than control rats (p < 0.0001).  
 
Growth rates of dacomitinib treated rats were significantly lower than control rats from 
day 10 (p < 0.0001) (Figure 2B). At day 21, the control group had gained 46.38 ± 2.459 
% body weight compared to day 1, and the dacomitinib group had gained 18.99 ± 5.602 








Figure 2 A: Rats treated with vehicle control did not develop diarrhoea. 100% of rats treated with 7.5 mg/kg dacomitinib developed diarrhoea. 
Diarrhoea data are expressed as a percentage of total animals (per day) with a particular grade of diarrhoea. B: Rats treated with 7.5 mg/kg 
dacomitinib had significantly lower weight gain than controls from day 10 onward (p < 0.0001). Data displayed as a percentage of weight 






Dacomitinib Alters Biochemistry and Histology   
In rats treated with dacomitinib, serum biochemistry revealed mildly elevated alanine 
aminotransferase (ALT) which, in the absence of histological changes in the liver, 
suggested increased permeability of hepatocyte cell membranes with leakage of this 
cytosolic enzyme into the blood (Supplementary Table 1). There was also a modest 
increase in blood urea nitrogen (BUN) and creatinine, particularly at 21 days, indicating 
mild renal dysfunction (Supplementary Table 1). A mild hypoalbuminemia was probably 
attributable to a combination of malabsorption due to villous atrophy, protein-losing 
enteropathy associated with severe diarrhoea, and renal proteinuria. All other MBA-20 
analytes were within the normal range (Supplementary Table 1). Kidneys of all rats, 
except one, treated with dacomitinib for 21 days showed acute papillary necrosis with 
severe coagulation necrosis of medullary tubules and collecting duct epithelium, either 
complete or with intraluminal, desquamated, necrotic epithelial cells and few, usually 
degenerating, lining epithelial cells with marked interstitial congestion. One rat treated 
with dacomitinib for 21 days showed mild hydronephrosis, with dilation of renal pelvis 
and patchy distension of tubules and collecting ducts. Rats treated with dacomitinib for 7 
days exhibited mild glomerulopathy with thickening of the glomerular basement 
membranes.  
 
Dacomitinib Causes Significant ileal Damage  
Rats treated with dacomitinib had significant ileal injury compared to controls at both 
time points (p < 0.0001). This was predominantly characterised by severe villus atrophy 
with stunting and fusion of villi, which was also attended by enterocyte metaplasia to a 
low columnar or cuboidal phenotype and mild compensatory expansion of the basal 





increased inflammatory infiltrate comprised of lymphocytes, macrophages, plasma cells 
and neutrophils, and dilation of lacteals (villous lymphatics) (Figure 3). There were no 
significant differences in tissue injury at any time point in the jejunum and colon (data 
not shown). Across both treatment groups no significant differences for both total 
number of goblet cells or percentage cavitated goblet cells in the jejunum, ileum or colon 








Figure 3 Histological injury was significantly increased in the ileum in rats treated with 
dacomitinib at both day 7 (p <0.0001) and day 21 (p <0.0001). Histological injury was 





metaplasia to a low columnar or cuboidal epithelium (indicated by black arrows), and 
increased inflammatory component in the lamina propria (indicated by black cross). 
There was no significant change in histological injury in the jejunum or colon. Tissue 






Dacomitinib Did Not Alter Gastrointestinal Apoptosis or Proliferation 
To assess gastrointestinal epithelial apoptosis, the number of caspase-3 positively stained 
crypt cells were counted and means calculated. Gastrointestinal apoptosis was not 
changed following dacomitinib treatment in the crypts of the jejunum at day 7 
(dacomitinib 0.11  0.053 vs control 0.04  0.02) or day 21 (dacomitinib 0.24  0.05 vs 
control 0.10  0.03). Gastrointestinal apoptosis was not changed following dacomitinib 
treatment in the crypts of the ileum at day 7 (dacomitinib 0.03  0.02 vs control 0.03  
0.01) or day 21 (dacomitinib 0.03  0.01 vs control 0.02  0.02). Gastrointestinal 
apoptosis was not changed following dacomitinib treatment in the crypts of the colon at 
day 7 (dacomitinib 1.27  0.37 vs control 1.20  0.27) or day 21 (dacomitinib 0.94  
0.17 vs control 0.82  0.18). To assess proliferation within crypts, the number of Ki-67 
positively stained cells were counted and means calculated. Gastrointestinal proliferation 
was not changed following dacomitinib treatment in the crypts of the jejunum at day 7 
(dacomitinib 21.72  0.53 vs control 21.07  0.07) or day 21 (dacomitinib 18.82  1.31 
vs control 22.70  0.68). Gastrointestinal proliferation was not changed following 
dacomitinib treatment in the crypts of the ileum at day 7 (dacomitinib 33.71  3.60 vs 
control 38.81  2.63) or day 21 (dacomitinib 39.02  1.66 vs control 40.57 1.84). 
Gastrointestinal proliferation was not changed following dacomitinib treatment in the 
crypts of the colon at day 7 (dacomitinib 12.85  0.87 vs control 14.56  3.74) or day 21 
(dacomitinib 11.91  2.30 vs control 16.22  1.88). 
 
ErbB1 Receptor is Highly Expressed in the Ileum 
The mRNA expression of ErbB1 was significantly higher in the ileum compared to the 





The expression of ErbB2 and ErbB4 was unchanged throughout the gastrointestinal tract 
(p > 0.05). Treatment with dacomitinib did not change the expression of the ErbB 







Figure 4 ErbB1 expression is significantly higher in the ileum compared to other areas of the gastrointestinal tract (p = 0.0336). Relative mRNA 






Dacomitinib Treatment Increases Levels of monocyte chemoattractant protein-1 
(MCP-1) in the ileum  
There were significant increases in the expression of MCP-1 in the ileum of rats treated 
with dacomitinib compared to controls (p = 0.001). No changes were seen in the colon. 
Rats treated with dacomitinib showed no statistically significant change in IL-1, IL-6, 
IL-17, TNF, IL-4, and IL-10 expression in the ileum or colon when compared to 








Figure 5 Cytokine expression in the mucosa of the ileum and colon. MCP-1 was significantly increased in the ileum of rats treated with 
dacomitinib (p = 0.001) compared to controls. Data presented as mean with SD (pg/mL). Multiple t-tests were performed to identify statistical 






Dacomitinib Caused Increased Gastrointestinal Permeability  
Serum FITC-dextran levels were elevated in rats treated with dacomitinib compared to 








Figure 6 Serum FITC-dextran levels were significantly increased in rats treated with dacomitinib (p = 0.0018) indicating intestinal barrier 







Dacomitinib is an emerging small molecule TKI for the treatment of NSCLC, with 
clinical trials showing diarrhoea as an adverse event in over 75% of patients [124]. The 
mechanisms of ErbB TKI-induced diarrhoea are unclear with conflicting hypotheses 
presented in the literature [16]. The present study found dacomitinib does not cause 
direct cytotoxicity to T84 epithelial cells, supporting the study hypothesis, and previous 
literature suggesting that ErbB TKI induced-diarrhoea is not due to direct cell death [14, 
89]. However, this may be explained because of the colorectal origin of T84 cells, as in 
rats dacomitinib causes diarrhoea that appears associated with histopathological 
alterations in the ileum and intestinal barrier disruption. This is the first time 
gastrointestinal morphometry and function have been characterised following 
dacomitinib, demonstrating dacomitinib causes histopathological damage confined to the 
ileum in rats. In murine models of ErbB TKI-induced gastrointestinal side effects, there 
has previously been evidence of histological changes characterised by villous atrophy 
[82-85, 87].  
 
TKI’s have previously been associated with diarrhoea, and this has been largely 
hypothesised to be of a secretory phenotype [16, 82]. In a previous rat model of 
lapatinib-induced diarrhoea, blood biochemistry showed a significant decrease in serum 
chloride. This decrease coincided with diarrhoea in rats treated with high-dose lapatinib, 
suggesting a possible secretory diarrhoea phenotype [90]. However, in the current study 
we saw no changes in serum chloride suggesting negligible secretory processes. 
Although not the primary focus of the study, the findings from blood biochemistry 
indicate rats treated with dacomitinib had significant changes in renal biochemistry, with 





clearance of dacomitinib being only minimal [131]. As such, the renal pathology seen in 
this model is likely to be a species-specific response to high dose dacomitinib.  The 
increased level of liver enzymes seen in the present study is consistent with elevations 
noted clinically [131], and are unsurprising given that dacomitinib is largely metabolised 
by the liver through oxidative and conjugative metabolism [131].  
 
Traditional chemotherapeutic agents are known to cause severe gastrointestinal 
cytotoxicity, resulting in histological damage manifesting as anatomic derangement 
diarrhoea [63, 129]. However, throughout the literature there are conflicting findings 
regarding the histopathological changes in the gastrointestinal tract associated with ErbB 
TKI-induced diarrhoea [16]. For example, a recent study by Bowen et al, (2012) showed 
lapatinib-induced diarrhoea was not associated with gastrointestinal histopathological 
changes, typically associated with anatomic derangement diarrhoea [15]. Hare et al 
(2007) showed treatment with gefitinib in a murine model was associated with villous 
atrophy, confined to the duodenum only [132]. However, Rasmussen et al (2010) 
suggested that inhibition of the ErbB receptors with erlotinib causes direct mucosal 
atrophy and damage, which, similar to this study, was most pronounced in the ileum of 
mice [83]. The present study showed largely negative results, with marginal changes 
noted in the jejunum or colon. However, significant histopathological changes were 
noted in the ileum, characterised by significant villus atrophy. Unlike traditional 
chemotherapy-induced diarrhoea, villus shortening and blunting was localised to the 
ileum, with terminally differentiated enterocytes being the most affected. There were 
only mild compensatory changes in the deep crypt progenitor compartment and no 





an alternative mechanism may be responsible for the changes seen following dacomitinib 
treatment.  
 
While small intestinal damage has previously been attributed to greater exposure of the 
unabsorbed drug to the mucosal surface compared to the colon [133], this is not a 
plausible explanation in the current study, as the jejunum showed minimal  
histopathological damage. The differential expression or ErbB receptors through regions 
of the gastrointestinal tract has not been previously characterised. Data from the present 
study indicates ErbB1 is preferentially expressed in the ileum compared to other regions 
of the gastrointestinal tract. It is therefore possible that the high degree of histopathology 
observed in the ileum may be linked to the high expression of ErbB1. Unlike first 
generation ErbB TKIs that are susceptible to mutations that affect binding affinity, 
second generation ErbB TKIs (such as dacomitinib) are irreversible and resistant to 
mutations, they have therefore demonstrated a higher binding affinity [134]. This may 
account for the more severe ileal damage seen in our model, and the associated 
diarrhoea.   
 
Elevated MCP-1 was evident in the ileum, suggesting an inflammatory response 
characterised, in part, by monocyte infiltration, which may contribute to the ileal tissue 
injury. This is of particular significance as inflammation has been associated with the 
induction of a ‘leaky’ gut [135, 136]. Mucosal enterocyte barrier disruption has been 
associated with a number of gastrointestinal pathologies characterised by diarrhoea 
[137]. It has been suggested that altered intestinal permeability worsens clinical 
outcomes, as it allows for translocation of endotoxin and bacteria [136]. Additionally, it 





diarrhoea through leak-flux mechanisms allowing passive movement of water into the 
lumen [138]. Our findings partially support this with increased serum FITC-dextran seen 
following dacomitinib treatment. The increased gastrointestinal permeability noted in 
this study is most likely indicative of tight junction disruption, the main regulators of 
paracellular permeability. Tight junctions join the apical margins of adjacent enterocytes 
and, while permeable to small molecules and water, form a barrier to transepithelial 
macromolecular movement; the basolateral aspect of enterocytes is the site of Na-K-
dependent ATPase that drives the sodium pump. Further studies are required to examine 
the impact of dacomitinib on specific tight junction proteins. Although barrier 
dysfunction is emerging as a key driver of chemotherapy induced diarrhoea, this is the 
first study to implicate barrier dysfunction in the development of TKI induced diarrhoea, 
and will form the basis of further investigation.  
 
Conclusion 
In summary, this study has shown that dacomitinib induces severe ileal damage and 
gastrointestinal permeability in this model.  The high expression of ErbB1 in the ileum, 
was also accompanied by the localised damage seen only in this region. This is the first 
study to provide a detailed interrogation of the intestinal changes associated with 
dacomitinib treatment and advances our understanding of diarrhoea processes induced by 
not only this agent, but assists in further characterising the poorly understood 






 7 day 21 day 
Control Dacomitinib Control Dacomitinib 
Sodium (mmol/L) 137.50 138.50 139.50 140.00 
Potassium (mmol/L) 7.88 7.98 6.80 6.95 
Chloride (mmol/L) 99.33 102.00* 100.00 99.33 
Bicarb (mmol/L) 31.17 29.83 29.33 27.50 
Anion gap (mmol/L) 14.83 14.50 17.00 19.17* 
Glucose (mmol/L) 8.82 8.55 9.15 7.12 
Urea (mmol/L) 6.77 5.83 6.40 12.38 
Creatinine (umol/L) 9.167 12.17 21.33 39.33* 
Cholesterol (mmol/L) 2.40 2.48 1.75 1.75 
Urate (mmol/L) 0.12 0.13 0.14 0.09 
Phosphate (mmol/L) 2.89 3.14 2.73 2.74 
Total Ca (mmol/L) 2.62 2.51 2.54 2.42 
Albumin (g/L) 11.83 10.50 13.33 10.67* 
Globulin (g/L) 36.50 35.55 40.33 43.67 
Protein (g/L) 48.33 45.83 53.67 54.33 
ALP (U/L) 395.80 268.70 238.80 205.80* 
ALT (U/L) 77.00 90.00 67.17 89.50 
AST (U/L)  107.80 148.70 153.00 218.70 
LD (U/L) 680.20 1269.00 1658.00 2208.00 






alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate 
aminotransferase, LD: lactate dehydrogenase. *indicates significantly different from 
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Abstract 
Dacomitinib, an irreversible small-molecule pan-ErbB TKI, has a high incidence of 
diarrhoea which has been suggested to be due to chloride secretory mechanisms. Based 
on this hypothesis, crofelemer, an anti-secretory agent may be an effective intervention. 
T84 monolayers were treated with 1µM dacomitinib and 10µM crofelemer, and mounted 
into Ussing chambers for electrogenic ion analysis. Crofelemer attenuated increases in 
chloride secretion in cells treated with dacomitinib. Albino Wistar rats (n=48) were 
treated with 7.5 mg/kg dacomitinib and/or 25 mg/kg crofelemer via oral gavage for 21 
days. Crofelemer significantly worsened dacomitinib-induced diarrhoea (p=0.0003), and 
did not attenuate weight loss (p<0.0001). Sections of the ileum and colon were mounted 
into Ussing chambers, and secretory processes analysed. This indicated that crofelemer 
lost its anti-secretory action in the presence of dacomitinib in this model. Mass 
spectrometry revealed that crofelemer did not change serum concentration of 
dacomitinib. Serum FITC dextran levels indicated that crofelemer was unable to 
attenuate dacomitinib-induced barrier dysfunction. Tight junction proteins were 
visualised with immunofluorescence. Qualitative analysis showed dacomitinib induced 





attenuated by crofelemer. Detailed histopathological analysis showed that crofelemer 
was unable to attenuate dacomitinib-induced ileal damage. Crofelemer worsened 
dacomitinib-induced diarrhoea, suggesting that antisecretory drug therapy may be 
ineffective in this setting. 
Introduction 
Dacomitinib (PF-00299804) is an orally administered, irreversible small-molecule pan-
ErbB receptor tyrosine kinase inhibitor (TKI) under development for the treatment of 
recurrent or metastatic non-small cell lung cancer (NSCLC) [42]. Dacomitinib acts by 
covalently binding to the intracellular adenosine triphosphate domain of each of the three 
kinase-active members of the ErbB family (ErbB1, ErbB2 and ErbB4). This effectively 
inhibits phosphorylation of the receptor and therefore inhibits downstream signalling 
[40]. The most commonly reported adverse event associated with dacomitinib therapy 
has been diarrhoea, with an incidence of around 73% [124]. Although less common, 
severe diarrhoea can result in dose reductions (28%), treatment interruptions (12%) and 
treatment discontinuation (8%) from clinical trials [139]. Of particular clinical 
importance, dacomitinib is delivered in a continuous manner over many months, 
meaning diarrhoea is often prolonged, and as such, impacts significantly on quality of 
life. Currently the treatment for TKI-induced diarrhoea is loperamide or octreotide, 
however very few studies have looked at antidiarrhoeal agents in a targeted approach 
[61, 140-142].  
 
Research in our laboratory has recently indicated that ErbB TKIs induce diarrhoea due to 
chloride secretory mechanisms [16]. ErbB receptors are abundantly expressed on the 
basolateral membrane of healthy intestinal epithelial cells, and are crucial for normal 





receptors in healthy settings are negative regulators of chloride secretion [41, 71]. This 
study therefore hypothesised that inhibition of these receptors through the action of 
dacomitinib would result in a loss of the negative regulation of chloride, thus resulting in 
a secretory diarrhoea phenotype.  
 
Crofelemer is an antisecretory antidiarrhoeal proanthocyanidin oligomer extracted from 
Croton lechleri. It is approved by the U.S Federal Drug Administration (FDA) for the 
treatment of diarrhoea induced by antiretroviral medication for HIV patients and has 
been proposed as an intervention for pertuzumab-induced diarrhoea [143]. Crofelemer 
inhibits the two principal apical channels for chloride secretion in enterocytes, with 
partial inhibition of the cAMP –dependent cystic fibrosis transmembrane conductance 
regulator (CFTR) and complete inhibition of the calcium activated chloride channel 
(CaCC) [118]. Clinical studies have demonstrated that crofelemer is a safe and tolerable 
drug, with no adverse effects being reported [119-121]. Crofelemer is also appealing 
because it is too large and polarised to be systemically absorbed, limiting any systemic 
effects including drug interactions and toxicities [16]. Therefore, this study investigated 
the effect of dacomitinib and crofelemer on chloride secretion in vitro, and then 
translated the study to a preclinical rat model of dacomitinib-induced diarrhoea.  
 
Materials and Methods 
Chemicals 
Dacomitinib (PF-00299804) was kindly provided by Pfizer. Dacomitinib is soluble in 
dimethyl sulfoxide (DMSO) at 19 mg/ml. Aliquots of dacomitinib in DMSO (Sigma 
Aldrich) were added to Ringer’s solution (composition in mmol/L: NaCl 115.4; KCl 5; 





concentration. Appropriate volumes were added to Ussing chambers to reach a final 
concentration of 1 M with previous studies demonstrating doses above this result in off-
target or non-specific effects [144]. Secretory effects below 1 M are therefore more 
likely to be due to the specific effect of the drug on its designed molecular target. 
Crofelemer (Salix Pharmaceuticals) was diluted with DMSO to 21 mg/ml (10 mM) and 
was diluted in ringer solution and administered at 10 M. This dose has previously been 
shown to inhibit secretagogue activated chloride secretion in T84 cells [118]. Exposure 
of DMSO to cells did not exceed 0.01%. The same concentration of DMSO was used as 
a vehicle control. For all in vivo experiments, dacomitinib was suspended in 0.5% (w/w) 
hydroxypropyl-methylcellulose (Sigma Aldrich) in sterile distilled water to a final 
concentration of 2 mg/ml. Crofelemer was suspended to a final concentration of 5 mg/ml 
in sterile distilled water. 
 
In vitro Model 
Cell Preparation and Maintenance 
This study utilised T84 cells (passage 5-15) derived from a human colorectal carcinoma 
(Culture Collections, Porton Down, UK). Cells were certified mycoplasma-free and 
authenticated by Culture Collections by DNA profiling and used within 6 months of 
receipt. Cells were maintained at 37C in 5% CO2/95% air in Dulbecco’s Modified Eagle 
Medium (DMEM)/Ham’s F-12 Nutrient Mixture containing 15mM HEPES, L-glutamine 
and 10% foetal bovine serum (FBS) supplemented with 1 % 
penicillin/gentamicin+fungizone and were grown in sterile, multi-well tissue culture 
plates under identical growth conditions. The T84 cell line retained its original 
morphology and growth characteristics over the range of passages used. Cells were 





inserts (Corning Life Sciences, MA, USA). Cell culture media in both the apical and 
basolateral chambers was changed every 48 hours. Transepithelial electrical resistance 
(TEER) was monitored daily using an EVOM2 epithelial volt-ohm-meter with chopstick 
electrodes (World Precision Instruments, Sarasota, FL, USA) for 1 week during the 
growth period and area adjusted for analysis using the following formula; TEER 
monolayer (Ω/cm2) = [raw TEER (Ω) – TEER blank (Ω)]/area of membrane (cm2).  
 
In vitro Electrophysiological Studies using Ussing Chambers 
To test whether dacomitinib increased intestinal epithelial cell Cl- secretion, short-circuit 
current (Isc) was measured in T84 cells in symmetrical physiological solutions in Ussing 
chambers. Once adequate resistance was reached (determined by TEER of > 1000 Ω 
cm2)[127], T84 monolayers were then placed onto 1.12 cm2 aperture sliders (Physiologic 
Instruments; P2302) and mounted into Ussing chambers and continuously bathed in an 
oxygenated, glucose-fortified Ringer’s solution at 37C. Cells were voltage clamped to 
zero potential difference by the application of short-circuit current (Isc) and baseline 
established. Cells were allowed to equilibrate for 20 minutes and before dacomitinib and 
crofelemer were administered. Dacomitinib was administered at a range of time points, 
with 15 minutes showing peak intestinal secretion, this time point was used for all 
further analyses. Both dacomitinib and crofelemer were administered in the Ussing 
chamber to the apical side. Crofelemer was added first, followed by dacomitinib after 10 
minutes. Once cells had been exposed to dacomitinib for 15 minutes, the baseline Isc 
(A/cm2) was determined as the mean over a 5-min period (5 values) immediately prior 
to administration of secretagogues. Cells were pretreated via the apical chamber with 
amiloride (20 mol/L), to inhibit the apical epithelial sodium channel before being 





The Isc response was then measured and determined as the change in Isc following 
agonist administration (A/cm2), representing stimulated chloride secretion using 
Acquire and Analyze software 2.3 (Physiologic Instruments). 
 
In vivo Model 
 Ethics 
The study was approved by the Animal Ethics Committee of The University of Adelaide 
(approval number: M215-13), and complied with the National Health and Medical 
Research Council (Australia) Code of Practice for Animal Care in Research and Training 
(2014). All experiments were conducted in male Albino Wistar rats (initial age 
approximately 6 weeks) obtained from The University of Adelaide Laboratory Animal 
Service (SA, Australia). Rats were group housed in ventilated cages with three to six 
animals per cage. They were housed in approved conditions on a 12-hour light/dark 
cycle. Food and water were provided ad libitum.  
 
 Experimental Design  
Rats were treated with crofelemer (25 mg/kg) and dacomitinib (7.5 mg/kg) administered 
daily for 21 days, both via oral gavage using a soft plastic feeding tube. Control animals 
received daily gavage with dacomitinib vehicle (0.5% (w/w) hydroxypropyl-
methylcellulose) and crofelemer vehicle (sterile distilled water). The dose volume for 
oral gavage was approximately 5 ml/kg. Rats were randomly assigned to treatment 
groups and killed at 21 days (n = 6/group). Rats were anaesthetised using isoflurane 






 Clinical Assessment of Gastrointestinal Toxicity 
All rats were monitored twice daily for the presence of diarrhoea for the duration of the 
study. Diarrhoea was quantified by two independent assessors using a well-established 
grading system where 0 = no diarrhoea, 1 = mild diarrhoea with soft stools and perianal 
staining, 2 = moderate diarrhoea with loose stools and perianal staining of fur, 3 = severe 
diarrhoea with watery stools +/- mucous and fur staining incorporating hind legs [15].  
Rats were weighed daily to track weight loss/gain. Rats were killed if they displayed > 
15 % weight loss from baseline or significant distress and clinical deterioration, in 
compliance with animal ethical requirements.  
Tissue Preparation 
At necropsy, the entire gastrointestinal tract from pyloric sphincter to rectum was 
dissected and flushed with saline to remove intestinal contents. Both the small and large 
intestines were weighed immediately after resection. Samples of jejunum, ileum and 
colon were collected and (1) fixed in 10 % formalin for embedding in paraffin, or (2) 
were placed in Ringer’s solution with 10 M indomethacin for Ussing chamber 
experiments.   
 
 In vivo Electrophysiological Studies using Ussing Chambers 
Distal colon and ileum tissue was cut longitudinally along the mesentery and external 
muscle layers were carefully dissected and removed under micro-dissection microscopes 
in a Ringer’s/indomethacin solution. Tissue was then immediately placed onto 0.5 cm2 
aperture sliders (Physiologic Instruments; P2305), mounted into Ussing chambers 
(Physiologic Instruments; #EM-CSYS-8) and continuously bathed in an oxygenated, 
glucose-fortified ringer solution at 37C for electrophysiological analysis. The 





circuit current (Isc) and baseline established. Throughout the experiment, the epithelium 
was continuously short-circuited by the automatic voltage clamp device with correction 
for solution resistance. In 1 min intervals, a voltage step of ±2 mV (U) was applied to the 
tissue and the change in short-circuit current (Isc) measured. Tissue was allowed to 
equilibrate for 20 minutes and baseline Isc (A/cm2) was determined as the mean over a 
5-min period (5 values) immediately prior to administration of secretagogues. Tissue was 
pretreated via the apical chamber with amiloride (20 mol/L), to inhibit the apical 
epithelial sodium channel before being treated with carbachol (Ca2+ agonist; 100 
mol/L) applied to the basolateral chamber. The Isc response was then measured and 
determined as the change in Isc following agonist administration (A/cm2), representing 
stimulated chloride secretion using Acquire and Analyze software 2.3 (Physiologic 
Instruments). 
 
 Serum Drug Analysis 
Determination of serum dacomitinib concentration (range 3-10000 ng/ml) by liquid 
chromatography/ mass spectrometry (LC/MS/MS) was conducted at the Pharmaceutical 
Science Sector Laboratory, School of Pharmacy and Medical Sciences, University of 
South Australia under GLP conditions. Blood samples were collected by cardiac 
puncture and serum separated. Dacomitinib and the internal standard was extracted from 
serum using a protein precipitation clean up, before separation by HPLC on a 
Phenomenex Luna C18 reverse phase column. Elutes were monitored by an API 3000 
MS/MS detector operated in positive MRN mode. Samples with dacomitinib 






 FITC-dextran Assay 
Two hours prior to culling, rats received a 600 mg/kg dose (120 mg/ml) of 4 kDa 
fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, NSW, Australia, Cat# FD4) 
via oral gavage. Blood was collected via cardiac puncture at necropsy into serum-gel 
clotting activator tubes and protected from light. Samples were centrifuged at 3,000 g for 
5 minutes and serum isolated. Serum samples were diluted 1:3 with 1 X phosphate buffer 
solution (PBS) and quantified using the Bio Tek Synergy Mx Microplate Reader (Bio 
Tek, Vermont, USA) and Gen5 version 2.00.18 software relative to a standard curve 
(range 0.0001-10 g/ml).  
 
 Histopathological Analysis 
Hematoxylin and eosin (H&E) staining was performed on 5 m sections of jejunum, 
ileum, and colon cut on a rotary microtome and mounted onto glass Superfrost 
microscope slides (Menzel-Gläser, Braunschweig, Germany). Slides were scanned using 
a NanoZoomer (Hamamatsu Photonics, Japan) and assessed with NanoZoomer Digital 
Pathology software view.2 (Histalim, Montpellier, France). The occurrences of eight 
histological criteria in the jejunum and ileum were examined to generate a total tissue 
injury score [136]. These criteria were villous fusion, villous atrophy, disruption of brush 
border and surface enterocytes, crypt loss/architectural disruption, disruption of crypts 
cells, infiltration of polymorphonuclear cells and lymphocytes, dilation of lymphatics 
and capillaries, and oedema. In the colon, the latter six criteria were examined. Each 







Immunohistochemical analysis was performed for apoptosis (caspase 3; Abcam, Vic, 
Australia; #ab4051), and proliferation (Ki67; Abcam, Vic, Australia #ab16667. 
Immunohistochemical analysis was performed using Dako reagents on an automated 
machine (AutostainerPlus, Dako, Denmark) following standard protocols supplied by 
the manufacturer. Briefly, sections were deparaffinised in histolene and rehydrated 
through graded ethanol before undergoing heat mediated antigen retrieval using an 
EDTA/Tris buffer (0.37 g/L EDTA, 1.21 g/L Tris; pH 9.0). Retrieval buffer was 
preheated to 65C using the Dako PT LINK (pre-treatment module). Slides were 
immersed in the buffer and the temperature raised to 97C for 20 minutes. After 
returning to 65C, slides were removed and placed in the Dako AutostainerPlus and 
stained following the manufacture’s guidelines. Negative controls had the primary 
antibody omitted. Caspase 3 and Ki67 were quantified by counting the number of 
positively stained cells for 15 crypts. Data presented as average positively stained cells 
per crypt. All analysis was done in a blinded fashion.  
 
 
 Tight Junction Analysis 
Immunofluorescence was carried out on 5 m sections of ileum and colon, cut on a 
rotary microtome, and mounted onto FLEX IHC microscope slides (Flex Plus Detection 
System, Dako; #K8020). Immunofluorescence analysis was performed for key tight 
junction proteins: claudin-1 (Abcam Ab15098; 2 g/ml; 1:100; Alexa Fluor anti-rabbit 
568 nm), ZO-1 (Invitrogen 61-7300; 2.5 g/ml; 1:100; Alexa Fluor anti-rabbit 568 nm), 
and occludin (Invitrogen 33-1500; 5 g/ml; 1:100; Alexa Fluor anti-rabbit 568 nm). 





(AutostainerPlus, Dako; #AS480) following standard protocols supplied by the 
manufacturer. Briefly, sections were deparaffinised in histolene and rehydrated through 
graded ethanol before undergoing heat-mediated antigen retrieval using an EDTA-NaOH 
buffer (0.37 g/L EDTA, pH 8.0). Retrieval buffer was preheated to 65C using Dako PT 
LINK (pretreatment module; Dako; #PT101). Slides were immersed in the buffer and the 
temperature raised to 97C for 20 minutes. After returning to 65C, slides were placed in 
the Dako AutostainerPlus, and returned to room temperature with the buffer applied. 
Tissue was blocked using 10% normal horse serum in 1 X PBS. The primary antibodies 
were applied for 1 hour using 5% normal horse serum as a diluent. A fluorescently 
labeled secondary antibody (donkey anti-rabbit or mouse IgG [H+L] secondary antibody, 
Alexa Fluor 568 conjugate, Invitrogen; #A10042) was applied at 0.8 g/ml for a further 
1 hour, using 1 X PBS + 1% BSA (Sigma-Aldrich; #A2058) and 2% FBS (Sigma-
Aldrich; #F2442) as a diluent. Slides were washed using 1 X PBS; counterstained using 
1 g/ml 4’,6-diamidino-2-phenylidole (DAPI; Life Sciences; #D1306), and cover slipped 
using an aqueous mounting medium (Fluorshield, Sigma-Aldrich; #F6182). Negative 
controls had the primary antibody omitted. Slides were visualised using the SP5 Spectral 
Scanning Confocal Microscope (Leica). Four areas from each tissue were imaged (40 X 
magnification) providing a range of areas for both qualitative and quantitative analysis.  
Immunofluorescence was assessed qualitatively for staining distribution in a blinded 
fashion. Quantitative analysis was conducted using ImageJ software. Briefly, channels 
were separated and RGB images converted to 8-bit. Automated thresholding was 
performed using the MaxEntropy algorithm, chosen based on qualitative assessment of 
its ability to identify tight junctions, and exclude non-specific staining [145, 146]. 
Epithelium only was selected, and total stained area was calculated and expressed as a 






Data were compared using Prism version 7.0 (GraphPad Software, San Diego USA). A 
D’Agostino Pearson omnibus test was used to assess normality. When normality was 
confirmed, a two-way analysis of variance (ANOVA) with appropriate post hoc testing 
was performed to identify statistical significance between groups. In other cases, a 
Kruskal-Wallis test with Dunn’s multiple comparisons test and Bonferroni correction 
was performed. Diarrhoea was assessed using a Chi-square test. A p-value of < 0.05 was 
considered significant.  
 
Results 
Crofelemer Inhibits Dacomitinib-Induced Chloride Secretion in vitro 
To test the hypothesis of dacomitinib inducing diarrhoea via a secretory mechanism, 
short-circuit current (Isc) was measured to assess intestinal cell Cl- secretion in T84 
colonic cells in symmetrical physiological solutions. Previous studies have shown that Isc 
is reflective of changes in transepithelial chloride secretion in T84 cells [147, 148]. 
Figure 1A shows baseline Isc, after cells have been exposed to dacomitinib and/or 
crofelemer, but with no agonist administration. Baseline Isc significantly increased 
following dacomitinib treatment (p < 0.0001; figure 1A) and crofelemer inhibited this 
dacomitinib-induced increase in Isc (p < 0.0001; figure 1A). Administration of CaCC 
agonist – carbachol – increased Isc in cells treated with dacomitinib (figure 1B). 








Figure 1 Baseline short-circuit current (Isc) and change in Isc following CaCC agonist carbachol. T84 monolayers were mounted into Ussing 
chambers and treated with dacomitinib (1 M) and crofelemer (10 M) via the apical chamber. A: Increased baseline Isc was seen in cells 
treated with dacomitinib (p < 0.0001) which was attenuated with crofelemer (p < 0.0001). B: Increased delta Isc was also seen in cells treated 
with dacomitinib following the administration of carbachol, a CaCC agonist, this was also attenuated with crofelemer (p <0.0001). Data 





Crofelemer is ineffective at reducing dacomitinib-induced diarrhoea 
Following the results seen in vitro, which showed dacomitinib increased chloride 
secretion and crofelemer inhibited it, treatment was then translated into an animal model. 
Our previous publication presents data of control and dacomitinib alone treated rats 
[149]. Rats treated with vehicle control did not develop diarrhoea at any time point 
[149]. Diarrhoea (grade1 - 3) occurred in 100 % of dacomitinib alone rats, which is 
comparable to the incidence seen in clinical trials [149]. Two rats treated with crofelemer 
alone developed mild grade 1 diarrhoea on the 3rd and 11th treatment day, likely due to 
stress (figure 2A). Diarrhoea developed in 100% of rats treated with 
dacomitinib/crofelemer combination (figure 2B). Approximately 50 % of rats treated 
with combination crofelemer and dacomitinib had severe diarrhoea (grade 3: severe 
diarrhoea as watery stools +/- mucous with fur staining incorporating hind legs). 
Approximately 30 % of rats treated with dacomitinib alone had severe diarrhoea [149]. 
Rats treated with dacomitinib/crofelemer combination had significantly worse diarrhoea 








Figure 2 Diarrhoea profiles shown for rats treated with A: crofelemer alone, and B: crofelemer and dacomitinib. To see data of rats treated with 
control and dacomitinib alone, see Van Sebille et al., 2017 [150]. A: Two rats treated with 25 mg/kg crofelemer developed mild, grade 1 
diarrhoea on the 3rd and 11th day. B: In 100% of rats treated with 7.5 mg/kg dacomitinib and 25 mg/kg crofelemer developed any grade 
diarrhoea. Rats treated with dacomitinb and crofelemer combination had significantly worse diarrhoea than rats treated with dacomitinib alone (p 
= 0.0003). Data expressed as percentage of total animals per day with a particular grade of diarrhoea. A Chi2 test was performed to identify 






In the crofelemer/dacomitinib combination group, two animals were killed due > 15% 
weight loss. These animals were not included in downstream analysis. Rats treated with 
crofelemer/dacomitinib combination had significantly less weight gain than controls 
from day 10-21 (p < 0.0001) (Figure 3). At day 21, the control group had on average 
gained 46.38 ± 2.459 % [149], the crofelemer group gained 39.27 ± 8.298 %, the 
dacomitinib group gained 18.99 ± 5.602 % [149], and the crofelemer/dacomitinib 








Figure 3 Body weight over the 21-day time course. Data presented as a percentage of 
weight change from baseline (day 1). A Kruskal-Wallis with post-hoc testing was 
performed to identify statistical significance. Rats treated with dacomitinib/crofelemer 
combination (7.5 mg/kg and 25 mg/kg respectively) had significantly less weight gain 
than the controls from day 10-21 (p < 0.0001). To see data of rats treated with control 
and dacomitinib alone, see Van Sebille et al., 2017 [150]. Rats treated with dacomitinib 





Crofelemer did not inhibit chloride secretion in the presence of dacomitinib in this 
model 
Samples of colon and ileum from each animal in the study were mounted in Ussing 
chambers to record electrogenic ion transport. Baseline readings were recorded to assess 
baseline differences in transepithelial short circuit current (Isc). Baseline Isc in the ileum 
was significantly higher in rats treated with combination crofelemer and dacomitinib 
compared to controls (p = 0.0408) (figure 4A). Baseline Isc in the colon was significantly 
higher in rats treated with combination crofelemer and dacomitinib compared to 
crofelemer alone (p = 0.0122) (figure 4B). Carbachol was administered to elevate levels 
of intracellular calcium to assess the role of the calcium-activated chloride channels, and 
indirectly, basolateral potassium channels. No differences were noted between groups in 
ileum samples following carbachol administration (figure 4C). The response to carbachol 
in colon samples of rats treated with combination crofelemer and dacomitinib was 
significantly higher compared to controls, crofelemer alone, and dacomitinib alone (p < 







Figure 4 Baseline short circuit current (Isc) of the distal ileum and colon. Segments of 
the distal colon and ileum were dissected, opened longitudinally and had the external 
muscle layers removed, before being mounted into Ussing chambers. Increased baseline 
Isc was seen in rats treated with dacomitinib/crofelemer combination (7.5 mg/kg and 25 
mg/kg respectively) compared to controls in the ileum (A: p = 0.0408) and compared to 
dacomitinib alone (7.5 mg/kg) in the colon (B: p = 0.0122). Following the administration 
of calcium agonist – carbachol – the colon of rats treated with dacomitinib/crofelemer 
combination had a significantly increased response compared to all other treatment 
groups (D: p < 0.0001). No significant changes were noted in the ileum (C). Data 
presented as mean ± SEM. A one-way ANOVA with Tukey post-hoc was performed to 





Crofelemer does not increase serum absorption of dacomitinib  
To assess if crofelemer was increasing the serum absorption of dacomitinib circulating 
dacomitinib levels were analysed by mass spectrometry in serum samples collected at 
death, after 21 days of treatment. The average blood concentration of dacomitinib in rats 
treated with dacomitinib alone was 258.2 ± 51.76 ng/mL and 260.8 ± 36.63 ng/mL in 
rats treated with dacomitinib and crofelemer combination (p > 0.05) (Supplementary 








Supplementary Figure 1 Serum dacomitinib concentration. Group mean serum 
dacomitinib concentration was not changed when given in combination with crofelemer 
(p > 0.05). Data presented as mean, ± min/max. An unpaired t test was performed to 





Dacomitinib induces gastrointestinal permeability 
FITC dextran was administered orally to measure gastrointestinal permeability. Serum 
FITC dextran levels were significantly elevated in rats of either treatment arm involving 
dacomitinib [149]. Rats treated with dacomitinib alone had significantly elevated levels 
of serum FITC dextran compared to controls (p = 0.0018) [149], and crofelemer alone (p 
= 0.0043). This was not attenuated with combination crofelemer/dacomitinib treatment, 
which had significantly elevated levels of serum FITC dextran compared to controls (p < 







Figure 5 Serum 4kDa FITC-dextran was administered as a 600 mg/kg dose, via oral 
gavage, 2 hours prior to kill time point. Data expressed as mean ± SEM and were 
analysed using a one-way ANOVA. To see data of rats treated with control and 
dacomitinib alone, see Van Sebille et al., 2017 [150]. Both treatment arms involving 
dacomitinib had significantly elevated levels of serum FITC-dextran, indicating 
gastrointestinal barrier dysfunction, with no significant differences between these 
groups. Rats treated with 25 mg/kg crofelemer and 7.5 mg/kg dacomitinib alone had 






Cytoplasmic redistribution of tight junction proteins contributes to dacomitinib-
induced barrier dysfunction 
To evaluate if dacomitinib alters permeability through tight junction disruption we 
investigated tight junction proteins in the intestine. Qualitative analysis of 
immunofluorescence for tight junction proteins showed membranous staining for all tight 
junction proteins in vehicle controls, and crofelemer alone controls (figure 6A, C, E, G, 
I, K, M, O, Q, S, U, W). Immunofluorescence staining for ZO-1 showed focal areas of 
proteolysis in the ileum (figure 6B, D) and colon (figure 6F, H) of rats treated with 
dacomitinib and dacomitinib/crofelemer combined. These focal areas of protein 
disruption were particularly evident in areas of epithelial injury, often occurring 
alongside phenotypically normal tight junction staining (indicated by arrows). Similar 
changes in occludin expression were also seen in the ileum (figure 6J, L) and colon 
(figure 6N, P), with focal areas of proteolysis corresponding with frank epithelial 
damage in rats treated with dacomitinib and dacomitinib/crofelemer combination. 
Claudin-1 staining presented with sharp apical intensities and membranous staining 
down the apicolateral border of the enterocyte in vehicle and crofelemer alone controls 
in both the ileum (figure 6Q, S) and colon (figure 6U, W). Marked caludin-1 
internalisation was evident in rats treated with dacomitinib and dacomitinib/crofelemer 
combination, particularly in the ileum (figure 6R, T), with complete loss of membranous 
staining specificity in some areas, and to a lesser extent in the colon (figure 6V, X). 
There were no apparent differences noted between the two dacomitinib treatment arms. 
To complement the observation of morphological changes in tight junction proteins, 
quantitative analysis was conducted on epithelium only, to assess mean percentage area 
stained. Vehicle control had a mean percentage area staining of 5.23% for claudin-1, 





staining of 6.8% for claudin-1, 2.5% for ZO-1, and 0.93% for occludin. Dacomitinib 
alone had a mean percentage area staining of 4.23% for claudin-1, 3.53% for ZO-1, and 
1.87% for occludin. Dacomitinib and crofelemer had a mean percentage area staining of 
2.8% for caludin-1, 3.23% for ZO-1, and 1.45% for occludin. No significant differences 











Figure 6 Representative images of claudin-1, occludin, and ZO-1 immunofluorescence 
in the ileum and colon of vehicle- crofelemer- dacomitinib- and dacomitinib/crofelemer 
combination- treated rats. Vehicle treated, and crofelemer alone treated rats showed 
phenotypically normal tight junction proteins, with apical staining intensities (A, C, E, 
G, I, K, M, O, Q, S, U, W). Rats treated with dacomitinib and dacomitinib/crofelemer 
combination showed no differences, with both displaying focal areas of ZO-1 and 
occludin disruption, particularly in areas of epithelial injury (B, D, F, H, J, L, N, P, 
arrows). Rats treated with dacomitinib and dacomitinib/crofelemer combination 
displayed claudin-1 internalisation, found alongside areas of phenotypically normal tight 
junctions (R, T, V, X, arrows). Sections of ileum and colon were stained with a primary 
antibody for claudin-1, occluding and ZO-1 and visualised using an AlexaFluor anti-






Crofelemer does not attenuate dacomitinib induced histopathological injury 
Rats treated with dacomitinib [149], or dacomitinib/crofelemer combination had 
significant tissue injury in the ileum compared to controls (p < 0.0001) (figure 7). This 
was predominantly characterised by severe villous atrophy with stunting and fusion of 
villi, which was also attended by enterocyte metaplasia to a low columnar or cuboidal 
phenotype and mild compensatory expansion of the basal proliferative compartment of 
crypts. In the congested lamina propria, there was an increased inflammatory infiltrate 
comprised of lymphocytes, macrophages, plasma cells and neutrophils, and dilation of 
lacteals (villous lymphatics). There were no significant differences in tissue injury in the 
jejunum and colon between any groups (data not shown). Dacomitinib did not cause 
increased apoptosis or proliferation in the gastrointestinal tract compared to controls 
[149]. When Dacomitinib and crofelemer were given in combination, there was no 







Figure 7 Histopathological parameters in H&E stained ileum. A: There were significant 
increases in tissue injury scores in rats treated with 7.5 mg/kg dacomitinib and 25 mg/kg 
crofelemer combination (p < 0.0001) compared crofelemer control. To see data of rats 
treated with control and dacomitinib alone, see Van Sebille et al., 2017 [150]. There 
were no significant differences between crofelemer dacomitinib combination and 
dacomitinib alone treated rats. B: Rats treated with crofelemer alone showed no 
histopathological damage. Scale bar indicates 250 µM. C: Villous atrophy and stunting 
is evident in the ileum of rats treated with dacomitinib and crofelemer combination. 
Fusion of villi is indicated by brackets. Compensatory expansion of crypts is indicated 
by crosses. Increased inflammatory infiltrate is indicated by arrow heads. Scale bar 
indicates 250 µM. D: Enterocyte metaplasia is indicated by arrows. Scale bar indicates 






Whilst dacomitinib - a second-generation small molecule pan-HER TKI - shows promise 
for the treatment of NSCLC, its’ most commonly reported adverse event is diarrhoea, 
which significantly impacts on clinical outcomes [124]. Currently no anti-diarrhoeal 
medication used for the treatment of TKI-induced diarrhoea offers a targeted approach 
due to the lack of understanding of the underlying mechanisms. HER TKI-induced 
diarrhoea has recently been hypothesised to be caused by ErbB down-regulation, where 
blockade leads to excess chloride secretion and thus secretory diarrhoea [16]. Therefore, 
this study first investigated this hypothesis in an in vitro model. We demonstrated that 
dacomitinib caused increased chloride secretion across polarised epithelia, and that 
crofelemer, an antisecretory antidiarrhoeal agent, was able to attenuate this increase. 
Given this positive finding we then aimed to determine if crofelemer was an effective 
prophylactic for dacomitinib-induced diarrhoea in a rat model.  
 
Despite the results seen in vitro, rats treated with dacomitinib/crofelemer combination 
had significantly worse diarrhoea than rats treated with dacomitinib alone [149]. 
Previous investigations of the antisecretory mechanism of crofelemer have demonstrated 
weak and partial inhibition of CFTR, and complete inhibition of CaCC [118]. 
Electrophysiological analysis in the present study conducted on T84 cells supported this, 
with crofelemer inhibiting chloride secretion at baseline, as well as following CaCC 
agonist administration. However, the electrophysiological analysis in the in vivo arm of 
this study demonstrated that the inhibitory effect of crofelemer on chloride secretion is 
lost when given in combination with dacomitinib over 21 days. This is the first time 
crofelemer has been used in a preclinical study of this duration, therefore the lack of 





experiments occurring 24 hours after the last dose of drugs. Furthermore, the tissue was 
significantly damaged, potentially altering the normal function of transporters. 
Nevertheless, crofelemer was unable to attenuate dacomitinib-induced diarrhoea. This 
may be explained by convective drug washout, a concern for drugs with an extracellular 
target in intestinal crypts, such as crofelemer [151]. Convective washout reduces the 
efficacy of enterocyte surface targeted Cl- channel inhibitors, which can be of concern in 
diarrhoea, due to the potential of washout forces impeding the inhibitor to reach the deep 
intestinal crypts. However, convective drug washout does not explain why crofelemer 
was not only ineffective, but also significantly worsened dacomitinib-induced diarrhoea.  
 
Chloride channel blockers have previously been suggested for the investigation of TKI-
induced diarrhoea [16], including CFTRinh-172, which binds to the cytoplasmic side of 
the CFTR channel and stabilises the channel closed state [114]; glycine hydrazides, 
which target the extracellular CFTR surface in the channel pore [113]; and CaCCinh-A01, 
a red wine extract that has been shown to prevent watery diarrhoea in a mouse model of 
rotavirus [115].  Crofelemer was selected as an intervention in this study because (a) it 
was reported as a safe and tolerable drug with no adverse events and was approved for 
clinical use, (b) its dual inhibitory action on the two principle Cl- channels in the apical 
membrane of intestinal epithelial cells, and (c) its lack of systemic absorption due to its 
size and polarity [118], suggesting that it would not interact with dacomitinib 
systemically. Given the worsened effects seen in the present study, this might suggest 
that crofelemer can be systemically absorbed if administered in conjunction with drugs 
that cause barrier disruption and small intestinal damage such as dacomitinib. Serum 
mass spectrometry did not indicate that crofelemer altered the absorption of dacomitinib 





be required to assess if the combination drug protocol altered maximum concentrations 
or time to peak. There are currently no reported contraindications for crofelemer and this 
is the first study to show that crofelemer may worsen diarrhoea in certain situations. The 
results from this study suggest that crofelemer should be investigated for 
contraindications before being used in combination with other drugs.  
 
Although the in vitro electrophysiological analysis indicated that dacomitinib induced 
excess chloride secretion, the ex vivo electrophysiological analysis did not suggest that 
dacomitinib causes excess chloride secretion in intestinal tissue following 21 days of 
treatment. This may be due to not only the timing of the Ussing experiments as 
previously mentioned, but additionally, the in vivo model was a chronic dosing schedule, 
whereas Ussing experiments in the in vitro model were conducted after only one 
treatment, 15 minutes after exposure.  The disadvantage of cell line work should also be 
considered. T84 monolayer cell lines lack other mucosal cell interactions, and of 
particular importance in this study, the impact that inflammation has on tight junctions. 
Clinical studies have also indicated that neratinib, a pan-HER ErbB TKI has a fecal 
osmotic gap that is consistent with the values for secretory diarrhoea [152].  Previous 
work investigating lapatinib, an ErbB1 and ErbB2 TKI, suggested that diarrhoea was 
associated with chloride secretion, indicated by decreased serum chloride levels, which 
the authors proposed may be due to loss of chloride via the intestinal lumen [15].  
However, this was the only measure of secretory mechanisms and is therefore 
inconclusive. Another kinase inhibitor, flavopiridol, has been reported to stimulate 
chloride secretion across monolayers of human colonocytes in modified Ussing 
chambers [94]. Nevertheless, given this was conducted in vitro the results need to be 





important considering the differing results of the in vitro and in vivo arms of the present 
study. Despite the growing support in the literature for the hypothesis of TKI-induced 
diarrhoea being due to excess chloride secretion, this is the first study to assess secretory 
diarrhoea ex vivo using Ussing chamber analysis.  The results of this study do not 
support the hypothesis that diarrhoea second to TKI treatment is due to excess chloride 
secretion. The potential flaw in the hypothesis (EGFR in normal settings are negative 
regulators of chloride secretion, and so when inhibited there is a loss of negative 
regulation, and thus increased chloride secretion), is that the hypothesis does not 
consider that the tissue may be inflamed, and hence behave differently. The assumption 
that inflamed tissue would behave in a similar manner to normal tissue is a fundamental 
caveat of the hypothesis. This is highlighted by McCole et al., who showed in a model of 
DSS-induced colitis, that EGF behaves in a contradictory way in inflamed tissue (i.e. 
enhances chloride secretion instead of inhibiting it) [153]. Therefore, future research 
could administer dacomitinib and crofelemer to healthy gastrointestinal tissue in Ussing 
chambers, instead of using ex vivo treated tissue, in order to dissect whether the 
inflammatory changes in the present model overshadow the effects of the drugs 
themselves.  
 
This is the first study to compare functional in vivo permeability, and morphological 
assessment of tight junction proteins in the setting of dacomitinib-induced gut toxicity. 
Our previous research has indicated that dacomitinib induces severe ileal damage and 
barrier dysfunction [149]. This study further characterised this barrier dysfunction; 
showing increases in barrier permeability to 4kDa FITC-dextran, and clear changes to 
tight junction proteins. Tight junctions are critical in maintaining gastrointestinal health 





transcriptional and -translational modification by a variety of pathological cues [154, 
155]. Tight junction disruption has been identified following treatment with a number of 
chemotherapeutic agents, both preclinically [137, 156] and clinically [157-159]. To date, 
many studies have shown architectural abnormalities, and functional alteration, of key 
tight junction proteins such as claudin-1, ZO-1, and occludin. As such, the current study 
focused on these three proteins, despite the numerous other proteins present within the 
junctional complex. Given the complexity of tight junction physiology, further 
investigation could be directed towards the behaviour of junctional adhesion molecule-A 
(JAM-A), following dacomitinib given its involvement in inflammatory settings [160]. 
Despite increased research in this area, assessment of barrier function, and in particular 
tight junction analysis has never been conducted in TKI models. The present study 
identified derangement of claudin-1, ZO-1, and occludin, characterised by severe 
cytoplasmic redistribution and disassembly of the tight junction unit. However 
quantitative analysis showed no significant differences in percentage area stained. This 
method of quantification may not have sufficient power to detect the subtle changes that 
occur upon protein translocation, thus explaining the disparity between qualitative and 
quantitative analyses. Internalisation of tight junction proteins is well recognised to 
contribute to poor barrier function, and loss of tight junction apposition [136, 155]. In the 
current study, cytoplasmic redistribution of claudin-1 was seen in the ileum, where peak 
histopathological damage was also seen. However, the mechanisms causing this tight 
junction dysfunction remain to be elucidated. Previous research has suggested that tight 
junction dysfunction can be pro-inflammatory cytokine mediated [136, 155, 161]. Given 
the increased inflammatory infiltrate noted in the lamina propria of the ileum in this 
study, this might suggest that this may be a contributive factor to tight junction 





dysfunction second to cancer treatment is becoming more evident in both preclinical 
[136] and clinical models [157]. Clinically, this is highly important as barrier 
dysfunction permits LPS translocation [129], systemic toxicity [157], bacterial 
translocation and colonisation in mesenteric lymph nodes and the spleen, increasing the 
risk of infection, graft-versus-host disease [162], and sepsis [163]. Intestinal barrier 
dysfunction has also been suggested to exacerbate direct gastrointestinal damage from 
the cancer therapy, worsening quality of life and clinical outcomes for patients [136]. It 
is therefore imperative that the mechanisms that lead to barrier dysfunction second to 
cancer treatment are further investigated, so that therapeutic targets may be identified 
and interventions developed to prevent local toxicity transitioning to systemic toxicity, to 






In summary, this study showed that crofelemer was unable to attenuate dacomitinib-
induced diarrhoea, and in fact, worsened it in the current model. Despite the growing 
support for secretory diarrhoea as the mechanism of TKI-induced diarrhoea, this study 
provided little support for this hypothesis, suggesting that antisecretory drug therapy may 
be ineffective in this setting. This is the first study to provide a detailed interrogation of 
the barrier changes associated with dacomitinib treatment. Tight junction disruption is a 
hallmark trait of many pathological states. A wealth of research now implicates poor 
tight junction integrity following treatment with various chemotherapeutic agents, 
however, this is the first study to implicate these changes in a TKI model. This study 
advances our understanding of diarrhoea processes induced by not only this agent, but 
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 Chapter 5 Use of zebrafish to model chemotherapy and 
targeted therapy gastrointestinal toxicity  
This chapter has been submitted to Supportive Care in Cancer. (Van Sebille, Y.Z., 
Gibson, R. J., Wardill, H.R., Carney, T.J., Bowen, J.M., 2017. Use of zebrafish to model 
chemotherapy and targeted therapy gastrointestinal toxicity. Supportive Care in Cancer, 
Under review.  
 
Abstract 
Gastrointestinal toxicity arising from cancer treatment remains a key reason for 
treatment discontinuation, significantly compromising remission. There are drawbacks to 
the currently used in vitro and rodent models, and a lack of translatability from in vitro to 
in vivo work. A screening-amenable alternative in vivo model such as zebrafish would, 
therefore, find immediate application. This study utilised a transgenic reporter line of 
zebrafish to investigate its utility as an alternative vertebrate model to bridge the gap 
between simple in vitro cellular studies and complex in vivo models for understanding 
gastrointestinal toxicity induced by chemotherapy and targeted therapy. Transgenic 
zebrafish larvae were administered afatinib or SN38 in water, and assessed for viability 
and eGFP induction. Adult zebrafish were administered afatinib via oral gavage, and 
SN38 via intraperitoneal injection. Fish were killed after 24 hours, and had 
gastrointestinal tracts removed and assessed for histopathological damage, goblet cell 
changes and apoptosis. Whilst treatment with either compound did not induce eGFP in 
the gastrointestinal tract of larvae, SN38 caused histopathological damage to adult 
intestines. The lack of eGFP induction may be due to poor solubility of the drugs. 





these models. Further progress in this area would be greatly facilitated by the generation 
of robust and reproducible genetic models of zebrafish intestinal toxicity that mimic the 
known pathobiological pathways in rodents and humans, and can be readily induced in a 
short time-frame.  
 
Introduction  
Gastrointestinal toxicity arising from systemic cancer treatment such as chemotherapy 
and targeted therapies remains a key reason for treatment cessation, significantly 
compromising chances of remission. These side effects are frequently associated with 
traditional chemotherapy drugs, and now are increasingly recognised to be associated 
with targeted therapies [124]. Patients commonly report gastrointestinal toxicity as being 
the most impactful on quality of life, influencing their willingness and ability to comply 
with treatment [51]. This results in dose reductions, interruptions and discontinuation, 
reducing remission rates [51].  
 
Currently, the animal models used to study gastrointestinal toxicity arising from cancer 
treatment are primarily rodent models[164]. These models have provided extensive 
information on mechanisms, and prompted specific hypotheses about the effect of cancer 
treatment on any regions of the gastrointestinal tract [164]. However, there are 
challenges associated with rodent models including being prohibitively expensive, time 
consuming, and the relative difficulty of genetic manipulation. In vitro models are also 
utilised to study gastrointestinal toxicity. Epithelial cell lines derived from the intestine 
are cultured as monolayers, in attempt to mimic the intestinal epithelium [127]. 
However, there are many limitations to in vitro work, and while they can be useful to 





is of key importance for modelling gastrointestinal toxicity. Further, they cannot 
recapitulate the complex systemic metabolism of compounds and thus do not assay the 
full spectrum of compound derivatives found in vivo. Considering the constraints of in 
vivo and in vitro models currently used, an alternative model to study cancer treatment-
induced gastrointestinal toxicity that allows rapid, miniaturised, multi-organ toxicity, 
screening-amenable testing is warranted.  
 
Recently, a new zebrafish transgenic eGFP reporter, Tg(cyp2k18:egfp), was developed 
by identifying highly upregulated genes as biomarkers of liver toxicity [165]. Although 
this transgenic zebrafish reporter line was initially developed for liver toxicity, upon 
further testing, it was identified that the line also induced eGFP in the gastrointestinal 
tract following drug treatment, highlighting this organ as a major detoxification site. 
Detailed investigations have also reported the intestinal morphology and genetic 
expression of the zebrafish, demonstrating it as a useful model for gastrointestinal 
disease models [166-168]. Transcriptome profiling has demonstrated that the large 
anterior portion (58%) of the zebrafish intestine has a similar RNA profile to the human 
small intestine, followed by a small transitional zone (14%), a tissue resembling the 
caecum (14%) and lastly a profile resembling the rectum (14%) [168]. Zebrafish do not 
have separated stomach or colon sections, and instead have a continuous tube with 
segments expressing some genes characteristic of human colon and rectum [168].  
 
Here we exploit this newly developed transgenic zebrafish reporter line to investigate its 
utility as an alternative vertebrate model to bridge the gap between simple in vitro 
cellular studies and complex in vivo models for understanding gastrointestinal toxicity 





gastrointestinal toxicity, manifesting as diarrhoea, and represent two classes of anti-
cancer agents; classical cytotoxic chemotherapy (SN38, a topoisomerase 1 inhibitor) and 
targeted agents (afatinib, a pan-HER tyrosine kinase inhibitor) [91, 169-172]. Thus, this 
study aimed to assess the efficacy of zebrafish as a platform to study gastrointestinal 




Experiments were conducted under the authority of the Institutional Animal Care and 
Use Committee (IAUCUC) of the Biological Resource Centre, A*STAR (Protocol 
number 120751), mandated by National Advisory Committee for Laboratory Animal 
Research Guidelines of the Agri-Food and Veterinary Authority, Singapore.  
Zebrafish (Danio rerio) were housed in the zebrafish facility of the Institute of 
Molecular and Cell Biology, a division of A*STAR, Singapore. Larvae were obtained 
through natural crosses and staged as previously described by Kimmel et al., 1995 [173]. 
Embryos and larvae were raised and treated in water containing 60 µg/ml sea salt (Red 
Sea Aquatics, UK), and 1% methylene blue.  
 
Zebrafish used included wildtype (AB strain), Tg(cyp2k18:egfp) reporter line and 
Tg(BACmpx:gfp) reporter line. The development of both the Tg(cyp2k18:egfp) reporter 
line and Tg(BACmpx:gfp) line have been described previously [165, 174].  
 
Drug Treatment 
For treatment of both larvae and adults, SN38 (Tocris bioscience, 2684) was used as the 





Both were administered to mimic clinical administration (afatinib orally, and SN38 via 
intraperitoneal injection). Diclofenac (Sigma D6899) was used as the positive control to 
cause hepatic and gastrointestinal toxicity reported by Tg(cyp2k18:egfp) zebrafish line 
(larvae only). Larvae were treated at 3 days post fertilisation (dpf). Drug compounds 
were dissolved in DMSO, and added to the egg water in a 12 well plate (volume 2 
ml/well), with 10 larvae/well. All treatments were conducted in duplicate. Compounds 
were dissolved in DMSO, and diluted in egg water for larvae treatment. DMSO exposure 
to larvae or adult fish did not exceed 0.01%. SN38 and afatinib were administered to 
larvae at a range of concentrations from 0.5-900 µM for 24 hours, and optimal dose for 
treatment was determined as 300 µM. Positive controls (Tg:cyp2k18 line only) were 
administered diclofenac at a concentration of 13 µM for 24 hours as this is known to 
induce eGFP in this line [165]. Controls were administered the corresponding solvent 
concentration (DMSO, 0.01%).  
 
Adult zebrafish were weighed and administered 100 µg/g afatinib via oral gavage, with 
the maximum volume administered not exceeding 1% of the fish bodyweight. Afatinib 
was dissolved in DMSO, and diluted in PBS. DMSO exposure did not exceed 0.01%. 
Controls were administered the corresponding solvent concentrations (DMSO, 0.01%). 
The oral gavage technique was modified from Collymore and colleagues [175]. A soft, 
flexible 20 µl ultra-micro tip (Eppendorf) was trimmed to 5cm in total length, and the cut 
edge was assessed under a dissection microscope to ensure cut edges were blunt, with no 
bevelled or sharp edges. A sponge was cut with a groove and soaked in facility system 
water to hold zebrafish during gavage procedure. The ultra-micro tip was attached to a 
pipette and appropriate volume drawn up, ensuring no bubbles were present, and gently 





transparent zebrafish [176], were gavaged with phenol red (1:10 dilution with a 0.5% 
phenol red solution in Dulbecco’s PBS). This indicated that the solution was entering the 
intestinal bulb and not exiting via the gills, and that fish did not expel the solution 
through their mouth (Supplementary Figure 1). Fish were killed 24 hours following 
gavage.  
 
Adult zebrafish were weighed and administered 100 µg/g SN38 via intraperitoneal 
injection, with the maximum volume administered not exceeding 1% of the fish 
bodyweight. SN38 was dissolved in DMSO, and diluted in PBS. DMSO exposure did 
not exceed 0.01%. Controls were administered the corresponding solvent concentrations 
(DMSO, 0.01%). Using a 10 µl micro syringe (Hamilton) the correct volume was 
injected into the fish on the ventral body wall, posterior to the pelvic girdle and anterior 
to the anus, roughly midway along the length of a pelvic fin. The tip of the needle was 








Supplementary Figure 1: Casper zebrafish gavaged with phenol red. Arrow 







Imaging and tissue preparation  
For imaging, larvae were anaesthetised with 0.02% Tricane (buffered to pH 7.0) and 
placed on a petri dish under a Leica MZ16FA. Only larvae were imaged for eGFP 
induction as they are transparent.  
Adult fish were culled by placing in 0.02% Tricane. A shallow longitudinal incision on 
the ventral side, from the gills to the anus, was made to remove the intestines which were 
uncoiled and the anterior 60% of the intestines were fixed in 4% PFA overnight before 
processing and embedding in paraffin.  
 
Histopathological analysis  
Hematoxylin and eosin (H&E) staining was performed on 4 m sections of intestine, cut 
on a rotary microtome and mounted onto glass Superfrost microscope slides (Menzel-
Gläser, Braunschweig, Germany). Slides were scanned using a NanoZoomer 
(Hamamatsu Photonics, Japan) and assessed with NanoZoomer Digital Pathology 
software view.2 (Histalim, Montpellier, France). The occurrences of six histological 
criteria in the intestine were examined to generate a total tissue injury score [136]. These 
criteria were villous fusion, villous atrophy, disruption of brush border and surface 
enterocytes, infiltration of polymorphonuclear cells and lymphocytes, dilation of 
lymphatics and capillaries, and oedema. Each parameter was scored as present = 1, or 
absent = 0, in a blinded fashion (YZVS).  
 
Goblet Cell Analysis 
Alcian Blue (1 % Alcian Blue 8GX (CI 74240) in 3 % glacial acetic)/ Periodic acid 
Schiff staining was performed on 4 m sections the intestine. Sections were oxidised in 1 





using a NanoZoomer (Hamamatsu Photonics, Japan) and assessed with NanoZoomer 
Digital Pathology software view.2 (Histalim, Montpellier, France). Data presented as 
average per villus. All analysis was done in a blinded fashion (YZVS). 
 
Immunohistochemistry 
Immunohistochemical analysis was performed for apoptosis analysis (caspase 3; BD 
Pharmingen #559565). Change in caspase-3 is a validated marker for altered tissue 
kinetics in previous models of cancer therapy induced-gastrointestinal toxicities [63, 69, 
70, 90]. Immunohistochemical analysis was performed using Dako reagents on an 
automated machine (AutostainerPlus, Dako, Denmark) following standard protocols 
supplied by the manufacturer. Briefly, sections were deparaffinised in histolene and 
rehydrated through graded ethanol before undergoing heat mediated antigen retrieval 
using an EDTA/Tris buffer (0.37 g/L EDTA, 1.21 g/L Tris; pH 9.0). Retrieval buffer was 
preheated to 65C using the Dako PT LINK (pre-treatment module). Slides were 
immersed in the buffer and the temperature raised to 97C for 20 minutes. After 
returning to 65C, slides were removed and placed in the Dako AutostainerPlus and 
stained following manufactures guidelines. Negative controls had the primary antibody 
omitted. Caspase 3 was quantified by counting the number of positively stained cells. 
Data presented as average positively stained cells per villus. All analysis was done in a 
blinded fashion (YZVS). 
 
Statistics 
Data were compared using Prism version 7.0 (GraphPad Software, San Diego USA). A 
D’Agostino Pearson omnibus test was used to assess normality. When normality was 





was performed to identify statistical significance between groups. In other cases, a 
Kruskal-Wallis test with Dunn’s multiple comparisons test and Bonferroni correction 




 Larvae Zebrafish  
Zebrafish larvae (n = 10/group) were treated with varying doses of afatinib and SN38, 
ranging from 100 µM to 1 mM to determine optimal treatment dose. SN-38 did not cause 
mortality in larvae at any concentration tested. In contrast, afatinib induced dose-
dependent mortality (Figure 1). The optimal dose of afatinib for larvae was determined 
as LC25 (300 µM).  
 
 Adult Zebrafish  
Adult zebrafish (n = 6/group) were treated with SN38 (by intra peritoneal injection) or 
afatinib (by oral gavage) at 10, 20, 30 and 40 µg/g based on previous publications [177]. 
SN-38 and afatinib did not cause mortality or noticeable morbidity in adult fish, and 








Figure 1: Percent death of larvae Administration of varying concentrations of afatinib 
caused lethality in zebrafish larvae. At does below 100 µM, no larvae died. Doses above 
600 µM caused lethality in 100% of larvae. LC25 (dotted line) was 300 µM, and this was 






Transgenic zebrafish larvae fluorescence imaging  
To assess the effectiveness of zebrafish Tg(cyp2k18:egfp) reporter line as a high-
throughput screening for gastrointestinal toxicity of cancer treatment, larvae were treated 
with SN38 and afatinib, anti-cancer compounds with known gastrointestinal toxicity 
profiles; and positive control, diclofenac [165].  Larvae were imaged for induction of 
eGFP in the gastrointestinal tract of Tg(cyp2k18:egfp) reporter line. To assess gut 
inflammation, the neutrophil reporter line, Tg(BACmpx:gfp) was also exposed to both 
compounds. As expected, diclofenac induced eGFP in the gastrointestinal tract of the 
Tg(cyp2k18:egfp) zebrafish larvae (figure 2a); SN38 and afatinib did not elicit a 
response (Figure 2c, d). SN38 and afatinib induced neutrophil translocation from the 
vasculature (indicated by white arrow in untreated control, figure 2e) to surrounding 
tissues, however, this was not specific to the gastrointestinal tract (Figure 2f, g). Visual 
inspection indicated a relative decrease in translocation of neutrophils in larvae treated 







Figure 2: Fluorescent microscope still images of Tg(cyp2k18:egfp) and 
Tg(BACmpx:gfp) larvae zebrafish at 4dpf. 2a: Diclofenac (positive control) induced 
eGFP in gastrointestinal tract of Tg(cyp2k18:egfp). 2b: Untreated larvae did not display 
eGFP in gastrointestinal tract Tg(cyp2k18:egfp). 2c: SN38 treatment did not induce 
eGFP in gastrointestinal tract Tg(cyp2k18:egfp). 2d: Afatinib treatment did not induce 
eGFP in gastrointestinal tract Tg(cyp2k18:egfp). 2e, white arrow: Untreated 
Tg(BACmpx:gfp) displayed neutrophils contained to the vasculature. 2f: SN38 treated 
Tg(BACmpx:gfp) displayed some neutrophil translocation from the vasculature. 2g: 






Histopathological intestinal analysis in adult zebrafish  
To assess the effect of cancer drugs on the histopathology of the gastrointestinal tract, six 
key markers of damage were assessed in adult zebrafish: disruption of brush border and 
surface enterocytes, infiltration of polymorphonuclear cells and lymphocytes, dilation of 
lymphatics and capillaries, oedema, villus fusion and villus atrophy. Both 
Tg(cyp2k18:egfp) (n=6) and wildtype AB (n=6) adult zebrafish treated with afatinib did 
not display histopathological damage to the intestines (p > 0.05) (figure 3a, b, c). Both 
Tg(cyp2k18:egfp) (n=6) (p = 0.0076) and wildtype AB (n=6) (p = 0.0407) zebrafish 
treated with SN38 had significantly increased histopathological scores compared to 
controls (n=6 Tg(cyp2k18:egfp); n=6 AB wildtype) (figure 3a, d). The adult 
Tg(cyp2k18:efp) zebrafish were not different from the wild type (AB) at baseline (p > 
0.05), or in response to treatment (p > 0.05). To assess the effect of cancer drugs on 
goblet cells in the gastrointestinal tract, AB-PAS staining was analysed. There was no 
significant difference between either the transgenic (5.736 +/- 1.49 cells per villus in 
DMSO IP; 7.446 +/- 1.092 cell per villus in DMSO gavage) or AB controls (5.923 +/- 
2.06 cells per villus in DMSO IP; 7.625 +/- 1.205 cells per villus DMSO gavage). There 
was no significant difference in fish treated with either SN38 (8.454 +/- 1.229 per villus 
in AB fish; 6.528 +/- 2.135 per villus in Tg(cyp2k18:egfp) fish), or afatinib (5.508 +/- 
1.482 cells per villus in AB fish; 6.392 +/- 1.957 cells per villus in Tg(cyp2k18:egfp) 
fish), (p > 0.05). Caspase 3 staining to identify apoptotic cells in the intestine showed no 
significant difference between either the transgenic or wildtype line in controls and fish 







Figure 3: Histopathological injury in zebrafish. 3a: Adult Tg(cyp2k18:egfp) and adult 
AB zebrafish treated with SN38 had significant histopathological intestinal injury 
compared to controls (**p=0.0076 and *p = 0.0407 respectively). 3b: Adult zebrafish 
treated with afatinib did not develop histopathological intestinal injury (p>0.05). 3c: 
Representative image of adult Tg(cyp2k18:egfp) zebrafish treated with DMSO control. 






Gastrointestinal toxicity is a common side effect of cancer therapies, and can restrict 
administration dose, and thus treatment efficacy. There is a pressing need for diverse 
models and assays to better understand the mechanisms, and identify toxicity early in 
drug development. The zebrafish model has been recognized as a powerful tool for 
human disease modelling, toxicology and drug screening assays, based largely on its 
ease of handling, fecundity, low cost, rapid external development, amenability to genetic 
manipulation as well as its genetic similarity to higher vertebrates [178]. There has been 
minimal use of the zebrafish model to study gastrointestinal toxicity; with one model 
reporting mucositis findings when developing a hand-foot disease model with PEGylated 
doxorubicin [177]. Here, we aimed to utilise a newly developed transgenic reporter line 
as a novel model to screen anti-cancer drugs that induce gastrointestinal toxicity. 
 
The Tg(cyp2k18:egfp) reporter line was developed to screen liver toxicity drugs, 
however, on testing it was noted that eGFP was also induced in the gastrointestinal tract 
if toxicity was induced [165]. Non-steroidal anti-inflammatory agents such as diclofenac 
have long been reported to induce gastrointestinal injury [179]. It was therefore logical to 
test the ability of this line as a reporter line for cancer treatments that induce both 
hepatotoxicity and gastrointestinal toxicity. In this model, two agents known to induce 
severe gastrointestinal-toxicity were used to assess the viability of the Tg(cyp2k18:egfp) 
line as a high throughput, low cost screening tool. However, upon testing it was noted 
that following treatment with both chosen drugs, SN38 and afatinib, no induction of 
eGFP was seen in larvae. It is now becoming appreciated that each toxicant is likely to 
induce a unique set of transcriptional responses and that a global toxic reporter is 





responded differently to hepatotoxicants [165]. Ideally any toxicity assay would involve 
a number of independent reporter lines. Unbiased transcriptional profiling of the toxic 
response to afatinib and SN38 in the zebrafish might yield novel markers for transgenic 
reporter development.  
 
A key drawback in using zebrafish for the study of toxicity, is that larvae must receive 
the compound in water. Drug solubility is therefore a major factor to be considered when 
utilising this model. While this study overcame this limitation in adult fish by 
administering drugs via oral gavage or intraperitoneal injection, such approaches are not 
feasible in larvae nor are adults readily screenable for reporter eGFP induction due to 
inherent opacity. Whilst understood that SN38 and afatinib engage a different pathway 
for metabolism than Cyp2K18, these agents have been shown to induce hepatotoxicity in 
other models, the precise mechanisms of which are unknown [180, 181]. Therefore, the 
potential confounding issue in this model may be that sufficient concentrations were not 
achieved to induce liver or gastrointestinal toxicity due to the low solubility, and thus 
lack of absorption. The solubility of SN38 has previously been identified as problematic, 
and hence development of soluble SN38 is now being investigated, and may be useful in 
this model in the future [182]. Nevertheless, afatinib was soluble, and indeed, caused 
some lethality at doses above 200 µM, however it is unclear if the lethality was of 
gastrointestinal origin.  
 
Adult zebrafish treated with afatinib did not show histopathological damage. There are a 
number of reasons to potentially explain this: (1) histopathological damage is only 
occasionally reported as a feature of targeted-therapy induced gastrointestinal toxicity; 





possible that given the differences in zebrafish gastrointestinal anatomy this was not 
seen. The zebrafish lacks a stomach, with the regionalisation of the adult zebrafish being 
more gradual. The morphology of the zebrafish intestine is analogous to the villus 
structure of mammalian intestines, with capacious folds of the epithelium that protrude 
into the lumen, increasing the surface area with the finger-like projections, however do 
not contain crypts [168]; (3) afatinib is typically administered daily over many weeks, 
and so a single dose may not cause gastrointestinal toxicity. Further studies are therefore 
needed to further investigate this model with a time-course, however the tolerance of 
daily gavage to zebrafish is unclear.  
 
While a robust and tractable genetic model of gastrointestinal toxicity is not available 
yet, the identification of genes required for the rapid proliferation of zebrafish intestinal 
epithelial cells during development has highlighted a number of essential genes that 
could be targeted to disable gastrointestinal toxicity [183]. Moreover, appreciation of the 
utility of zebrafish to study intestinal inflammation is gaining momentum. In particular, 
zebrafish provide opportunities to investigate the integrity of intestinal epithelial barrier 
function, a key emerging marker of gastrointestinal toxicity second to cancer treatment, 
with FITC-dextran gavage. With currently available tools, the interplay between 
epigenetic regulators, intestinal injury, microbiota composition and innate immune cell 
mobilisation can be analysed in exquisite detail [183]. This provides excellent 
opportunities to define critical events that could be targeted therapeutically. Furthermore, 
the use of zebrafish larvae as hosts for xenografts of human tissue, while still in its 
infancy, holds great promise that zebrafish could provide a practical, preclinical 
personalised medicine platform for the rapid assessment of the drug sensitivity of the 





transgenic zebrafish lines for more accurate reconstitution of human drug metabolism 
[184].   
Conclusion  
Zebrafish are providing several productive avenues for toxicology research, however a 
timely screening model for gastrointestinal toxicity second to cancer treatment is yet to 
be developed. Here, we aimed to utilise a newly developed transgenic reporter line to 
address this need, however, the transgenic line did not report gastrointestinal toxicity 
using the compounds tested. This may be explained due to poor solubility, providing an 
unclear picture of whether these larvae were induced for any type of injury. We therefore 
had to concentrate our attention on the adult fish in the direct delivery of the compounds. 
Chemotherapy agents with high solubility and permeability would be more amenable to 
these models. In addition, different drugs may invoke highly unique genomic responses, 
and hence we did not see induction of eGFP in larvae in response to these compounds. 
Further progress in this area would be greatly facilitated by the generation of robust and 
reproducible genetic models of zebrafish intestinal toxicity that mimic the known 
pathobiological pathways in rodents and humans, and can be readily induced in a short 
time-frame. This would include identification of more gastrointestinal toxicity reporter 
genes in zebrafish from these and other drugs. Suitably apt models will have the 
potential to deliver novel cancer drugs by providing a platform for high throughput 







Chapter 6 General Discussion 
 
Introduction 
The use of TKIs is increasing, and despite intentions of reduced toxicity, the prevalence 
of diarrhoea, one of the most troublesome and prevalent symptom of toxicity, has 
increased [124]. This has been further exacerbated with the advent of second generation 
pan-HER TKIs [124]. Initial research suggested the mechanisms causing diarrhoea were 
consistent with chemotherapy-induced mucositis, characterised by direct mucosal 
atrophy [16]. However, as more research emerged, conflicting findings made it unclear if 
there was indeed a uniform pattern to characterise toxicity of tyrosine kinase inhibitors 
as previously hypothesised.  
 
This thesis aimed to address the knowledge gap and provide a detailed interrogation of 
mechanisms underpinning gastrointestinal toxicity second to pan-HER TKI treatment 
(Chapter 3). I selected, dacomitinib as an ideal agent, as it (a) was associated with high 
levels of diarrhoea (Chapter 1), (b) is a second generation TKI characterised by 
irreversible receptor binding [37] and (c) inhibits all active members of the HER family 
[37]. Given the growing body of evidence in support for a chloride secretory mechanism 
of HER TKI-induced diarrhoea (Chapter 2), this thesis also investigated crofelemer as an 
intervention for dacomitinib-induced diarrhoea (Chapter 4). I chose crofelemer as it (a) 
dose-dependently inhibits the two major apical chloride channels found in the intestines 
[118], and (b) has previously been approved for the treatment of diarrhoea [185].  
Utilising gold standard Ussing chambers, electrogenic ion movement across the 





induced diarrhoea being attributable to chloride secretion, now resulting in crofelemer 
being proposed in clinical trials for the treatment of cancer therapy induced diarrhoea 
[143]. The body of work described in this thesis: 
• Characterised dacomitinib-induced diarrhoea, with strong evidence provided of 
barrier dysfunction and mucosal atrophy.  
• Showed that damage was confined to the ileum following dacomitinib treatment. 
This was also the area with highest relative expression of ErbB1. 
• Suggested that crofelemer is not useful in this particular setting, as not only was 
it unable to attenuate diarrhoea, it also made it worse.  
• Did not support the initial hypothesis of chloride secretion being a mechanism of 
dacomitinib-induced diarrhoea in this model. 
 
Given the stark contrast seen between the in vitro and in vivo studies of Chapter 4, where 
the in vitro proof of concept was not translated to the whole-organism model, Chapter 5 
aimed to bridge the gap between in vitro and rodent models, with a zebrafish model of 
gastrointestinal toxicity. Zebrafish are providing several productive avenues for 
toxicology research and Chapter 5 aimed to harness this to develop a timely screening 
model for gastrointestinal toxicity second to cancer treatment. The transgenic reporter 
line utilised in this model did not report gastrointestinal toxicity as predicted. However, 
it did highlight that the generation of robust and reproducible genetic models of zebrafish 
intestinal toxicity is warranted. A model that can be readily induced in a short time-
frame will have the potential to provide a novel platform for high throughput 







Histopathological damage to the ileum, barrier dysfunction, and 
inflammation: traits of dacomitinib-induced gastrointestinal toxicity 
With the advent of targeted therapies, it was anticipated that side effects would be few, 
however this has not come to fruition [14, 122]. In fact, the incidence of gastrointestinal 
toxicity is increasing with their use, which is exacerbated by the chronic oral 
administration and concomitant treatment [16]. Despite this increasing incidence, there is 
still limited understanding of mechanisms underpinning the toxicity, with literature 
reporting varying findings ranging from no histopathological damage seen, to significant 
damage. It is therefore imperative to provide a detailed investigation of mechanisms 
underpinning TKI-induced gastrointestinal toxicity. Dacomitinib was an attractive agent 
to use to interrogate mechanisms as it is associated with high levels of diarrhoea, and 
irreversibly targets all active members of the HER family.  
 
There have been contradictions throughout the literature about whether TKI-induced 
diarrhoea is associated with histopathological damage (as is this case with traditional 
chemotherapy-induced diarrhoea) [16]. The study presented in Chapter 3 demonstrated 
for the first time that dacomitinib was associated with significant histopathological 
damage. This was characterised by a number of validated features of mucosal injury, 
with terminally differentiated enterocytes being the most affected. Importantly, this 
damage was isolated to the ileum, with no other areas of the gastrointestinal tract 
identified as displaying histopathological damage.  
 
Furthermore, an analysis of 7 cytokines common to mucosal injury following cytotoxic 
treatment, were analysed, and only MCP-1 was found to be upregulated, and again this 





upregulated in patients with inflammatory bowel disease (IBD) [186]. IBD is 
characterised by increased permeability and an influx of granulocytes and monocytes 
which exacerbate inflammation and tissue injury. The parallels could open the avenue 
for future therapeutic interventions such as granulocyte and monocyte adsorptive 
apheresis (GMA), which has been successful in the IBD field [187]. However, when 
considering systemic interventions such as this, careful considerations must be made 
about their safety in regards to tumour growth.   
 
The localisation of injury to the ileum may begin to explain why there has been such 
variation in the literature around histopathology of TKI-induced gastrointestinal toxicity, 
as if the ileum specifically was not assessed, no damage would be noted. The publication 
arising from Chapter 3 was also the first to characterise ErbB receptor expression along 
the gastrointestinal tract of rats, revealing that ErbB1 is expressed at a relatively higher 
rate in the ileum compared to other regions of the tract. This correlates with the site of 
histopathological damage, which may suggest why peak damage was seen at this site.  
 
Mucosal enterocyte barrier disruption has been associated with a number of 
gastrointestinal disorders characterised by diarrhoea, and is suggested to worsen clinical 
outcomes, as it allows for translocation of endotoxin and bacteria [136]. Additionally, 
previous research has shown alterations in intestinal barrier function following various 
cytotoxic treatments, with tight junction dysfunction gaining momentum as a key feature 
of chemotherapy-induced gastrointestinal toxicity [137, 188]. However, the role barrier 
function has in TKI-induced gastrointestinal toxicity has been largely ignored. The study 
described in Chapter 3 utilised FITC-dextran to show barrier dysfunction following 





study described in Chapter 4, with tight junction defects characterised in the ileum and 
colon. Three important tight junction proteins were investigated given their established 
role in maintaining barrier function [188]. Notably, these changes also coincided in the 
ileum, the region where peak histopathological damage and inflammation was seen. This 
is of particular importance, as inflammation has been associated with the induction of a 
‘leaky’ gut [135, 136]. Furthermore, although not presented, I found that colon tissue 
mounted into Ussing chambers from rats treated with dacomitinib in either treatment 
schedule, showed no difference in conductance, a measure of permeability (p > 0.05). 
Conversely, rats treated with crofelemer and dacomitinib combination showed 
significantly increased conductance in the ileum compared to all other treatment groups 
(p < 0.003), indicating increased barrier dysfunction in this group. Characterising 
intestinal barrier dysfunction is central to understanding the development of 
gastrointestinal toxicity, as it is proposed that breakdown of the intestinal mucosal 
barrier contributes to diarrhoea through leak-flux mechanisms allowing passive 
movement of water into the lumen [138]. In addition, inflammation in the 
gastrointestinal tract is also reported to decrease sodium absorption, thereby further 
contributing to fluid loss in diarrhoea [189]. Furthermore, given the histopathological 
damage is pronounced at the ileum, it is likely to lead to decreased bile acid uptake, 







Highlighting limitations to the hypothesis of chloride secretory 
mechanisms for TKI-induced diarrhoea with crofelemer  
The gold standard in management of cancer-therapy induced diarrhoea are the 
MASCC/ISOO clinical practice guidelines for the management of mucositis second to 
cancer treatment [60]. Although no recommendations are made by these guidelines on 
how to treat diarrhoea second to TKIs, there is a call for more research of TKI-induced 
diarrhoea [191]. Currently, pharmacologic management of ErbB TKI-induced diarrhoea 
is largely limited to loperamide, a synthetic oral opioid drug that decreases peristalsis 
and fluid secretion [61]. However, no anti-diarrhoeal medication used for the 
management of TKI-induced diarrhoea offers a targeted approach, primarily due to the 
lack of understanding of the underlying mechanisms. This thesis (Chapter 2) described 
the emerging anecdotal evidence for chloride secretion as a mechanistic hypothesis for 
TKI-induced diarrhoea, and offered crofelemer, an anti-secretory, anti-diarrhoeal as a 
targeted treatment. This publication was provided as the rationale for a phase II 
evaluation of crofelemer for the prevention and prophylaxis of diarrhoea in patients 
administered pertuzumab-based regimens by Gao and colleagues, who are currently 
recruiting patients [143]. 
 
The research presented in Chapter 4 demonstrated that in vitro experiments supported the 
hypothesis of chloride secretion as the underlying mechanism of dacomitinib-induced 
diarrhoea. However, when these findings were translated into a whole organism, and ex 
vivo model, there was minimal evidence supporting chloride secretion as a mechanism 
for dacomitinib-induced diarrhoea. Although my study utilised the gold standard of 
assessing electrogenic ion movement across an epithelium, the Ussing chamber 





measure electrogenic secretion, however are unable to measure electroneutral sodium 
chloride transport [192]. In the context of other inflammatory bowel diseases, sodium 
transport is considered important in measuring changes in bowel function. In fact, the 
predominant mechanism of IBD associated diarrhoea involves impairment of 
electroneutral sodium chloride absorption, with very little role, if any played by anion 
secretion [193]. However, as this was not the primary outcome of interest given the 
prevailing chloride secretion hypothesis, this was not assessed in this thesis. Although 
the ex vivo Ussing chamber investigations did not return evidence for a secretory 
diarrhoea phenotype following dacomitinib treatment, blood biochemistry results may 
indicate otherwise. There was a significant increase in the anion gap, a marker of 
metabolic acidosis. Acidosis occurs when bicarbonate is lost, however, our results 
showed no significant loss in bicarbonate, thus making the interpretation quite difficult 
in this context. Given the decreased albumin results, which can be related to kidney 
damage, this further exacerbates complications in interpretation. Nevertheless, the 
blatant differences and lack of translatability from the in vitro and in vivo components of 
this thesis should be considered. T84 monolayers lack other neuro-immune mucosal cell 
interactions, and of particular importance to this thesis, the impact that inflammation has 
on tight junctions, which can influence chloride secretion via leak flux mechanisms. The 
ex vivo analysis of this study utilised tissue from animals exposed to dacomitinib for 21 
days, and was therefore inflamed. This is in stark contrast to the in vitro component, in 
which dacomitinib was administered to healthy cells. While future studies could consider 
administering dacomitinib in the Ussing chamber to ‘healthy’ animal tissue to see acute 






When a drug is added to healthy tissue to model response, it does not take into account 
that clinically the gut would be in an inflamed state. The tissue hence reacts very 
differently than in the healthy state due to altered expression of proteins and transporters 
[153]. Therefore, this method of analysis does not adequately represent the true changes 
in function and signalling. In fact, the state of gastrointestinal inflammation may point to 
potential flaws in the hypothesis of TKI-induced diarrhoea being due to secretory 
mechanisms. The hypothesis is based on ErbB being a negative regulator of chloride 
secretion in normal settings, and so when inhibited there is a loss of negative regulation, 
and thus increased chloride secretion. This hypothesis was supported by previous 
research with HER-1 TKI, lapatinib, which was not associated with inflammation [90]. 
However, the hypothesis does not consider that the tissue may be inflamed, and hence 
behave differently, a fundamental caveat. This is primarily demonstrated with DSS-
induced colitis models, that have shown that when tissue is in an inflamed state, ErbB1 
phosphorylation actually enhances chloride secretion, instead of inhibiting it [153].  
 
Crofelemer has previously been shown to exert its antisecretory effect via partial 
inhibition of CFTR, and complete inhibition of CaCC (TMEM16A) [118]. Current 
literature suggests it has no contraindications. It was chosen for use in this thesis based 
on its lack of systemic absorption and its reported selectivity in acting only on the apical 
side of the CaCC and CFTR chloride channels of the gastrointestinal tract [118]. The in 
vitro arm presented in Chapter 4 clearly demonstrated that crofelemer inhibited chloride 
secretion, supported by the current literature.  Conversely, when I translated crofelemer 
to the in vivo arm, the electrophysiological analysis demonstrated that crofelemer had no 
inhibitory effect on chloride secretion. Additionally, crofelemer was unable to attenuate 





washout may explain the lack of effect seen with crofelemer, but does not explain the 
significantly worse clinical presentation. It was unlikely that this was associated with 
increased dacomitinib exposure given the cMin was unaffected with crofelemer co-
treatment, however without doing a more in-depth pharmacokinetic analysis, conclusions 
cannot be confidently drawn. Regardless, this is the first study to suggest that crofelemer 
may have paradoxical effects, and warrants further investigation before crofelemer is 
used in conjunction with other pharmaceuticals. Research with crofelemer has previously 
been focused on non-infectious diarrhoea, driven by chloride secretory mechanisms 
[117], with only one study suggesting that crofelemer may be effective in an infectious 





Bridging the gap between in vitro and whole-organism models with 
zebrafish 
The study presented in Chapter 5 aimed to harness zebrafish as a model to overcome the 
prohibitive expense and time constraints of currently used rodent models. While in vitro 
models have helped for high throughput screening, the lack of surrounding cells and 
tissues limits their usefulness. Often this results in a lack of translatability, as was clearly 
seen in Chapter 4. Zebrafish allow for rapid, miniaturised, whole-organism toxicity 
testing due to their ease of handling, fecundity, low cost, rapid external development, 
amenability to genetic manipulation and the genetic similarity to higher vertebrates 
[183]. To date, there has been minimal use of zebrafish for the study of gastrointestinal 
toxicity, however their use in other gastrointestinal diseases is gaining momentum [178].  
 
Zebrafish express ErbB receptors [195], and chloride channels [196, 197]. As such, I 
decided to further exploit zebrafish and investigate their feasibility in this field. Chapter 
5 utilised the Tg(cyp2k18:egfp) transgenic reporter line with the hypothesis that the 
eGFP would be induced in the gastrointestinal tract if toxicity was induced in larvae, 
allowing for rapid screening of gastrointestinal toxicity. Unfortunately, due to the 
material transfer agreement (MTA) with Pfizer Pharmaceuticals, dacomitinib was unable 
to be used in this model. Afatinib was therefore selected as the pan-HER TKI, as it is 
readily available and is the same class as dacomitinib (characterised in Chapters 3 and 
4). The active metabolite of irinotecan, SN38, was selected as the cytotoxic as it has been 
well characterised in the literature as causing severe gastrointestinal toxicity and 
diarrhoea [127]. Together, they represent two different classes of cancer drugs known to 
cause gastrointestinal toxicity. Upon testing with SN38 and afatinib, I found that the 





following either of these two drugs, as eGFP was not induced in the gastrointestinal 
tracts of the larvae. One of the key limitations of using aquatic animals, is that all drugs 
must be administered in water, making drug solubility a major contributing factor in the 
success of the model. Therefore, the potential confounding issue in this model may be 
that sufficient concentrations were not achieved to induce liver or gastrointestinal 
toxicity due to low solubility and/or poor permeability, and thus lack of gastrointestinal 
absorption. This may offer an explanation as to why no fluorescence was seen. While 
this study overcame this limitation in adult fish by administering drugs via oral gavage or 
intraperitoneal injection, such approaches are not feasible in larvae nor are adults readily 
screenable for reporter eGFP induction due to inherent opacity. Nevertheless, the use of 
zebrafish to screen new compounds is gaining momentum [198-201]. Their use is not 
just attractive to toxicity, but also molecular oncology, with the opportunity to 
investigate multiple genetic alterations associated with the development of human 
cancers and validation of novel anticancer drug targets [198]. Particularly, the 
transparent zebrafish models can be used as a xenotransplantation system to rapidly 
assess tumorigenesis and metastatic behaviour of cancer stem or progenitor cells [198]. 
Given the success of zebrafish reporter lines for toxicity screening others have yielded, it 
may be worthwhile taking a more targeted approach, such that soluble cancer drugs 
known to induce gastrointestinal toxicity are administered to zebrafish. In this way, 
highly upregulated genes in the gastrointestinal tract can be identified as biomarkers of 
toxic response, and tagged with eGFP. Creating such a model could subsequently be 
used for high throughput screening of new cancer drugs, however the heterogeneity of 






Despite overcoming treatment difficulties in adults, afatinib still did not induce 
gastrointestinal histopathological damage, potentially due to regionalisation of the 
zebrafish intestine not representing the ileum closely enough. As outlined in Chapters 3 
and 4, the ileum is the key region damaged following pan-HER TKI administration. 
Additionally, this model used a single dose administration, as opposed to the typical 
protracted administration of pan-HER TKIs, where 7 days is needed to see 
histopathological damage, which may explain the lack of damage seen in zebrafish. 
Given this, it is possible that afatinib exposure may not have been sufficient, and future 
studies would need to test for retention and absorption of any drug used.  
 
Although the transgenic reporter line was unable to screen for gastrointestinal toxicity, 
the adult zebrafish administered SN38 did show histopathological damage to the 
intestines reminiscent of changes seen in clinical samples. This is the first time SN38 has 
been administered in adult zebrafish, and given the positive result, could be expanded on 
to other drugs, particularly the growing area of oral formulations of SN38. Given the 
many advantages of utilising zebrafish, and the evidence that zebrafish can indeed 
develop gastrointestinal injury from cytotoxic agents, further investigation is warranted. 
While a robust and tractable genetic model of gastrointestinal toxicity is not available 
yet, the identification of genes required for the rapid proliferation of zebrafish intestinal 
epithelial cells during development has highlighted a number of essential genes that 
could be targeted to disable gastrointestinal toxicity [202]. Moreover, zebrafish are being 
exploited for other gastrointestinal inflammatory pathologies, and intestinal epithelial 
barrier function has been identified as a characteristic in these models [166]. Given the 
increasing acknowledgement of barrier dysfunction as a key factor in the development of 





platform to investigate this. With currently available tools, the interplay between 
epigenetic regulators, intestinal injury, microbiota composition and innate immune cell 
mobilisation can be analysed in exquisite detail [183]. This provides excellent 








It is clear that second generation, pan-HER TKIs induce diarrhoea in a high proportion 
of patients. With the increasing use of these agents, understanding the mechanisms of 
HER TKI-induced diarrhoea are crucial. This will enable researchers to investigate 
potentially effective interventions to help prevent adverse event aggravation, dose 
reductions or therapy discontinuation.    
 
The studies presented in this thesis have shown that pan-HER TKI-induced 
gastrointestinal toxicity is associated with histopathological damage, inflammation, and 
intestinal barrier dysfunction in the ileum, the region where ErbB1 is preferentially 
expressed. It is likely that this injury seen following HER TKI treatment, is the cause of 
diarrhoea. Through a number of investigations, this thesis highlighted limitations to the 
mechanistic hypothesis of HER TKI-induced diarrhoea being of secretory phenotype. 
Furthermore, the publications airing from this thesis are the first to suggest that 
crofelemer may have contraindications, emphasising the importance of preclinical trials, 
and that crofelemer should be used with caution when prescribed with other medications.   
This thesis has also brought light to the potential future use of zebrafish as a high 
throughput screening tool for gastrointestinal toxicity. Further progress in this area 
would be greatly facilitated by the generation of robust and reproducible genetic models 
of zebrafish intestinal toxicity that can be readily induced in a short time-frame, allowing 
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STATEMENT BY STUDY DIRECTOR 
The current study was conducted in the School of Medical Sciences, The University of Adelaide, 
South Australia. Whilst all experiments were conducted with the utmost rigor, this laboratory is 
not GLP certified. With the exception of the blood serum analysis, which was carried out at the 
IMVS under GLP conditions, all data presented is derived from work not conducted in a GLP 
laboratory.  
Rat experiments were designated in WR (Wistar rat) and were approved by the Animal Ethics 
Committee of the University of Adelaide and complied with the National Health and Medical 
Research Council (Australia) Code of Practice for Animal Care in Research and Training (2014).  
Analyses performed in the School of Medical Sciences, The University of Adelaide were 
according to the principles of good laboratory practice, following standard operating procedures.  
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SUMMARY 
Study Findings 
PART 1  
Ethics approved the use of Albino Wistar rats to investigate the mechanisms of dacomitinib-
induced diarrhoea and prevention with crofelemer. 34 rats were used in 4 dose-finding pilot 
studies, 48 rats were used in the main study, 24 rats were used in a follow-up repeat study.  
Dose-finding pilot study 1 (n = 8) 
Dacomitinib was administered at 7.5 mg/kg/day via oral gavage at 12 pm daily and induced mild 
to severe diarrhoea without mortality and was deemed appropriate for all further investigations. 
Crofelemer was administered at 10 mg/kg via oral gavage at 9 am daily. Crofelemer given with 
control (methyl-cellulose buffer) was safe and showed no clinical signs in rats. When combined 
with dacomitinib, crofelemer reduced the number of days with diarrhoea compared to 
dacomitinib alone from 19 to 12. While this dose of crofelemer did decrease the total number of 
days with diarrhoea, this decrease was not significant.  
Dose-finding pilot study 2 (n = 8) 
Dacomitinib was administered at 7.5 mg/kg/day via oral gavage at 12 pm daily and induced mild 
to severe diarrhoea without mortality and was deemed appropriate for all further investigations. 
Crofelemer was administered at 50 mg/kg via oral gavage at 9 am daily. Crofelemer given with 
control (methyl-cellulose buffer) was safe and showed no clinical signs in rats. When combined 
with dacomitinib, crofelemer increased the number of days with diarrhoea compared to 
dacomitinib alone from 9 to 13. As this dose of crofelemer increased the total number of days 
with diarrhoea, it was not deemed appropriate.  
Dose-finding pilot study 3-4 (n = 16) 
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Dacomitinib was administered at 7.5 mg/kg/day via oral gavage at 12 pm daily and induced mild 
to severe diarrhoea without mortality and was deemed appropriate for all further investigations. 
(3) Crofelemer was administered at 25 mg/kg via oral gavage at 9 am daily. Crofelemer given 
with vehicle control (methyl-cellulose buffer) was safe and showed no clinical signs in rats. One 
rat treated with 25 mg/kg in combination with dacomitinib was removed from the study early 
due to excessive weight loss (> 15 %). When combined with dacomitinib, crofelemer reduced the 
number of days with diarrhoea from 19 to 9 and the severity from grade 3 to grade 1, compared 
to dacomitinib alone.  
(4) To assess the best treatment schedule, 25 mg/kg crofelemer was given at 4 pm via oral 
gavage from the onset of diarrhoea. Crofelemer given in this treatment schedule reduced the total 
number of days with diarrhoea from 12 to 11. This treatment schedule did not significantly 
reduce the total number of days with diarrhoea and was not deemed appropriate.  
Combination of dacomitinib and crofelemer at 25 mg/kg in the treatment schedule of daily at 9 
am (3) was most effective, decreasing the number of days with diarrhoea from 19 to 9. Previous 
research in mice has shown that 30 mg/kg crofelemer is effective at reducing cholera toxin-
induced water accumulation in the intestines.  As such, it seems feasible that 25 mg/kg 
crofelemer in our pilot study reduced diarrhoea by preventing water accumulation in the 
intestines following dacomitinib treatment. This dose and treatment schedule was continued for 
the main study. 
Main study (n = 48) 
Rats were randomly allocated to receive either vehicle controls (water + methyl-cellulose buffer) 
(n = 12), water + dacomitinib (n = 12), 25 mg/kg crofelemer + methylcellulose buffer (n = 12), 
or 25 mg/kg crofelemer + dacomitinib (n = 12). All animals completed the study and were killed 
at either 7 days of treatment (n = 24) or 21 days of treatment (n = 24). There were no significant 
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differences in the overall incidence (83 % vs. 92 %) or number of days (14 vs. 15) with any 
grade diarrhoea between groups treated with dacomitinib alone or crofelemer + dacomitinib, 
respectively. The incidence of severe grade 3 diarrhoea was 50 % and 67 % in dacomitinib alone 
and crofelemer + dacomitinib groups, respectively.   
Animals treated with dacomitinib gained less weight than control animals. Small intestine, 
stomach, spleen and liver weights were significantly decreased in rats treated with dacomitinib 
alone compared to water control at 21 days.  
In serum biochemistry, anion gap, urea, cholesterol, ALT and LD was significantly increased at 
day 21 in the groups treated with dacomitinib compared to the water control group.  In contrast, 
albumin was decreased.   
Follow up study (n=24) 
To further investigate intestinal changes induced by dacomitinib and crofelemer an additional rat 
study (n = 24) was conducted to assess small intestinal functional changes in Ussing chambers 
and barrier integrity with FITC dextran. Rats were dosed identically to the previous main study 
and were killed at 21 days of treatment.  A number of rats treated with crofelemer + dacomitinib 
(n = 2) and water + dacomitinib (n = 2) were removed from the study early due to excessive 
weight loss (> 15 %) and ethical constraints. Diarrhoea and weight loss trends were consistent 
with the main study. Ussing camber analysis showed no differences in the ileum. Colon samples 
were used to increase the n from the main study, results were consistent with the main study. 
FITC dextran analysis showed that serum concentrations were increased in dacomitinib alone 
and crofelemer/dacomitinib combination rats.  
PART 2 
T84 cell culture study 
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Cell culture was conducted on T84 monolayers grown on polyester Transwell systems, 
mounted into Ussing chambers. Dacomitinib (1 M ) and crofelemer (10 M) were administered 
via apical routes. Exposure time of T84 monolayers to dacomitinib included 5, 20, 60, and 90 
minutes (administration in Ussing chambers), and 3, 6, 24 and 48 hours (administration in 
Transwell). Dacomitinib administration caused significantly increased baseline chloride 
secretion following 5 and 20 minutes of exposure, therefore, crofelemer was only assessed at 
these times. Results showed that dacomitinib induces chloride secretion, and this was inhibited 
when crofelemer was administered, primarily via the calcium stimulated chloride channel. All 
experiments were repeated eight times.   
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PART 1 
IN VIVO STUDY   Compound: Dacomitinib  
(PF-00299804)  
Information Type: Repeat Dose Study   
 
Title: Part 1: Prevention of dacomitinib-induced diarrhoea by targeting chloride 
secretion – In vivo study  
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p.o. dacomitinib  
(0.5% HPMC)  
p.o. crofelemer 
(sterile distilled water) 
 
21 days 0, 7.5 
q.d. (12 
pm) 




24 male  Pf1 
Key: p.o. per oral (oral gavage to stomach), q.d. once daily dose (with time indicated in brackets) 
 
 
Table 1 (Continued).   Report Title: Progress report and results Test Article:  Dacomitinib and crofelemer 
Report No.:  1 
Study No.: Pf1 
Duration of Dosing:  21 days 
Duration of Recovery:  0 days 
Location: UoA animal holding facility 
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Species/Strain:  Rat /albino Wistar Route/Frequency:  Oral gavage, once daily  Necropsy Dates: 16/6/14, 17/6/14, 29/07/14 
Weight Range on Day 0 (g): 
Male:  186 – 268  
 
Test Material:  Dacomitinib, crofelemer 
Batch Number: 0015 
Dosing Period Dates: 
First Dose: 26/05/14 
Final Dose: 28/07/14 
Initial Weight (g):  219.4  25.2 Vehicle:  0.5% HPMC in sterile distilled water Testing Facility: UoA - Physiology 
Study in Compliance With GLP:  
N/A 
Dose Frequency:  Once daily 
Data Collected:   Clinical observations, body weight, organ weight, necropsy findings, daily diarrhoea. 
  
Daily Dose dacomitinib  (mg/kg) 0 0 0 0 7.5 7.5 7.5 7.5 
Daily Dose crofelemer (mg/kg) 0 10 25 50 0 10 25 50 
Numbers of Animals:   6 2 2 2 6 2 2 2 
         
Noteworthy Findings:  No treatment-related adverse events. One rat with chronic renal changes required 
removal  
Number of Unscheduled Deaths: 0                       1 
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Clinical Observations:  Restraint stress caused urination and defecation during gavage process as expected. Dacomitinib caused 
persistent diarrhoea without mortality. Crofelemer treatment caused no clinical changes.  
 
Table 1 (Continued).   Report Title: Pf1 repeat dose study pilot     
Clinical Observations         

















Number of Animals: 6 2 2 2 6 2 2 2 
Any loose feces G1 - 3 (and severe diarrhoea G3 only) 2 (0) 1 (0) 2 (0) 2 (0) 6 (2) 2 (1) 2 (0) 2 (1) 
Weight loss (at any time) 0 0 0 0 4 0 1 0 
Distended Abdomen 0 0 0 0 0 0 0 0 
Decreased activity/Lethargic 0 0 0 0 2 1 1 1 
Piloerection 2 2 2 2 4 2 2 2 
Hunched posture 0 0 0 0 0 0 0 0 
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Red discoloration (discharge, material, staining) of fur 
(around eyes, snout, forelimbs, mouth, penis) 
6 2 2 2 6 2 2 2 
Swollen extremities (i.e. face, paws) 0 0 0 0 0 0 0 0 
Gaunt (stomach sucked in and animal appearing to be in 
pain) 
0 0 0 0 0 0 0 0 
Cold 0 0 0 0 0 0 0 0 
Hot 0 0 0 0 0 0 0 0 
Feet peeling 0 0 0 0 0 0 0 0 
Dribbling from mouth 0 0 0 0 0 0 0 0 
Touch sensitive 0 0 0 0 0 0 0 0 
Eye issues (inflamed and/or blindness) 0 0 0 0 0 0 0 0 
Body Weight (g): Mean 
Day 0 232 193 220 220 220 221 213 227  
Day 21 341 330 350  
 3
28 
260 265 280 274 
 























Organ Weights Mean 
         
Spleen  Absolute (g) 0.68 0.75 0.59 0.55 0.48 0.51 0.48 0.72 
  Relative (%) 0.2 0.21 0.18 0.17 0.19 0.19 0.19 0.26 
         
Liver  Absolute (g) 13.25 13.25 14.15 14.63 9.69 10.16 9.2 11.31 
  Relative (%) 3.84 3.98 4.05 4.46  3.
42 
3.89 3.82 4.12 
         
         
Table 1 (Continued).   Report Title: Pf1 repeat dose study pilot 
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Kidney  Absolute (g) 2.53 2.66 2.78 2.44 2.49 2.58 2.61 3.0 
  Relative (%) 0.74 0.8 0.79 0.74 0.91 1.0 1.1 1.1 
         
Stomach  Absolute (g) 1.82 1.46 1.88 1.83 1.32 1.07 1.62 1.49 
  Relative (%) 0.53 0.43 0.54 0.56 0.6 0.42 0.55 0.54 
                                                                 
Small Intestine Absolute (g) 9.36 10.59 9.86 9.76 7.65 9.53 7.55 9.45 
  Relative (%) 2.72 3.20 2.83 2.89 2.74 3.66 3.07 3.55 
           
Large Intestine  Absolute (g) 1.76 2.41 1.89 1.96 1.77 1.87 1.92 1.94 
  Relative (%) 0.51 0.72 0.74 0.6 0.69 0.72 0.74 0.72 
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Table 1 (Continued).   Report Title: Pf1  repeat dose study pilot     


















Necropsy Findings Incidence  
No. of Rats Examined: 6 2 2 2 6 2 2 2 
Inflamed       Peritoneal Cavity 0 0 0 0 0 0 0 0 
    Small Intestine 0 0 0 0 1 0 0 1 
                     Large Intestine 0 0 0 0 1 0 0 1 
    Mesenteric Lymph Nodes 0 0 0 0 1 0 0 0 
Peritoneal cavity Fluid     Pink/Red 0 0 0 0 0 0 0 0 
                                        Clear/Opaque 0 0 0 0 0 0 0 0 
Discoloured Spleen 0 0 0 0 0 0 0 0 
                      Liver                  0 0 0 0 1 0 0 0 
                      Kidney 0 0 0 0 0 0 0 0 
Lesions          Small Intestine 0 0 0 0 0 0 0 1 
                       Large Intestine 0 0 0 0 0 1 0 0 
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                       Caecum 0 0 0 0 0 0 0 0 
Stomach        Bedding in 0 0 0 0 1 2 1 2 
                      Bloated 2 1 0 0 6 1 1 1 
Liver              Swollen 0 0 0 0 0 0 0 0 
Intestines      Blocked 1 0 1 0 0 0 0 1 
                     Perforated 0 0 0 0 0 0 0 0 
                     Telescoped 0 0 0 0 1 0 0 0 
                     Adhered to themselves 0 0 1 0 2 0 0 1 
                     Watery Contents 0 0 0 0 0 0 0 0 
                     Yellow contents (includes stomach) 

















Intestines     Vascularised 0 0 0 1 3 0 1 1 
                     Thin Wall of 0 0 0 0 0 0 0 0 
Caecum        Blood in 0 0 0 0 1 0 0 0 
Colon            Gaseous/Distended 
 
2 1 2 1 6 1 1 2 
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Table 1 (Continued) 
Percentage of rats per day with diarrhoea 
(any) 
Report title: Pf1 repeat dose 
study pilot 
     

















Day 1 0 0 0 0 0 0 0 0 
2 33 0 0 0 0 0 0 0 
3 0 0 0 0 33 0 0 0 
4 0 0 0 0 33 0 50 100 
5 0 50 0 0 83 50 50 100 
6 0 0 0 0 50 100 100 100 
7 0 0 0 0 33 100 50 50 
8 0 0 0 0 83 100 100 0 
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Table 2 Report Title: Pf1 main experiment  Test Article:  Dacomitinib and crofelemer  
9 0 0 0 0 50 100 50 0 
10 0 0 0 0 67 100 50 50 
11 0 0 0 0 100 50 50 100 
12 0 0 0 0 83 0 100 100 
13 0 0 100 0 83 0 0 100 
14 0 0 0 100 83 0 0 100 
15 0 0 0 0 83 0 0 100 
16 0 0 0 50 83 100 0 100 
17 0 0 0 0 83 100 0 50 
18 17 0 0 0 50 100 0 100 
19 0 0 0 50 100 100 0 0 
20 0 0 0 0 83 100 0 0 
21 0 0 0 0 100 100 0 0 
         
 



















p.o. dacomitinib in 
vehicle 
(0.5% HPMC) 
p.o. crofelemer in 










q.d. (9 am) 
 
 
48 males  PF1 main 
Key: p.o. per oral (oral gavage to stomach), q.d. once daily dose (with time indicated in brackets) 
 
 
Table 2 (Continued).   Report Title: Progress report and results Test Article:  Dacomitinib and crofelemer 
Report No.:  1 Duration of Dosing:  21 days Location: UoA animal holding facility 
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Study No.: Pf1 main Duration of Recovery:  0 days 
Species/Strain:  Rat /albino Wistar Route/Frequency:  Oral gavage/Once daily  Necropsy Dates: 22/09/14, 23/09/14, 
24/09/14, 9/10/14, 10/10/14  
Weight Range on Day 0 (g): 
Male:  147 – 245  
 
Test Material:  Dacomitinib, crofelemer 
Batch Number: 0015 
Dosing Period Dates: 
First Dose: 15/09/14 
Final Dose: 09/10/14 
Initial Weight (g):  194.6  30.4 Vehicle:  0.5% HPMC in sterile distilled water Testing Facility: UoA - Physiology 
Study in Compliance With GLP:  
N/A 
Dose Frequency:  once daily 
Data Collected:  Clinical observations, body weight, clinical biochemistry, organ weights, necropsy findings, daily diarrhoea. 
 
Daily Dose dacomitinib  (mg/kg) 0 0 7.5 7.5 
Daily Dose crofelemer (mg/kg) 0 25 0 25 
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Noteworthy Findings: No treatment-related adverse events 
Number of Unscheduled Deaths: 0 0 0 0 
Clinical Observations:  Restraint stress caused urination and defecation as expected. Dacomitinib caused persistent diarrhoea. 
Crofelemer did not reduce diarrhoea in rats. 
 
Table 2 (Continued).  Report Title: Pf1 main study  
Clinical Observations   
Daily Dose dacomitinib (D), crofelemer 
(C) mg/kg  
0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 
 Incidence 
Number of Animals: 12 12 12 12 
Any loose faeces G1-3 (and severe diarrhoea 
G3 only) 
4 (0) 2 (0) 10 (6) 11 (8) 
Weight loss (at any time) 0 0 4 3 
Distended Abdomen 0 0 0 0 
Decreased activity/Lethargic 0 0 2 1 
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Piloerection 2 9 10 12 
Hunched posture 0 0 4 6 
Red discoloration (discharge, material, 
staining) of fur (around eyes, snout, 
forelimbs, mouth, penis) 
9 10 9 10 
Swollen extremities (i.e. face, paws) 0 0 0 0 
Gaunt (stomach sucked in and animal 
appearing to be in pain) 
0 0 0 0 
Cold 0 0 0 0 
Hot 0 0 0 0 
Feet peeling 0 0 0 0 
Dribbling from mouth 0 0 0 0 
Touch sensitive 0 0 0 0 
Eye issues (inflamed and/or blindness) 0 0 0 0 
Body Weight (g): Mean 
Day 0 196.8 191.2 192.1 198.3 
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 Day 7 237.8 235.1 220.3 222.3 
Day 21 341.2 331.8 258.2 265.8 
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Table 2 (Continued).    Report Title: Pf1 main study 
Daily Dose dacomitinib (D), crofelemer 
(C) mg/kg 
0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 
Organ Weights1: Mean 
Spleen - Day 7Absolute (g) 0.54 0.57 0.49 0.51 
 - Day 21 Absolute (g) 0.68 0.68 0.51* 0.54* 
     
Liver - Day 7Absolute (g) 9.33 10.06 8.71 9.71 
 - Day 21 Absolute (g) 13.25 13.36 9.48* 10.21* 
     
Kidney - Day 7Absolute (g) 1.87 1.84 1.84 1.84 
 - Day 21 Absolute (g) 2.54 2.37 2.6 2.42 
     
Stomach - Day 7Absolute (g) 1.47 1.65 1.42 1.4 
 - Day 21 Absolute (g) 1.82 1.97 1.32* 1.6 
 









different from water control group (Two-Way ANOVA with Tukey post-hoc test, p<0.05) 
  
     
Small Intestine- Day 7 Absolute (g) 8.33 9.18 7.03 7.02 
  -  Day 21 Absolute (g) 9.36 9.99 7.35* 8.38 
     
Large Intestine- Day 7 Absolute (g) 1.63 1.71 1.44 1.57 
 -   Day 21 Absolute (g) 1.76 1.9 1.83 1.66 
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Table 2 (Continued). Report Title: Pf1 main study 
 
Daily Dose dacomitinib (D), crofelemer (C) 
mg/kg 
0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 
Pathology findings Incidence  
No. of Rats Examined: 12 12 12 12 
Inflamed       Peritoneal Cavity 0 0 0 0 
    Small Intestine 0 0 0 0 
                     Large Intestine 0 0 1 0 
    Mesenteric Lymph Nodes 0 0 0 0 
Infected        Mesenteric Lymph Nodes 0 0 0 0 
                     Intestines/Surrounds 0 0 0 0 
Peritoneal cavity Fluid     Pink/Red 0 0 0 0 
                                        Clear/Opaque 0 0 0 0 
Discoloured Spleen 0 0 0 0 
                      Liver                  0 0 0 0 
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                      Kidney 0 0 0 0 
Lesions          Small Intestine 0 0 0 0 
                       Large Intestine 0 0 0 0 
                       Caecum 









Stomach        Bedding in 0 0 1 3 
                      Bloated 









Liver              Swollen 0 0 0 0 
Intestines      Blocked 1 1 0 1 
                     Perforated 0 0 0 0 
                     Telescoped 0 0 0 0 
                     Adhered to themselves 0 1 0 0 
                     Watery Contents 0 0 2 0 
                     Yellow contents (includes stomach) 0 0 2 0 
                     Undigested contents 0 0 0 0 
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Table 2 (Continued).  Report Title:  Pf1 main study  
















Blood Biochemistry: Mean  Mean 
Sodium  (mmol/L) Day 7 









Anion Gap  (mmol/L)         
Day 7 











Caecum        Blood in 0 2 3 5 
Intestines     Vascularised 0 0 0 0 
                     Thin Wall of 0 0 0 0 
Colon           Gaseous/Distended 5 7 7 8 
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Potassium  (mmol/L) Day 7 










Glucose  (mmol/L)             
Day 7 
                                          









Chloride  (mmol/L) Day 7 









Urea  (mmol/L)                  
Day 7 










Bicarb  (mmol/L) Day 7 










Creatinine  (umol/L)          
Day 7 
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Cholesterol  (mmol/L)Day 7 










Albumin  (g/L)                  
Day 7 











Urate (mmol/L) Day 7










Globulin  (g/L)                  
Day 7 











Phosphate  (mmol/L) Day 7










Protein  (g/L)                    
Day 7 
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Total Calcium  (mmol/L)
 Day 7 










Tot. Bilirubin (mmol/L)      
Day 7 











ALP  (U/L) Day 7 










AST  (U/L)                         
Day 7 











ALT  (U/L) Day 7 










LD   (U/L)                           
Day 7 












*Indicates significantly different from water control group (Two-Way ANOVA with Tukey post-hoc test, p < 0.05) 
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Table 2 (Continued) 
Percentage of rats per day with diarrhoea (any) 
Report Title Pf1 main study 
  
Daily Dose dacomitinib (D) & crofelemer (C) 
mg/kg 
0D, 0C 0D, 25C 7.5D, 0C 7.5D, 
25C 
Day % 
1 8.3 0 0 0 
2 0 0 8.3 25 
3 0 8.3 0 41.7 
4 0 0 16.7 41.7 
5 0 0 50 91.7 
6 0 8.3 66.7 83.3 
7 0 0 75 91.7 









































































Average no. days with diarrhoea (only 21 day kill 
group incl.) 
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Table 2 (Continued)  
 
Report Title:  Pf1 main study 






0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 




















*Indicates significantly different from control group (One-Way ANOVA with Tukey post-hoc 
test, p < 0.05) 
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Table 2 (Continued)  
 
Report Title:  Pf1 main study 





0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 
           Group Mean 































































































































































































































 *Indicates significantly different from crofelemer/buffer control group (Two-Way ANOVA with 
Tukey post-hoc test, p < 0.05) 
** Indicates significantly different from water/buffer control group (Two-Way ANOVA with 
Tukey post-hoc test, p < 0.05) 
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Table 2 (Continued)  
 
Report Title:  Pf1 main study  





0D, 0C 0D, 25C 7.5D, 0C 7.5D, 25C 
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Table 2 (Continued)  
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* Indicates significantly different from water/buffer control group (Two-Way ANOVA 
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Table 2 (Continued)  
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* Indicates significantly different from water/buffer control group (Two-Way ANOVA with 
Tukey post-hoc test, p < 0.05) 
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End of Results 
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Data, left over samples, and reports will be stored in the School of Medical Sciences, The 
University of Adelaide. 
 
INTRODUCTION 
PF-00299804 (Dacomitinib) is an irreversible pan-HER tyrosine kinase inhibitor that is currently 
in clinical trials for the treatment of non-small cell lung cancer and head and neck squamous cell 
cancer. The most common adverse event reported is diarrhoea, although the underlying cause of 
this side effect is currently unknown. Despite promising response data, the frequency of 
diarrhoea is higher compared to treatment with 1st generation HER inhibitors and is a dose 
limiting toxicity impeding optimal treatment.  All doses and concentrations are expressed in 
terms of the parent compound, which for the purpose of this report is referred to as 
DACOMITINIB.  
Crofelemer is produced from the plant, Croton lechleri (active component oligomeric 
proanthocyanidin), and inhibits both cAMP cystic fibrosis (CFTR) and calcium activated (CaCC) 
chloride channels.  If inhibition of HER signaling results in increased mucosal chloride secretion, 
this agent may be effective at reducing dacomitinib-induced diarrhoea.  Crofelemer is currently 
in clinical trials for treatment of secretory diarrhoea of multiple different etiologies and has 
recently been FDA approved for the treatment of diarrhoea in HIV/AIDS patients on anti-
retroviral therapy. It is not systemically absorbed, only acting locally on the gastrointestinal tract 
to modify water balance without affecting motility.  As such, this agent is potentially an effective 
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The objective of the study was to determine the gastrointestinal changes induced by dacomitinib 
and assess the efficacy of chloride secretion inhibition with crofelemer in a 21 day oral 
administration study in rats.  
Rationale for Selection of Dose 
Dacomitinib and crofelemer doses were selected based on experiments conducted in our 
laboratory.   
Dacomitinib was administered at 7.5 mg/kg via daily oral gavage, which induced mild to severe 
diarrhoea without mortality and was deemed appropriate for all investigations. Crofelemer was 
given daily via oral gavage at 10, 25 and 50 mg/kg doses and were compared in different 
treatment schedules to determine the optimal dose. Combination of dacomitinib at 7.5 mg/kg and 
crofelemer at 25 mg/kg was most effective, decreasing the number of days with diarrhoea from 
19 to 9. Previous research in mice has shown that 30 mg/kg crofelemer is effective at reducing 
cholera toxin-induced water accumulation in the intestines.  As such, it seemed feasible that 25 
mg/kg crofelemer in our pilot study reduced diarrhoea by preventing water accumulation in the 
intestines following dacomitinib treatment. This dose and treatment schedule was considered to 
best reflect the clinical setting and so was chosen for subsequent experiments.   
Rationale for Selection of Species and Route of Administration 
The rat was selected because it is a standard rodent species recognised by international 
regulatory agencies for use in safety evaluation studies.  The Crl:WI(Han) rat was chosen 
because of the knowledge of this strain’s general pathology and response to HER TKI’s.  Male 
rats were used in this study to be consistent with previous experiments that have shown that male 
Wistar rats effectively metabolise HER TKI’s.  
The oral route was selected for dacomitinib and crofelemer because this is the intended route of 
administration to humans. For dacomitinib, this route of administration has been used 
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extensively in preclinical studies, and the pharmalogical response is well documented. For 
crofelemer, previous studies in rats have also preferred this route of administration.  
This study did not replicate any known previous work. 
Regulatory Guidelines 
N/A 
MATERIALS AND METHODS 
Test Article and Dose Preparation 
PF-00299804 (Dacomitinib) was supplied by Pfizer and was stored at room temperature (18C) 
and protected from light. 
Dacomitinib at concentration of 2 mg/mL (as active moiety) in methylcellulose buffer vehicle 
was prepared daily and used immediately. The vehicle was prepared weekly and stored at 
refrigerated temperature (4C) protected from light.  Crofelemer was in tablet form and stored at 
room temperature protected from light in a sterile container. Crofelemer was ground and diluted 
with sterile distilled water to 5 mg/ml immediately before use.  
Fluorescein isothocyanate dextran (FITC) 2-5 kDa made at a solution of 120 mg/ml was 
administered via oral gavage at a dose of 600 mg/kg, 2 hours prior to kill to assess gut barrier 
permeability. 
The compounds, vehicle components, suppliers, and batch numbers used are as follows. 





Crofelemer (Fulyzaq) 3106372 Salix 
   
 













  Animals and Maintenance 
Male Crl:WI(Han) rats were obtained from The University of Adelaide, Waite Campus breeding 
facility, and randomly allocated to study groups.  The rats were housed in groups of 2 to 6 (of the 
same treatment arm) in individually ventilated cages with paper litter.  Following randomisation, 
rats were acclimatised to local housing conditions for a minimum of 7 days prior to the first day 
of dosing.  On Day 1 of treatment, the rats were approximately 6 - 8 weeks old and weighed on 
average 193 g to 233 g. 
Standard pellet rodent chow and filtered water were available ad libitum. If rats were considered 
to be experiencing treatment-related toxicity (e.g., diarrhoea, weight loss, stress marks) they 
were allowed soaked chow in addition, or in severe cases (n = 1) were gavaged lectade oral 
rehydration therapy (Jurox) (glycine, citric acid, potassium phosphate monobasic, potassium 
citrate, sodium chloride, glucose). Available information on the diet used and results from 
periodic analysis of the water in this facility does not indicate the presence of any substance at a 
concentration likely to influence the outcome of the study. 
The environmental controls were set to maintain temperature within the range 19 to 23 C and 
relative humidity within the range 45 % to 70 %; with a 12 - hour light and 12 - hour dark cycle. 
A general check including availability of food and water and environmental conditions was 
performed up to thrice daily. Clinical record sheets were filled in during each check. The clinical 
sheets requested information on piloerection, reluctance to move, reduced food/water intake, 
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diarrhoea and weight loss.  Each category was scored from 0 to 3 (0 = none, 1 = mild, 2 = 
moderate, 3 = severe). Scores of 12 or above required the rat to be checked 4 times daily and 
veterinary advice was sought regarding the removal of the rat from the study. 
STUDY DESIGN 
For each experiment, all rats were randomly allocated to group by randomize.org.  Rats were 
identified by a unique animal number written with an indelible marker on the tail. 
During the 21 day treatment period, rats received daily oral doses of dacomitinib or vehicle at a 
constant dose volume of approximately 5 mL/kg at 9 am. Individual dose volumes were adjusted 
daily according to body weight.  The first day of dosing was designated Day 0, days in the pre-
treatment period were assigned negative numbers.  The final dose was given on the day before 
scheduled necropsy, or in the case of the additional study on the same day as necropsy.  The 
terminal necropsy was conducted on Days 7 and 21.  
Deviations from dose regimen: 
The following table summarises study group assignment and dose information. 
Table of study outline 
  Dose  
Group Dose Concentration  
Number (mg/kg/day) (mg/mL) Number/Sex 
Pf1 
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1 – Water vehicle 
control 
 














1 – Water vehicle 
control 
 











1 – Crofelemer 
 












1 – Crofelemer 
 











MEASUREMENTS AND OBSERVATIONS 
Mortality  
A viability check was performed near the start and end of each working day. If rats appeared 
excessively toxic, checks increased to thrice daily. A necropsy was performed on any animals 
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that were killed early during the treatment period, but these animals were not included in final 
analysis.  
Clinical Observations 
A check of the condition and behaviour of all animals was made daily throughout the treatment 
period.  During the treatment period, all animals were examined and clinical signs recorded twice 
daily. Detailed clinical examinations were performed prior to initiation of dosing, during days 0 - 
21 and on the day of necropsy. 
Where identical findings (including no abnormalities detected) were recorded for an animal more 
than once on the same day, only one instance of the finding has been reported. 
Mild diarrhoea was defined as soft stools (G1), moderate diarrhoea as loose stools with perianal 
staining of fur (G2), and severe diarrhoea as watery stools +/- mucous with fur staining 
incorporating hind legs (G3).  
Body Weight 
The animals were weighed at 9 am once daily during the treatment period and on the day of 
necropsy. 
Food Consumption 
Animals were allowed ad libitum access to standard rat chow and water. Food consumption was 
not recorded. 
Clinical Pathology 
Blood was collected at scheduled necropsy by cardiac puncture under deep isoflurane 
anaesthesia. Serum was separated and biochemical analysis performed at an external facility 
(Institute of Medical and Veterinary Science, The Royal Adelaide Hospital).  
Clinical Chemistry 
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Samples for clinical chemistry were collected into serum tubes without anticoagulant. The 
following parameters were measured from serum samples. 
Alanine aminotransferase Urea 
Aspartate aminotransferase Creatinine 
Alkaline Phosphatase Phosphate 
Lactate dehydrogenase Bicarbonate 
Total bilirubin Sodium  
Glucose  Potassium  
Total protein 
Globulin 
Gamma-glutamyl transpeptidase  
Anion Gap 
 
Fluorescein isothocyanate dextran 
Fluorescein isothocyanate dextran (FITC) 2-5 kDa made at a solution of 120 mg/ml was 
administered via oral gavage at a dose of 600 mg/kg, 2 hours prior to kill. Levels of FITC were 
determined using fluorescent reading conducted on serum samples collected at necropsy to 
assess gut barrier permeability.  
Terminal Procedures 
After 7 and 21 days of treatment animals were killed by exsanguination under deep isoflurane 
anaesthesia followed by cervical dislocation. 5 mL of blood without anticoagulant for serum 
together with tissue samples from the digestive tract were obtained from all animals.   
Organ Weights 
The following organs were weighed: 
Small intestine Liver   
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Large intestine Spleen  
Stomach (empty) Kidney  
 
Tissues Fixed and Examined 
Following a detailed external and internal examination, the tissues highlighted below were taken 
from each animal and preserved in either: 10% neutral buffered formalin (NBF), snap frozen in 
liquid nitrogen (SF), frozen in RNA later (RNA) (Sigma Aldrich), or placed in Ringers with 
indomethacin (R) (composition in mmol L−1: NaC1 115.4; KCl 5; MgCl2 1.2; NaH2PO4 0.6; 
NaHCO3 25; CaCl2 1.2 and glucose 10).  
 Tissues  Tissues 
Tissues Fixed Examined Tissues Fixed Examined 
Adrenals X Pituitary X 
Animal identification  Preputial/clitoral gland  X 
Aorta (thoracic) X Prostate X 
Brain X Rectum X 
CAECUM NBF Salivary gland - X 
Cervix X mandibular X 
COLON 
NBF, R, SF, 
RNA 
sublingual X 
DUODENUM NBF, SF, RNA parotid X 
Epididymides  X Sciatic nerve X 
Eyes/Optic nerves  X Seminal vesicles X 
Femur (Femoro-tibial joint) X Skeletal muscle (hindlimb) X 
Harderian glands  X SKIN NBF 
HEART NBF Spinal column - X 
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 Tissues  Tissues 
Tissues Fixed Examined Tissues Fixed Examined 
ILEUM  
NBF, R, SF, 
RNA  
spinal cord (cervical) X 
[Injection site(s)  X spinal cord (thoracic) X 
JEJUNUM NBF, SF, RNA spinal cord (lumbar) X 
KIDNEYS NBF SPLEEN NBF 
Larynx  X Sternum with bone marrow X 
LIVER [and gallbladder] NBF STOMACH  NBF 
LUNG NBF Testes  X 
Lymph node -  X Thymus/Thymic area X 





Mammary gland (inguinal) X OBSERVATIONS NBF 
Nasal cavities and nasopharynx (with  X TONGUE NBF 
skull) X Trachea  X 
OESOPHAGUS NBF URINARY BLADDER NBF 
ORAL MUCOSA NBF Uterus X 
Pancreas X Vagina  X 
Parathyroids X Tibial long bone  
 
Samples of the jejunum and colon tissues fixed in NBF were processed to paraffin wax, 
sectioned, stained with haematoxylin and eosin, alcian blue periodic acid Schiff (AB-PAS) or 
immunohistochemistry and examined microscopically for all animals killed at the end of the 
dosing period.  
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Specialized immunohistochemical staining (caspase-3, Ki-67, MPO, IL-1β) were applied to 
additional sections of the jejunum and colon using a DAKO reagents on an automated machine 
(AutostainerPlus Dako, Denmark) following standard procedures supplied by the manufacturer 
(Flex Plus detection system, Dako, Denmark).  
All slides were scanned using a NanoZoomer and analysed with NanoZoomer Digital Pathology 
Software version 2.3.14. All assessments were done in a blinded fashion.  
Colon and Ileum pieces were placed in Ringers solution with indomethacin (R), and immediately 
had the muscularis layer stripped via microdissection while remaining in R and being gassed 
with carbogen (95 % O2 – 5 % CO2) to maintain tissue integrity. It is important to remove the 
muscularis layer in Ussing chamber experiments to ensure that results can be solely attributed to 
mucosal chloride secretion.  
Gastrointestinal Electrogenic Ion Transport  
Once muscularis was removed, samples were mounted in Ussing chambers. The tissue samples 
were bathed with 4 ml of carbogen-gassed R solution (no indomethacin) on each side. Each 
reservoir was gassed with 95 % O2 - 5 % CO2 and kept at constant temperature of 37 °C. 
Electrogenic ion transport was monitored continuously as short-circuit current (Isc) by using an 
automated multichannel voltage/current clamp apparatus (VCC MC8) (Physiologic Instruments) 
linked through Acquire Analyze 2.3 computer program. Baseline readings were recorded to 
assess baseline differences in electrophysiological function. Forskolin was administered at a 
concentration of 10μM to the basolateral chamber to elevate levels of cAMP to activate CFTR 
chloride channels. Carbachol was administered at a concentration of 100 μM to the basolateral 
chamber to elevate levels of calcium to activate the Calcium activated chloride channels.  
Material Batch Number Supplier 
Indomethacin BCBK0293V Sigma 
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The computer systems that were used on this study to acquire and quantify data include: 
Windows (Word, Excel), Prism version 6, NanoZoomer Digital Pathology, DAKO autostainer 
software, Acquire and Analyse (Physiologic Instruments), Gen 5.  
Analysis of Data 
Numeric data for body weights, body weight changes, organ weights, and clinical pathology are 
expressed as the arithmetic mean for each group. The test article groups were compared with the 
control groups. 
The assumptions of equality of variance for each group and normally distributed data were tested 
using Tukey’s test after performing the 2 way analysis of variance (ANOVA) for body weights, 
organ weights, clinical biochemistry, histopathology, goblet cells, Ki-67, caspase-3, IL-1β, 
MPO, Isc, and FITC. Chi squared test was performed for diarrhoea scores.  
The numerical data presented in this report were generated by different computer systems.  
When performing calculations, these systems may round numbers differently or may not report 
values to the same number of significant digits.  Because of these differences, means or standard 
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deviations in tables and appendices may differ slightly, and recalculation of derived values from 
individual data presented in this report will, in some instances, yield minor variation. 
RESULTS 
Noteworthy findings are described in this section.  No specific mention is made of minor 
differences between treated and control groups if considered not related to test article 
administration. 
Clinical Observations 
Clinical observations were conducted twice daily during the treatment period. 
The most commonly recorded clinical observations throughout the experiments were loose 
faeces.  Diarrhoea severity ranged from mild (grade 1) to severe (grade 3).  Diarrhoea (grade1 - 
3) occurred in 100 % of water and dacomitinib and crofelemer and dacomitinib treated rats. 
Approximately 50 % of rats treated with combination crofelemer and dacomitinib had severe 
diarrhoea (grade 3: severe diarrhoea as watery stools +/- mucous with fur staining incorporating 
hind legs). Approximately 30 % of rats treated with dacomitinib only had severe diarrhoea. 
Combination of crofelemer and dacomitinib caused significantly (p = 0.0003) worse diarrhoea 
than dacomitinib alone.  
The second most common clinical observations were piloerection and red discolouration of the 
fur around the nose and eyes.  These signs indicate stress in the animal and were most common 
in the combination groups. 
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Although rare (n = 2), other clinical observations included skin toxicity (pictured below), 
characterised by hair loss, and red inflamed skin. Animals displaying skin toxicity were treated 
with crofelemer and dacomitinib. This clinical observation preceded removal of the rats from the 
study due to excessive weight loss. All other clinical observations were rare. 
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The third most common clinical observation was weight loss. From day 10 – 21 rats treated with 
crofelemer and dacomitinib had significantly less weight gained compared to controls (p < 
0.0340). From day 13 – 21 rats treated with dacomitinib alone had significantly less weight 
gained compared to controls (p < 0.00167). A number of rats treated with crofelemer and 
dacomitinib (n = 4) and rats treated with dacomitinib alone (n = 1) were removed from the study 
due to excessive weight loss of > 15 %, due to ethical guidelines.  
 
Clinical Chemistry 
All serum biochemistry and liver enzyme results are shown in the summary section, table 2. 
Serum biochemistry and liver enzyme analysis showed mixed results.  Liver enzymes were 
increased in rats treated with dacomitinib. ALP was significantly increased in rats treated with 
crofelemer and dacomitinib and dacomitinib alone compared to water and buffer control rats 
after 7 days of treatment. ALT was significantly increased after 21 days of treatment in rats 
treated with crofelemer and dacomitinib compared to water and buffer control rats.  
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Urea, creatinine and albumin levels were significantly different at 21 days post treatment in rats 
treated with crofelemer and dacomitinib and dacomitinib alone compared to control rats treated 
with water and buffer. The anion gap was increased at 21 days post treatment in rats treated with 
crofelemer and dacomitinib and dacomitinib alone compared to control rats treated with water 
and buffer. LD was significantly increased in rats treated with crofelemer and dacomitinib 
compared to control rats treated with water and buffer at 21 days.  
Organ Weights 
All data for organ weights is shown in summary section, table 2.  
Stomach, small intestine, large intestine, kidneys, liver and spleen were weighed and compared 
as total weight.  
No differences were noted in large intestine and kidney weights. Spleen weights were 
significantly less in rats treated with dacomitinib alone (p = 0.0018) and combination crofelemer 
and dacomitinib (p = 0.0091) compared to water and buffer treated control rats. Liver weights 
were significantly less in rats treated with dacomitinib alone (p < 0.0001) and combination 
crofelemer and dacomitinib (p < 0.0001) compared to water and buffer treated control rats. Small 
intestine weights were significantly less in rats treated with dacomitinib alone (p = 0.0017) and 
combination crofelemer and dacomitinib (p = 0.0134) compared to water and buffer treated 
control rats. Stomach weights were significantly less in rats treated with dacomitinib alone (p = 
0.0089) compared to water and buffer treated control rats.  
Terminal Necropsy 
Groups of rats were killed at 7 days and 21 days of treatment. Macroscopic pathology was more 
frequently observed in rats treated with dacomitinib alone or combination crofelemer and 
dacomitinib. The most common pathology was distended, bloated caecum and large intestines. 
Inflamed, vascular intestines were also observed in a number of rats.  
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Gastrointestinal Permeability 
Fluorescein isothocyanate dextran (FITC) 2-5 kDa made at a solution of 120 mg/ml was 
administered via oral gavage at a dose of 600 mg/kg, 2 hours prior to kill. Levels of FITC were 
determined using fluorescent reading conducted on serum samples collected at necropsy to 
assess gut barrier permeability. Rats treated with combination crofelemer and dacomitinib had 
significantly increased serum levels of FITC dextran compared to water and buffer treated 
control rats (p = 0.0202) and crofelemer and buffer treated rats (p = 0.0172).  
 
Gastrointestinal Electrogenic Ion Transport 
Samples of colon and ileum were mounted in Ussing chambers to record gastrointestinal 
electrogenic ion transport as short circuit current (Isc). Baseline readings were recorded to assess 
baseline differences in electrophysiological function. Baseline Isc in the colon was significantly 
higher in rats treated with combination crofelemer and dacomitinib compared to dacomitinib 
alone (p = 0.0445), and crofelemer alone (p = 0.0145) at 7 days, and at 21 days compared to 
crofelemer alone (p = 0.0078). Baseline conductance in the colon was significantly higher in rats 
treated with combination crofelemer and dacomitinib compared to crofelemer alone at 21 days (p 
= 0.0409). Samples of ileum from rats treated with combination crofelemer and dacomitinib had 
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significantly increased baseline conductance compared to water and buffer control rats (p = 
0.0030), crofelemer alone rats (p = 0.0077) and dacomitinib alone rats (p = 0.0282) at 21 days. 
No significant differences were noted in baseline voltage or resistance in ileum or colon samples.  
Forskolin was administered at a concentration of 10μM to the basolateral chamber to elevate 
levels of cAMP to activate CFTR chloride channels. No differences were noted between groups 
in ileum samples following forskolin administration. The colon samples of rats treated with 
combination crofelemer and dacomitinib for 21 days had significantly increased Isc following 
forskolin administration compared to water and buffer control rats (p = 0.0087) and dacomitinib 
alone rats (p = 0.0201).  
Carbachol was administered at a concentration of 100μM to the basolateral chamber to elevate 
levels of calcium to activate the Calcium activated chloride channels. No differences were noted 
between groups in ileum samples following carbachol administration. The colon samples of rats 
treated with combination crofelemer and dacomitinib for 21 days had significantly increased Isc 
following carbachol administration compared to water and buffer control rats (p = 0.0020), 
crofelemer alone rats (p = 0.0006), and dacomitinib alone rats (p = 0.0022). 
Microscopic Observations 
Histopathological analysis included investigation of colon and jejunum paraffin fixed samples. 
Specific stains included: haematoxylin and eosin (H&E) to asses anatomical derangement, alcian 
blue periodic acid Schiff (AB-PAS) to asses mucin changes, immunohistochemistry with a 
variety of antibodies to asses apoptosis (Caspase-3), proliferation (Ki-67), and inflammation 
(MPO and IL-1β).  
The jejunum and colon were assessed for changes in morphometry in H&E stained sections. 
Specifically, villus height and crypt depth were measured and a validated injury score was used 
to assess damage. Briefly, this score includes evaluation of brush border and surface enterocyte 
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disruption, crypt loss and architectural disruption, disruption of crypt cells, infiltration of 
polymorphonuclear cells and lymphocytes, dilation of lymphatics and capillaries, oedema, villus 
fusion and villus atrophy. There was no significant difference in crypt depth between groups in 
the colon or jejunum at 21 days. At 7 days, rats treated with combination crofelemer and 
dacomitinib had significantly decreased jejunum crypts compared to water and buffer control rats 
(p = 0.00185). Villus height was significantly decreased at 7 days in rats treated with dacomitinib 
alone (p = 0.0009) and combination crofelemer and dacomitinib (p < 0.0001) compared to water 
and buffer controls. At 21 days dacomitinib alone (p = 0.0003) and combination crofelemer and 
dacomitinib (p = 0.0065) had significantly decreased villus heights compared to controls. There 
was no difference in injury scores between groups in the colon or jejunum at either time point. 
Changes in mucin secretion was analysed using AB-PAS stained sections of the colon and 
jejunum. The number of positively stained cells were counted. No significant differences were 
noted in either the colon or the jejunum at either time point.  
Apoptosis was analysed using caspase-3 stained sections of the colon and the jejunum. The 
number of positively stained cells were counted. No significant differences were noted in either 
the colon or the jejunum at either time point.  
Proliferation was analysed using Ki-67 stained sections of the colon and the jejunum. The 
number of positively stained cells were counted. No significant differences were noted in either 
the colon or the jejunum at either time point.  
Inflammation was assessed using MPO and IL-1β stained sections of the colon and the jejunum. 
MPO is a marker of granulocytes; the number of positively stained cells were counted in the 
colon and the jejunum. There were no significant differences in the number of MPO positively 
stained cells between groups in colon samples at either time point. In jejunum samples, the 
number of MPO positively stained cells was significantly increased in rats treated with 
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combination crofelemer and dacomitinib compared to water and buffer control rats at 7 days (p = 
0.0259). There were no significant differences in the number of Il-1 β positively stained cells 
between groups in jejunum or colon samples at either time point. 
DISCUSSION 
The purpose of these experiments was to develop a rat model of dacomitinib-induced diarrhoea 
that could be interrogated for mechanisms of diarrhoea and be used to assess chloride channel 
inhibition as an intervention.  This study was conducted over two phases; the first phase aimed to 
determine the optimal dose of dacomitinib and crofelemer administration, the second phase 
aimed to determine the effect of concurrent crofelemer on dacomitinib-induced diarrhoea. 
Crofelemer administered alone did not induce diarrhoea and was safe and well tolerated.  
We were successful in designing a model that reflects the clinical picture by inducing moderate 
diarrhoea in all rats when treated with 7.5 mg/kg dacomitinib. At a dose of 7.5 mg/kg, 
dacomitinib induced diarrhoea in a pattern whereby diarrhoea had a slow onset, increasing in 
frequency and severity as the study progressed. A similar pattern was noted in rats treated with 
combination crofelemer and dacomitinib. Diarrhoea that occurred in the first 3 days of the 
experiment was possibly due to restraint stress as dacomitinib-induced diarrhoea occurred more 
predominantly from day 5 of treatment. During this experiment, diarrhoea in the combination 
crofelemer and dacomitinib treated rats occurred at an increased frequency and severity than all 
other groups. Inhibition of chloride channels with crofelemer did not effectively treat diarrhoea. 
Body weight of rats is a frequently used measure of health. Rats treated with dacomitinib alone 
or combination crofelemer and dacomitinib had significantly less weight gain from baseline 
indicating that rats in these groups had increased toxicity. Combination crofelemer and 
dacomitinib rats had significantly lower body weights than controls from day 10 onwards, 
whereas dacomitinib alone rats did not have significantly lower body weights until day 13. This 
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suggests that crofelemer induced dacomitinib induced-toxicity earlier than when dacomitinib is 
administered alone.  
Liver enzymes were increased in rats treated with dacomitinib. ALP and ALT was significantly 
increased in rats treated with dacomitinib alone and combination crofelemer and dacomitinib rats 
compared to control rats. This suggests that dacomitinib causes liver dysfunction, further 
supported, as liver weights were significantly lighter in rats from these groups. Urea, creatinine 
and albumin levels were significantly different at 21 days post treatment in rats treated with 
dacomitinib alone and combination crofelemer and dacomitinib rats compared to control rats, 
suggesting that dacomitinib causes renal dysfunction. The anion gap was increased at 21 days 
post treatment in rats treated with dacomitinib alone and combination crofelemer and 
dacomitinib rats compared to control rats, this may suggest renal dysfunction, or could be a 
result from the severe diarrhoea. LD was significantly increased in rats treated with crofelemer 
and dacomitinib compared to control rats suggesting tissue injury. No differences were noted in 
serum chloride concentrations.  
FITC dextran is a fluorescent-labelled sugar that is administered via oral gavage 2 hours prior to 
blood collection to assess gastrointestinal barrier permeability. Levels of FITC were determined 
using fluorescent reading conducted on serum samples collected at necropsy. Rats treated with 
combination crofelemer and dacomitinib had significantly increased serum levels of FITC 
dextran compared to water and buffer treated control rats. This indicates that rats treated with 
combination crofelemer and dacomitinib had decreased barrier function. This is further 
confirmed in Ussing chamber experiments, where ileum and colon samples from rats treated with 
crofelemer and dacomitinib showed increased baseline conductance, suggesting that rats from 
this group had increased gastrointestinal permeability. This is consistent with gastrointestinal 
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toxicity induced by traditional chemotherapy. Further investigations are needed to determine the 
cause of the increased permeability.  
Ussing chamber experiments were conducted on distal portions of the colon and the ileum to 
investigate ex vivo the electrogenic transport of the gastrointestinal mucosa. Short circuit current 
(Isc) is a measure of chloride secretion across the epithelium. In these experiments, baseline Isc 
was decreased in rats treated with crofelemer alone, indicating that when given in isolation, 
crofelemer is effective at inhibiting chloride secretion. However, when given in combination 
with dacomitinib, this effect is lost as Isc is increased. Forskolin and carbachol were 
administered to assess CFTR and CaCC chloride channels. Colon samples of rats treated with 
combination crofelemer and dacomitinib had significantly increased Isc following both forskolin 
and carbachol administration, suggesting that this treatment increases chloride secretion via the 
both chloride channels. Results from Ussing chamber experiments do not indicate that 
dacomitinib-induced diarrhoea is due to secretory mechanisms, as dacomitinib alone treated rats 
did not have an increase in baseline Isc, or in reaction to forskolin or carbachol administration. 
This explains why crofelemer is not effective at inhibiting dacomitinib-induced diarrhoea, but 
does not address why crofelemer worsens dacomitinib-induced diarrhoea.  
This study found mixed results in tissue pathology. Histopathological analysis did not suggest an 
increased mucin secretion or an inflammatory component to be responsible for the clinical 
measures of gastrointestinal toxicity noted.  All rats treated with dacomitinib (alone, or in 
combination with crofelemer) had decreased villus height, suggesting dacomitinib induces 
atrophy of the small intestine. This is further supported as rats in these groups had significantly 
lighter small intestine weights. Contrary to the study hypothesis, and the currently available 
literature, these results imply that dacomitinib may cause small intestinal atrophy. Decreased 
surface area of the small intestine caused by said atrophy can lead to diarrhoea due to an inability 
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to control solute absorption and secretion. These characteristics are consistent with traditional 
chemotherapy-induced gut toxicity, and inconsistent with previously published preclinical 
studies of oral small molecule TKIs. Nevertheless, no differences were noted in apoptosis, 
proliferation or injury scores, which is inconsistent with typical small intestinal atrophy/damage 
caused by traditional chemotherapy.  
The mechanisms underlying development of diarrhoea in this model require more investigation. 
The results from this study are inconclusive as to whether the mechanism of dacomitinib-induced 
diarrhoea is due to small intestinal atrophy, or chloride secretion. Theoretical causes may include 
that unabsorbed dacomitinib acts as an irritant within the small and large intestine, causing 
activation of neural and immune signals that lead to increased motility as a reflex for removal of 
the stimulus. Further studies are needed to determine changes in expression and function of 
membrane channels, which control solute and water movement along the length of the tract in 
response to dacomitinib.   
 
CONCLUSION 
In conclusion, the findings from this study support the Albino Wistar rat as an appropriate choice 
to model dacomitinib-induced diarrhoea.  We have shown that combining crofelemer with 
dacomitinib causes worse diarrhoea compared to either alone, indicating that it is unlikely that 
dacomitinib induces diarrhoea due to secretory mechanisms. Further research is required to 
understand the mechanisms of dacomitinib-induced diarrhoea to best target interventions.
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PART 2 
IN VITRO STUDY   Compound: Dacomitinib  
(PF-00299804)  




Title: Part 2: Investigating the effect of dacomitinib on chloride secretion in 




  260 
Table 1  
 
Report Title:  Part 2 in vitro study 



















5 minutes 7.481 9.387** 36.08* 6.707** 
20 minutes   30.54* 9.175** 
60 minutes   6.851  
90 minutes   5.383  
3 hours   3.354  
6 hours   11.04  
24 hours   9.948  
48 hours   15.31  
* Indicates significantly different from DMSO control group (One-Way ANOVA, p < 0.0001) 
** Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.0001) 
Table 2  
 
Report Title:  Part 2 in vitro study 
Baseline Resistance 
 


















5 minutes 554.4 956.5 717.1** 1659* 
20 minutes   604.7** 1130* 
60 minutes   911.7  
90 minutes   430.5  
3 hours   591.9  
6 hours   559.7  
24 hours   757.1  
48 hours   708.2  
* Indicates significantly different from DMSO control group (One-Way ANOVA, p < 0.0003) 
** Indicates significantly different from crofelemer/dacomitinib group (One-Way ANOVA, p 
<0.0001) 
 
Table 3  
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Dose dacomitinib 















5 minutes 2.204 1.158 1.540 0.6220* 
20 minutes   1.663 0.8856* 
60 minutes   1.136  
90 minutes   2.375  
3 hours   2.024  
6 hours   1.839  
24 hours   1.509  
48 hours   1.763  




Table 4  
 
Report Title:  Part 2 in vitro study 
Δ Isc after forskolin  
 
Dose dacomitinib 
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(D) & crofelemer 
(C) μM 
0D, 0C 0D, 10C 1D, 0C 1D, 10C 




5 minutes 16.70 14.45 2.164* 14.68 
20 minutes   4.551* 3.471* 
60 minutes   16.28  
90 minutes   14.02  
3 hours   23.59  
6 hours   7.481  
24 hours   19.95  
48 hours   12.28  
* Indicates significantly different from DMSO control group (One-Way ANOVA, p < 0.05) 
 
 
Table 5  
 
Report Title:  Part 2 in vitro study 
Δ Isc after carbachol  
 
Dose dacomitinib 
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5 minutes 107 28.60* 96.58*** 16.81*,** 
20 minutes   145.1*** 12.50*,** 
60 minutes   97.36***  
90 minutes   132.5***  
3 hours   141.6***  
6 hours   90.67***  
24 hours   139.2***  
48 hours   107.6***  
* Indicates significantly different from DMSO control group (One-Way ANOVA, p < 0.0001) 
** Indicates significantly different from dacomitinib group (One-Way ANOVA, p <0.0001)  
*** Indicates significantly different from crofelemer group (One-Way ANOVA, p <0.05) 
Table 6  
 
Report Title:  Part 2 in vitro study 















 Baseline Isc (μA/cm2) 
 
Group mean 
5 minutes 7.481*,** 19.20*,*** 36.08**,*** 27.25**, *** 
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20 minutes  18.67*,*** 30.54*** 5.066*, ** 
* Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.0001) 
** Indicates significantly different from tetraethylammonium group (One-Way ANOVA, p 
<0.005)  
*** Indicates significantly different from DMSO control group (One-Way ANOVA, p <0.005) 
Table 7 
 
Report Title:  Part 2 in vitro study 



















5 minutes 555.4* 759.2 717.1 636.6 
20 minutes  682.2* 604.7* 1179 
* Indicates significantly different from dacomitinib + tetraethylammonium 20 minute group 
(One-Way ANOVA, p < 0.005) 
Table 8 
 
Report Title:  Part 2 in vitro study 
Baseline conductance in presence of tetraethylammonium 
chloride pre-treatment  
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Dose dacomitinib (D) μM 
& Tetraethylammonium 
(T) mM 
0D, 0T 0D, 1T 1D, 0T 1D, 1T 




5 minutes 2.204 1.360 1.540 1.653 
20 minutes  1.666 1.663* 1.177 




Report Title:  Part 2 in vitro study 
Δ Isc after forskolin in the presence of tetraethylammonium 
chloride pre-treatment  
 
 
















5 minutes 16.70 5.08* 6.133* 9.258 
20 minutes  8.618* 4.551* 13.06** 
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* Indicates significantly different from DMSO vehicle control group (One-Way ANOVA, p < 
0.005)  
** Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.001)  
Table 10 
 
Report Title:  Part 2 in vitro study 
Δ Isc after carbachol in the presence of tetraethylammonium 
chloride pre-treatment  
 
 
















5 minutes 107 90.51 96.58 112.2 




Report Title:  Part 2 in vitro study 
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& Tetraethylammonium 
(T) mM 




5 minutes 7.481*,** 19.20 36.08 4.174*,** 
20 minutes  18.67** 30.54 5.968*,** 
* Indicates significantly different from DMSO + Tetraethylammonium group (One-Way 
ANOVA, p < 0.005)  
** Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.001)  
Table 12 
 
Report Title:  Part 2 in vitro study 
Baseline Resistance in the presence of tetraethylammonium 
chloride post-treatment  
 
 















5 minutes 554.4* 759.2 717.1* 1211 
20 minutes  682.2* 604.7* 1125 
* Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.003)  
 




Report Title:  Part 2 in vitro study 
Baseline conductance in the presence of tetraethylammonium 
chloride post-treatment  
 
 















5 minutes 2.204 1.360 1.540 0.8957* 
20 minutes  1.666 1.663 0.9492* 
* Indicates significantly different from DMSO group (One-Way ANOVA, p < 0.0005)  
Table 14 
 
Report Title:  Part 2 in vitro study 
Δ Isc after forskolin in the presence of tetraethylammonium 
chloride post-treatment  
 
 











 Δ Isc after forskolin Group mean 
 




5 minutes 16.70 5.080*,** 6.133*,** 16.42 
20 minutes  8.618* 4.551* 6.544* 
* Indicates significantly different from DMSO vehicle control group (One-Way ANOVA, p < 
0.003)  
** Indicates significantly different from dacomitinib + tetraethylammonium group (One-Way 




Report Title:  Part 2 in vitro study 
Δ Isc after carbachol in the presence of tetraethylammonium 
chloride post-treatment  
 
 
















5 minutes 107 90.51 96.58 139.7 
20 minutes  118 145.1 93.74* 
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* Indicates significantly different from dacomitinib group (One-Way ANOVA, p < 0.05) 
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INTRODUCTION 
Part 1 of this report indicated that the most common adverse event of dacomitinib treatment in rats is 
diarrhoea. Despite promising response data, the underlying cause of this side effect was not evident in the 
preclinical (PART 1) component of this study. Therefore, PART 2 was conducted in vitro to further 
investigate the potential role of chloride secretion on dacomitinib-induced diarrhoea. All doses and 
concentrations are expressed in terms of the parent compound, which for the purpose of this report is 
referred to as DACOMITINIB.  
Crofelemer is produced from the plant, Croton lechleri (active component oligomeric proanthocyanidin), 
and inhibits both cAMP cystic fibrosis (CFTR) and calcium activated (CaCC) chloride channels.  It was 
hypothesized that If inhibition of HER signaling results in increased intestinal chloride secretion, this 
agent may be effective at reducing dacomitinib-induced diarrhoea, however PART 1 of this study 
indicated that crofelemer is not effective at attenuating dacomitinib-induced diarrhoea.  
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Objective 
The objective of the study was to interrogate and correlate changes induced by dacomitinib in 
PART 1 in an in vitro model.  
Rationale for Selection of Dose 
Dacomitinib and crofelemer doses were selected based on previous literature.   
Dacomitinib was administered at 1 M in both Ussing chambers (5, 20, 60, 90 minutes) and in 
Transwells (3, 6, 24, 48 hours) via apical routes to mimic the clinical oral administration. It has 
previously been described that doses above 1 M of dacomitinib are where off-targeting or non-
specific effects manifest, based on enzymatic analysis (Ather, 2013). Effects at or below 1 M 
are therefore more likely to be due to the specific effect of dacomitinib on the HER receptors.  
Crofelemer was administered at 10 M in Ussing chambers (5 and 20 minutes) via apical routes 
to mimic the clinical oral administration. Crofelemer was only administered at 5 and 20 minute 
time points, as these times were where most dacomitinib induced chloride secretion was 
observed. The dose of crofelemer was based on previous research that has shown that 10 M 
crofelemer is effective at inhibiting chloride secretion in T84 cells (Tradtrantip, 2014).  
Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, et al. (2013) Dacomitinib, an Irreversible Pan-
ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit 
Low Response to Cetuximab. PLoS ONE 8(2).  
Tradtrantrip L, Namkung W, Verkman AS. (2010) Crofelemer, an Antisecretory Antidiarrhoeal 
Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal 
Chloride Channels. Mol Pharmacol 77(1).  
Rationale for Selection of Cells for in vitro Experiments 
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T84 cells are a representative cell line of colonic epithelium. This cell line has previously been 
shown to reliably replicate the chloride secretory mechanisms of the intact intestine permitting a 
detailed examination of intracellular mechanisms intrinsic to the epithelium that regulates the 
secretory diarrhoea mechanism. 
 
MATERIALS AND METHODS 
Test Article and Dose Preparation 
PF-00299804 (Dacomitinib) was supplied by Pfizer and was stored at room temperature (18C) 
and protected from light. Dacomitinib is soluble in dimethyl sulfoxide (DMSO) at 19 mg/ml; 
2.4734 L aliquots of dacomitinib in DMSO were added to 2 ml of appropriate vehicle (Ringers 
for Ussing treatment, Media for Transwell treatment), to create a 50 M concentration. 
Appropriate volumes were added to either Transwells (3, 6, 24 and 48 hour treatments) or Ussing 
chambers (5, 20, 60 and 90 minutes) to reach a final concentration of 1 M. The vehicles were 
prepared daily.  Exposure of DMSO to cells did not exceed 0.01%. The same concentration of 
DMSO was used as a vehicle control.  
Crofelemer was in tablet form and stored at room temperature protected from light in a sterile 
container. Crofelemer was ground and diluted with DMSO to 21 mg/ml (10 mM) immediately 
before use, 5 L of this was added to 5 ml of Ringers in Ussing chambers to reach a desired 
concentration of 10 M.   
The compounds, vehicle components, suppliers, and batch numbers used are as follows. 
Material Batch Number Supplier 
Dulbecco’s Modified Eagle’s 
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Normocin NOL-37-04 Invitrogen 
Penicillin/Gentamicin/Fungiz
one 
AF-28 IMVS Media Production 
Unit 
Foetal Bovine Serum (FBS) 12768 Bovogen 
L-glutamine GLUT-65 IMVS Media Production 
Unit 
Dimethyl Sulfoxide (DMSO) SHBD9856V Sigma 
Snapwell polyester 
Transwells 
10915014 Corning Costar 
Crofelemer (Fulyzaq) 3106372 Salix 
Dacomitinib PF-00299804 Pfizer 
  Cell Preparation and Maintenance 
Cryopreserved T84 cells (passage 5-15) derived from a human colorectal carcinoma were 
obtained from Culture Collections (Porton Down, UK; 88021101). The T84 cell line retained its 
original morphology and growth characteristics over the range of passages used. 
Cells were thawed in a 37°C water bath and maintained in a 75 cm2 or 150 cm2 sterile cell 
culture flask (Corning Life Sciences, MA, USA) at 37°C with 5 % CO2. T84 cell culture media 
was Dulbecco’s Modified Eagle Medium/Ham’s F-12 Nutrient Mixture containing 15 mM 
HEPES, L-glutamine and sodium bicarbonate, supplemented with 1 % 
penicillin/gentamicin+fungizone, 10 % foetal bovine serum and 1 mM l-glutamine (complete 
DMEM). Experimental cell cultures were grown in sterile, multi-well tissue culture plates under 
identical growth conditions. Cell lines were routinely passaged when culture monolayers reached 
approximately 80 % confluence at subculture ratios between 1:3 and 1:6 in fresh growth 
medium. Cells were detached by aspirating growth medium, washing with 1X phosphate 
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buffered saline (PBS; pH 7.4) and incubating with 3 ml of trypsin-EDTA for 10 min at 37°C. 
The reaction was then quenched by the addition of growth medium. Cells were centrifuged at 
300 g for 5 min, supernatant removed and cells resuspended in fresh, complete DMEM. Cell 
counts were conducted using an automated cell counter (BioRad, NSA, Australia) and were 
seeded into 1.12 cm2, 0.4 mm pore polyester Transwell inserts (Corning Life Sciences, MA, 
USA; CLS3801). T84 cells were seeded at a density of 100,000 cells/cm2. Cell culture media in 
both the apical and basolateral chambers was changed every 48 hours. Transepithelial electrical 
resistance (TEER) was measured daily using am EVOM2 epithelial volt-ohm-meter with 
chopstick electrodes (World Precision Instruments, Sarasota, FL, USA) for 1 week during the 
growth period and area adjusted for analysis using the following formula; TEER monolayer 
(W/cm2) = [raw TEER (W) – TEER blank (W)]/area of membrane (cm2). All experiments were 
repeated eight times. 
STUDY DESIGN 
Ion channel analysis: To test whether dacomitinib increased intestinal epithelial cell Cl- 
secretion, short-circuit current (Isc) was measured in T84 cells in symmetrical physiological 
solutions in Ussing chambers. T84 monolayers were grown on polyester Transwell membranes 
and once adequate resistance was reached (determined by TEER of > 1000 Ω  cm), were then 
treated with 1 µM dacomitinib, DMSO (negative control) and mounted into Ussing chambers. 
Exposure time of T84 monolayers to dacomitinib included 5, 20, 60, and 90 minutes 
(administration in Ussing chambers), and 3, 6, 24 and 48 hours (administration in Transwell). 
Inserts were mounted into sliders and bathed in Ringers solution (R) (composition in mmol/L: 
NaCl 115.4; KCl 5; MgCl2 1.2; NaH2PO4 0.6; NaHCO3 25; CaCl2 1.2 and glucose 10) 
continuously gassed with carbogen. Short circuit current and resistance were measured 
throughout the experiment set up using Acquire and Analyse software (Physiologic Instruments). 
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Peak activity of dacomitinib-induced chloride secretion was assessed, and crofelemer was 
administered at these times points.  
The following table summarises study design. 
 


















5 minutes n=8 n=8 n=8 (pre-treatment 
tetraethylammonium) 
n=8 (post-treatment  
tetraethylammonium) 
n=8 
20 minutes n=8 n=8 n=8 (pre-treatment 
tetraethylammonium) 
n=8 (post-treatment  
tetraethylammonium) 
n=8 
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MEASUREMENTS AND OBSERVATIONS 
Monolayer Integrity 
A viability check was performed prior to monolayer treatment and mounting in Ussing chambers 
to assess the integrity of the monolayer. If monolayers had a TEER of < 1000 Ω  cm they were 
excluded from the study, as reliable results could not be assured.  
Epithelial Electrogenic Ion Transport  
T84 monolayers on Transwells were bathed with 5 ml of carbogen-gassed ringers solution on 
each side. Each reservoir was gassed with 95 % O2 - 5 % CO2 and kept at constant temperature 
of 37°C. Electrogenic ion transport was monitored continuously as short-circuit current (Isc) by 
using an automated multichannel voltage/current clamp apparatus (VCC MC8) (Physiologic 
Instruments) linked through Acquire Analyze 2.3 computer program. Baseline readings were 
recorded to assess baseline differences in electrophysiological function. Amiloride was 
administered at a concentration of 20 M to the apical chamber to inhibit the epithelial sodium 
channel (ENaC). This priming step was conducted in all experiments to inhibit sodium 
reabsorption, so that all results can be solely attributed to the movement of ions in a luminal 
direction. Forskolin was administered at a concentration of 10 M to the basolateral chamber to 
elevate levels of cAMP to activate CFTR chloride channels. Carbachol was administered at a 
concentration of 100 M to the basolateral chamber to elevate levels of calcium to activate the 
CaCC. Tetraethylammonium was administered at a concentration of 1 mM to the basolateral 






Material Batch Number Supplier 
Amiloride BCBC4358V Sigma 
 
Tetraethylammonium BCBF2894V Sigma 
   











The computer systems that were used on this study to acquire and quantify data include: 
Windows (Word, Excel), Prism version 6, Acquire and Analyse 2.3 (Physiologic 
Instruments).  
Analysis of Data 
Numeric data for delta short circuit current, baseline resistance, conductance, short 
circuit current, and voltage are expressed as the arithmetic mean for each group. The test 
article groups were compared with the DMSO control groups. All baseline readings are 
an average of each monolayer over 5 minutes. All data has been area adjusted (1.12 cm2) 
The assumptions of equality of variance for each group and normally distributed data 
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Noteworthy findings are described in this section.  No specific mention is made of minor 
differences between groups if considered not related to test article administration. 
Determining optimal time point to investigate dacomitinib-induced chloride secretion 
All measurements were taken using Acquire and Analyse linked to Physiological 
systems Ussing chambers.   
To test whether dacomitinib induced intestinal chloride secretion, short circuit current 
(Isc) was measured in T84 cell monolayers in symmetrical physiological solutions. 
Analysis began with T84 monolayers treated with dacomitinib only, to determine the 
optimal time point to further investigate precise mechanisms. Dacomitinib was exposed 
to T84 monolayers at 5, 20, 60 and 90 minutes, and 3, 6, 24 and 48 hours. Baseline 
chloride secretion was significantly increased (p < 0.0001) compared to controls in cells 
that had 5 and 20 minutes exposure time to dacomitinib. Baseline resistance and 
conductance were also measured, however the results of this are not considered 
noteworthy. All further experiments were conducted at 5 and 20 minute time points.  
 
* Indicates significantly different from DMSO vehicle control (One-Way ANOVA, p < 
0.0001) 
Investigating dacomitinib-induced chloride secretion via the CFTR and CaCC chloride 
channels 
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To test the effect of dacomitinib on the CFTR chloride channel, delta values of short 
circuit current were measured following the administration of cAMP agonist forskolin. 
Exposure to dacomitinib did not increase chloride secretion specifically via the CFTR 
chloride channel, as there was a significantly decreased response to CFTR chloride 
channel activation with administration of forskolin compared to controls (p < 0.05).  
 
*Indicates significantly different from DMSO vehicle control (One-Way ANOVA, p < 
0.05) 
To test the effect of dacomitinib on the calcium activated chloride channel, delta values 
of short circuit current were measured following the administration of calcium agonist 
carbachol. Exposure to dacomitinib did not increase chloride secretion specifically via 
the CaCC, as there was no significant difference in response to CaCC activation with 
administration of carbachol compared to controls (p > 0.05).  
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Investigating the effect of dacomitinib-induced chloride secretion via the potassium 
channel 
Given the role of the HER receptors on inhibiting the basolateral potassium channel, 
tetraethylammonium was administered to inhibit this channel. Treatment included both 
pre and post exposure to dacomitinib, with no significant differences noted in treatment 
schedule. The presence of tetraethylammonium did not change the effect of dacomitinib 
on short circuit current described in sections 14.1, and 14.2.   
Investigating the effect of crofelemer on inhibiting dacomitinib-induced chloride 
secretion 
To assess if crofelemer was effective at inhibiting dacomitinib-induced intestinal 
chloride secretion, baseline short circuit current was assessed at key time points. 
Baseline short circuit current indicated that crofelemer significantly attenuated 
dacomitinib-induced intestinal chloride secretion (p < 0.0001) supporting the study 
hypothesis.  
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*Indicates significance (One-Way ANOVA, p < 0.00001) 
 
To assess if the decrease in baseline short circuit current induced by crofelemer was due 
to CFTR chloride channels, the cAMP agonist forskolin was applied to activate the 
CFTR chloride channels, and the delta Isc recorded. Results indicated that crofelemer 
does not decrease chloride secretion via the CFTR chloride channel. At the 5 minute 
time point, the inhibitory action of crofelemer on dacomitinib induced chloride secretion 
was lost, and was significantly higher (p = 0.0023). Crofelemer administered alone did 
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*Indicates significance (One-Way ANOVA, p < 0.00001) 
To assess if the decrease in baseline short circuit current induced by crofelemer was due 
to CaCC, the calcium agonist carbachol was applied to activate the calcium activated 
chloride channels, and the delta Isc recorded. Crofelemer exposed cells had a decreased 
response to carbachol compared to controls (p < 0.0001). These results indicate that 
crofelemer works primarily via the CaCC, consistent with the literature. Response to 
carbachol was significantly decreased in cells exposed to dacomitinib/crofelemer 
combination compared to dacomitinib alone at both time points (p < 0.0001), suggesting 
that changes seen in baseline short circuit current are due to inhibition of CaCC and not 
CFTR.  
 
*Indicates significance (One-Way ANOVA, p < 0.00001) 
DISCUSSION 
The purpose of these experiments was to investigate the mechanisms of dacomitinib-
induced diarrhoea by investigating intestinal chloride secretion. The first component of 
the in vitro arm (PART 2) of this study aimed to determine the optimal time to 
investigate dacomitinib-induced intestinal chloride secretion, the second component 
aimed to investigate the mechanisms of chloride secretion, and the effect of inhibiting 
chloride secretion with crofelemer.  
 
  286 
We were successful in determining the optimal time to investigate dacomitinib-induced 
chloride secretion. After 5 and 20 minutes of exposure to dacomitinib, T84 monolayers 
had significantly increased chloride secretion. This effect was lost at exposure times 
exceeding 20 minutes. Therefore, only these time points were continued for all other 
investigations. The results of this study indicate that dacomitinib increases intestinal 
chloride secretion. However, this is inconsistent with the in vivo (PART 1) aspect of the 
study. This may be due to timing, as in vivo secretory analysis occurred a number of 
hours after dacomitinib treatment. The in vitro aspect of this study showed that 
dacomitinib significantly increased chloride secretion, but not when exposure exceeds 20 
minutes. This suggests that the effect of dacomitinib on intestinal chloride secretion is 
immediate and transient.  
The cellular secretory targets of dacomitinib were further investigated, focusing on the 
principal luminal membrane determinants of intestinal fluid secretion by administering 
forskolin and carbachol. We found that dacomitinib induced chloride secretion via the 
apical membrane calcium-stimulated Cl- channels, but not the cAMP-stimulated CFTR 
Cl- channels. In normal physiological conditions, the HER receptors negatively regulate 
basolateral K+ channels, therefore these channels were inhibited with 
tetraethylammonium to assess the role of this ion channel in dacomitinib-induced 
intestinal chloride secretion. The baseline effects seen following dacomitinib treatment 
did not change when K+ channels were inhibited, suggesting that this ion channel is not 
involved in dacomitinib-induced chloride secretion.  
Crofelemer was administered at key time points, when dacomitinib-induced intestinal 
chloride secretion was most increased. When crofelemer was administered to T84 
monolayers that had been exposed to dacomitinib, baseline chloride secretion was 
significantly reduced. This is consistent with the study hypothesis. However, this result 
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was lost when implemented in the in vivo setting, suggesting that the cellular secretory 
processes of dacomitinib and crofelemer are not translatable into a fully functioning 
physiological setting. The administration of forskolin and carbachol indicated that 
crofelemer inhibited chloride secretion predominantly via the CaCC, which is consistent 
with previous literature on crofelemer and optimal for dacomitinib-induced intestinal 
chloride secretion; given that we determined that this was driven predominantly via the 
CaCC.  
CONCLUSION 
The mechanisms underlying development of diarrhoea in this model require further 
investigation. The hypothesis of this study was that dacomitinib-induced diarrhoea is 
driven by intestinal chloride secretion; because in normal physiological settings HER 
receptors negatively regulate the principal chloride channels, and so when dacomitinib 
inhibits these receptors, the negative regulation is lost. The in vitro component of this 
study supported this hypothesis, and was able to attenuate the increased chloride 
secretion with crofelemer, identifying the CaCC as the primary channel for this. 
However, this did not translate in the in vivo component of the study. Nevertheless given 
the in vitro findings, this hypothesis should not be discounted.  
 
